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ABSTRACT
Various aspects of the pharmacokinetics of endogenous and 
synthetic glucocorticoids have been examined in an attempt to 
understand the prolonged physiological effects of the synthetic 
steroids, and to characterise their metabolic fate. The 
biochemical interactions of these compounds with the hepatic 
mixed-function oxygenase system have also been studied, and 
this enzyme complex has been used to resolve the mediating 
factors in the expression of circadian rhythms.
The results have demonstrated that betamethasone and 
dexamethasone are metabolised primarily by hydroxylation in both 
rat and guinea pig, and that this occurs less rapidly than does the 
reductive metabolism of the endogenous corticosteroids. The hepatic 
clearance of the synthetic glucocorticoids is also slower than that 
of corticosterone, and this, by virtue of their prolonged tissue 
retention, may contribute towards the greater biological potency 
of the synthetic analogues.
Glucocorticoids influence hepatic drug metabolism, largely by 
their effects on the levels of cytochrome P-450 and the rate of its 
reduction. Such changes seem to result from effects on protein 
synthesis, but other phenomena, possibly allosteric in nature, 
appear important. It seems likely that the same glucocorticoid 
mediated effects may be responsible for expression of the observed 
diurnal rhythms in drug metabolism and steroid metabolism.
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The observation that the adrenal cortex was responsible for the 
maintainance of life was made over a hundred years ago. Although the 
earliest recorded experiments attempting to extract the life-prolonging 
substances were made by Brown-Sequard in 1856, it was not until the late 
1920*s that several workers succeeded in isolating the lipids concerned 
(Hartmaniiand Brownell, 1930$ Rogoff and Stewart, 1929$ Swingle and 
Pfiffner, 1930). Their identification as steroids was separately made 
by Kendall and Reichstein and their co-workers in the 1930*s and led to 
the trivial system of nomenclature still used today.
Although nearly twenty steroids have since been identified as adrenal 
products in venous adrenal blood (Samuels and Uchikawa » 196?) many of 
these occur in amounts which are small compared with those found at other 
sites of steroid biosynthesis, and the major steroids of the adrenal cortex 
fall into two groups, namely glucocorticoids and mineralocorticoids. This 
terminology arose from the ability of these two classes of corticosteroids 
to control various aspects of carbohydrate and electrolyte metabolism 
respectively. Cortisol and corticosterone are the major natural 
glucocorticoids, and deoxycorticosterone and aldosterone the major 
natural mineralocorticoids (Figure 1:1).
All natural corticosteroids share the same parent structure, namely 
pregnane (Figure lsl) and probably as a result of their structural 
similarities, may show overlap in functional activity between the 
glucocorticoid and raineralocorticoid types (White et al, 1968).
The present study is restricted to those compounds whose 
glucocorticoid properties predominate, and which are characterised by 
the possession of several common, functional groups on the pregnane 
skeleton. These substituents, the lip-hydroxyl group, the A -3-keto 
moiety of ring A and the a-ketol side-chain at ((3), are essential
FIGURE 1:1 STRUCTURAL RELATIONSHIPS OF THE NATURAL CORTICOSTEROIDS.
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for glucocorticoid activity. The 17a-hydroxyl group (present in 
cortisol, hut absent in corticosterone) is not obligatory for such 
activity, but may facilitate it in certain species e.g. man.
THE SYNTHETIC GLUCOCORTICOIDS.
The wide spectrum of activity of the glucocorticoids led to 
complications during their early clinical use. While the efficacy 
of cortisol and cortisone in treatment of rheumatoid arthritis was 
soon recognised (Hench et al, 19^9)f their undesirable side-effects 
initiated the search for compounds which were more specific in their 
actions. It was gradually recognised that only one of these side- 
effects, the sodium retention and potassium loss, could be largely 
removed. While the search for the •ideal* glucocorticoid has proved 
fruitless, so for, several compounds which are many times more active 
than the natural steroids have emerged. The discovery of these potent 
drugs led to the requirement for an accurate evaluation of their 
properties, and among the various parameters now forming the basis of 
bio-assays are: glycogen deposition, thymus involution, sodium
retention, eosinopenia and anti-inflammatory activity. While far 
from comprehensive in determining the effects of the synthetic analogues, 
these tests are the most reliable, relevant and convenient for the 
laboratory animals upon which they are necessarily performed.
Extrapolation of the results to the human subject is usually valid.
Prednisolone and prednisone were the first of these derivatives
to be synthesised. They differed from the corresponding natural
glucocorticoids, cortisol and cortisone, by the presence of an
1additional double bond between positions and Cg (A )» so producing
i jL 14 t # 4
the A  * -3-keto configuration which characterises most synthetic
glucocorticoids. Other substituents, especially at C^ and C^, but 
also at Cg and C^ * were later shown to accentuate the glucocorticoid 
properties of the endogenous steroids. Some differential effects of 
these substituents ore shown on Table 1:1.
TABLE 1:1 EFFECT OF CHEMICAL SUBSTITUENTS ON THE BIOLOGICAL 
_______ACTIVITY OF CORTISOL. _____________ __
SUBSTITUENT EFFECT
90r-F Generally increased glucocorticoid 
activity.
A1
Decreased sodium retention, 
increased anti-inflammatory 
properties.
2o-methyl As 9a-F, but sodium retention 
especially increased.
6a~methyl Increased anti-inflammatory 
properties.
16-methyl (a or (3) Increased anti-inflammatory 
properties} sodium retention 
eliminated.
l6a-OH Decreased sodium retention.
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Several synthetic glucocorticoids incorporating one or more of 
these substituents have been used in the present study* Their trivial 
and systematic names are given in Table 2:1. The two examined in most 
detail, namely betamethasone and dexamethasone, are compared with 
cortisol and prednisolone in Figure 1:2. Betamethasone and 
dexamethasone are almost unique among biological compounds in that, 
despite the different configurations of the methyl group, both 
are similarly potent.
FHAHMACOKXNETICS OF GLUCOCORTICOIDS.
The term pharmacokinetics has been widely used, but in the present 
study it describes, in some quantitative detail, those complex 
interactions involved in the stages between the biosynthesis or 
administration of the steroid and its ultimate excretion. It is not 
used in the context of the hypothetical mathematical relationships 
which may be used to quantitatively define the variuus stages in this 
process.
The complex interactions of biosynthesis, secretion, distribution, 
metabolism and excretion provide a dynamic basis of control of endogenous 
glucocorticoid hormone function which is capable of responding to 
constantly changing physiological demands. In conditions where 
administration of glucocorticoids is required, their dose and absorption 
characteristics replace the synthesis and release of the endogenous 
steroids as partial determinants of efficacy.
a) Biosynthesis and release.
The biosynthesis of glucocorticoids occurs in the zona fasciculata 
of the adrenal cortex. Release from the adrenal is primarily controlled
by adrenocorticotrophic hormone (ACTH) which is produced in the 
adenohypophysis, and whose secretion is mediated through corticotrophin 
releasing factor which originates in the hypothalamus. Glucocorticoids 
con influence their ora biosynthesis and release, at both the adrenal 
and central nervous levels, but an over-riding neural control of 
hormone release also exists. Reviews on the mechanisms of 
glucocorticoid biosynthesis and secretion appear elsewhere (Cope, 1972J 
Garren et al, 1971? Samuels and'Uchikawa, 19&7? Yates 19&7).
b) Absorption.
The pharmacological preparations of the many glucocorticoids used 
in the treatment of numerous clinical disorders are designed to satisfy 
the different requirements of these disorders. The physical properties 
of the steroids and of their derivatives, as well as the routes used 
for their administration, are prime determinants of their uptake. Such 
properties also influence the degree and duration of their action. 
Although studies have been made on the effect of different steroid 
derivatives and routes of administration on the absorption of various, 
steroids (Cope, 1972; Hyde and Y/illiams, 1957? Kitagawa et al, 1972; 
Symchowics et al, 19&5), there is a general paucity of information on 
the absorption characteristics of administered glucocorticoids.
c) Transport.
Endogenous and administered glucocorticoids are rapidly mobilised 
from their site of origin. This rapid and widespread distribution is 
facilitated by the solubility characteristics of the steroids and by 
their high capacity for plasma protein binding. Such binding falls 
into two categories, namely, non-specific binding in large amounts to
albumin, and binding in smaller amounts, but with high affinity and 
specificity, to a a^-globulin (Daughaday, 1958).
The specific fel£idey? transcortin or corticosteroid-binding globulin^  
has a mol. wt. around 52,000 and possesses a single corticosteroid 
binding site per molecule. Its component amino acids and carbohydrates 
have been identified by Seal and Doe (1964). The specificity of 
binding is governed primarily by the presence of the 20-keto group 
and the A^-^-keto moeity of ring A. Secondary substituents, 
contributing to the strength of attachment, are the 17a- and 21-hydroxyl 
groups and, especially, the ll|3-hydroxyl group. Other structural 
modifications to the steroid usually result in a decreased capacity 
for tx'anscortin binding, and it appears that the a-surfaee (below the 
plane of the steroid skeleton) is most involved in transcortin binding 
(Daughaday, 19&7). A similar conclusion was reached by Y/estphal and 
Ashley (1959) who studied the binding of progesterone by albumin.
As a result of these structural limitations, the more complex 
synthetic glucocorticoids are less well bound to transcortin than 
their endogenous analogues (Cope, 1972; FIorini and Buyske, 1961).
The binding of triamcinolone to albumin was also reported to be less 
marked than that of cortisol (Florini and Buyske, 1961). Consequently, 
a significantly higher proportion of unbound steroid is found after 
the administration of synthetic glucocorticoids than after the 
endogenous types.
d) Distribution.
Several studies on the gross tissue and subcellular distribution 
of natural glucocorticoids have been made (Bellamy, 1963; Bottoms and
Goetsch, 1967» Devenuto et al, 1962; Firschein et al, 1957; Gulyassy 
et al, 1958; Ulrich, 1959; Wyngaarden et al, 1955), hut comparable 
work using the synthetic derivatives is rare (Florini et al, 196la).
Few experiments were designed to give quantitative distribution patterns 
at various times after the administration of the radioactively labelled 
steroids, and the differences in routes of administration, dose levels, 
species and status of the animals used complicate overall considerations. 
Furthermore, many of the studies with natural glucocorticoids were 
conducted in rats using cortisol, the primary glucocorticoid of man, 
but one which is found in insignificant amounts in the rat (Bush, 1953)*
A further consideration of the tissue distribution of glucocorticoids 
appears in Chapter 3.
e) Metabolism and excretion.
The catabolism of cortisol and corticosterone has been extensively 
investigated in several species, including man. While several reports 
on the metabolism of the simple synthetic glucocorticoids (e.g. prednisone, 
prednisolone, 9or-fluorocortisol) have also appeared, the more extensively 
substituted synthetic analogues (e.g. triamcinolpae, betamethasone, 
dexamethasone) have been little studied. Existing results have 
demonstrated that these compounds are metabolised more slowly and 
by different routes.
Although the products of natural glucocorticoid metabolism in 
different species are qualitatively similar, their excretion patterns 
differ* Published work suggests that species differences may also 
occur in the excretion patterns of the synthetic glucocorticoids, as 
well as in the comparative patterns of excretion of natural and
synthetic glucocorticoids. However, the same problems that confound 
the interpretation of tissue distribution studies, especially 
variations in dose, are equally relevant in comparing metabolism and 
excretion data.
Glucocorticoid metabolism and excretion is discussed in greater detail 
in Chapter 4.
ENDOGENOUS GLUCOCORTICOIDS AND PHYSIOLOGY.
Cortisol and corticosterone perform almost identical roles in 
glucocorticoid function and either may predominate, depending upon 
the species. In rat, the l7or*hydroxylase is of low activity and 
corticosterone is the principal hormone of its type (Samuels and 
Uchihawa, 1967). Corticosterone is also the major glucocorticoid 
in several other rodents, birds and reptiles, but in man, other 
primates, fish, guinea pig, and many carnivora and herbivora, cortisol 
predominates (Bursiein and Dorfman, 1954; Bush, 1953; Bush and 
Sandberg, 1953| Heard et al, 1954; Holmes et al, 1963). The hamster 
also secretes cortisol primarily, but at the lowest levels of any 
animal so far studied (Schindler and Khigge, 1959). Sex differences 
in circulating plasma levels of glucocorticoids also exist (iCitay, 1968) 
and a correlation between these levels and adrenal size has been noted 
in the rat and hamster (Yates et al, 1958a).
Variations in circulating plasma levels of glucocorticoids ore 
common. They often result from environmental stimuli which produce 
elevated levels of plasma glucocorticoids by initially increased 
secretion and by subsequently increased biosynthesis. Collectively, 
these stimuli are often termed stress, and their various types have
been discussed elsewhere (Yates, 19&7). After stress, plasma 
glucocorticoid levels return to those persisting under normal 
conditions, and fall below these basal levels only rarely.
Apart from clinically induced suppressions, little evidence exists 
for stimuli producing sub-normal circulating glucocorticoid levels. 
However, these exist in normal animals at various times of the day 
during the circadian rhythm (Halberg, 1959) of plasma glucocorticoid 
levels. Their existence, and associated rhythmic parameters, are 
discussed in Chapter 6.
BIOCHEMICAL EFFECTS OF GLUCOCORTICOIDS.
Despite numerous small differences which have been demonstrated in 
various aspects of the plasma protein binding, biological efiebts and 
metabolism of cortisol and corticostei’one, these may only exist when 
comparisons are made in the same species. Thus, the biochemical 
effects of corticosterone in the rat are likely to be similar to those 
of cortisol in man, and probably arise by the same mechanisms.
Glucocorticoids have been implicated in a large number of 
biochemical roles, which have been reviewed elsewhere (Ashmore and 
Morgan, 1967; Grant 1967; McKerns 1968; Rosen and Milkolland 1971). 
These include specific effects on certain enzymic components of 
carbohydrate and protein metabolism. Thus, glucocorticoids have been 
shorn to influence the synthesis of tyrosine aminotransferase, tryptophan 
pyrrolase, proline hydroxylase, alanine aminotransferase and fat.
It has been suggested that cyclic AMP may mediate some of these 
glucocorticoid effects (Baxter and Forsham, 1972). Anti-inflammatory, 
immunological, haematological and electrolyte effects have also been 
demonstrated, as well as an involvement in other hormonal functions.
The synthetic glucocorticoids apparently function similarly to their 
endogenous analogues, hut confirmatory evidence on their biological 
effects is scarce. While the mode of action of glucocorticoids is 
yet unresolved, several cellular components have been revealed which 
appear to function in a mediating role. These are discussed more 
fully in Chapter 3.
ABNORMALITIES IN ADRENAL CORTICAL FUNCTION.
Malfunction of the hypothalamus-pituitary-adrenal axis can occur 
at any level. While the most extreme condition of hypofunction is a 
result of hypophysectomy or adrenalectomy, hypoadrenalism may be of 
varied origin. Primary hypoadrenalism is a result of destruction of 
the adrenal glands themselves, is often termed Addison’s disease and 
usually arises from invasive growth or infection. A reduced secretion 
of both glucocorticoids and mineralocorticoids and an over-compensatory 
production of ACTH usually results. Secondary hypoadrenalirm arises 
from reduced or impaired secretion of ACTH. A third and rarer type 
of hypoadrenalism can occur where the anabolism of the glucocorticoids 
is affected. Supplementation with administered glucocorticoids provides 
satisfactory alleviation of hypoadrenal conditions. Discussions of the 
origins and consequences of adrenal cortical hypofunction have appeared 
elsewhere (Cope, 1972; Frawley, 1967).
Adrenal cortical hyperfunction, known as Cushing’s syndrome, may 
result from adrenal tumours which produce glucocorticoids (and other 
adrenal steroids) in large amounts and which are insensitive to ACTH.
The high glucocorticoid levels resulting from such conditions may also 
arise in cases where ACTH production is excessive. Pituitary tumours
may be responsible for this, but tumours at other sites have been 
implicated in the production of an ACTH-iike substance (Liddle 
et al, 1965). The physiological consequences of excessive 
glucocorticoid production have been discussed by Liddle (1967)*
Adrenal disorders, especially hyperactivity, can result in 
significant changes in the output of the adrenal steroids normally 
produced in smaller amounts. Adrenal tumours and congenital adrenal 
hyperplasia are the major causes of such changes. Tumour tissue may 
possess general adrenal activity, or may be specific in the production 
of male or female sex steroids, so giving rise to virilisation or 
feminisation. Congenital hyperplasia of the adrenal is a result 
of compensatory mechanisms attempting to correct for inborn errors 
in adrenal steroid biosynthesis. Clinical manifestations depend on 
the enzymic defect involved and may be expressed by virilisation, 
loss of salt and hypertension. A detailed account of congenital 
adrenal hyperplasia has been given by Baulieu et al (19&7)•
Malfunction of thb hypothalamus-pituitary-adrenal axis can be 
diagnosed by analysing levels of corticosteroids and their metabolites 
in plasma and urine, and by studying the effects of various drugs on 
these levels. The drugs used include ACTH (to stimulate adrenal 
secretion and biosynthesis), dexamethasone (to suppress pituitary 
release of ACTH) and meiyrapone (to inhibit cortisol biosynthesis 
and stimulate ACTH production). The use of these compounds in 
diagnosis of adrenal malfunction has been discussed by Cope (1972).
GLUCOCORTICOIDS IN THERAPEUTICS.
The vast number of clinical disorders which hove been shown to 
respond to glucocorticoid administration include inflammation, glaucoma
and other diseases of the eye, cerebral oedema, asthma and, most 
especially rheumatoid arthritis and various dermatoses. Glucocorticoid 
replacement therapy is demanded after adrenalectomy or in severe cases 
of adrenal hypofunction. The different pharmacological requirements of 
these disorders have led to the development of several glucocorticoid 
derivatives including acetates, succinates, propionates and valerates, 
as well as to the large number of synthetic glucocorticoids of varied^ 
potency. While many of the undesired side-effects resulting from 
treatment arise from the natural expression of glucocorticoid 
activity, several are less easily explained, fhey include headaches, 
dizziness, nausea, abdominal pain, weakness and fatigue. Although 
these symptoms are usually rare, they are more frequent after 
triamcinolone therapy. In addition, this steroid can cause anorexia 
and subsequent weight loss, in contrast to dexamethasone which 
stimulates appetite (Cope, 1972). Perhaps of greater concern, 
however, is the ability of triamcinolone to induced teratogenesis 
in certain animals (Fraser and Fainstat, 1951; Pinsky and DiGeorge, 19&5) 
There is little evidence for a similar effect in man, however 
(David et al, 1970).
The widespread clinical use of glucocorticoids, and the prolonged 
periods of prescription which many of the steroid-sensitive conditions 
demand, makes multiple drug therapy common during periods of treatment 
with glucocorticoids. Little is known of the effects of such polypharmacy 
both with regard to the metabolism of the steroids themselves and that 
of the co-administered drugs. As many foreign compounds, or xonobiotics, 
have been shown to influence both steroid and drug metabolism (Chapters 
4 and 5 respectively), the corresponding interactions of glucocorticoids 
seem likely, especially in the light of their widely documented effects 
on intermediary metabolism.
THE PRESENT STUDY.
Less is known of the properties of the synthetic glucocorticoids 
than of their endogenous analogues. Furthermore, interpretation of 
existing data is hindered by the widespread use of high dose levels 
of the synthetic corticoids. Studies with synthetic steroids are of 
an almost unique nature in that immediate comparisons with endogenous 
hormone levels are possible. Consequently, the use of dose levels which 
greatly exceed comparative physiological amounts should be avoided, 
especially in studies using synthetic steroids of greater bdological 
potency than their endogenous analogues,
It is also interesting to surmise on the less extreme but equally 
non-physiological nature of the widespread use of cortisol in 
glucocorticoid studies in rat. It has already been emphasised that 
this steroid is effectively absent in rat, and although cortisol is 
the principal hormone of its type in several other species, including 
man, this seems poor justification for its use in rat. While it seems 
likely that the major glucocorticoid in a particular species may have 
the same physiological and biochemical effects as a correspondingly 
major, but different glucocorticoid in another species, there is 
increasing evidence to suggest that the two compounds may possess 
different pharmacokinetic properties and play different roles if 
present in the same species. It seems reasonable to presume that, 
where one of these compounds is effectively exogenous, these 
differences may be further pronounced,
.With these reservations in mind, the present study was conducted 
in on attempt to clarify several of the previously mentioned unresolved 
aspects of the pharmacokinetics and biochemistry of glucocorticoids.
Its main aims were;
1) To characterise the distribution, metabolism and excretion patterns 
of two potent synthetic glucocorticoids, betamethasone and 
dexamethasone, in the rat and to compare these with the corresponding 
properties of corticosterone.
2) To examine the effect on drug metabolism of natural glucocorticoids 
and their metabolites and to compare these with similar effects of 
various synthetic glucocorticoids of varied potency.
3) To study the nature of circadian rhythms, in the particular context 
of such rhythms in drug metabolism, and to examine their relationship 
to rhythmic changes in adrenal steroids.
4) To attempt to elaborate on the role, and modes of action, of both 
endogenous and synthetic glucocorticoids.
MATERIALS AND METHODS.
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M A T E  B I A L S
2.1 SUBSTRATES.
2.1.1 Steroids.
Unlabelled steroids are detailed in Table 2:1* They were used as 
provided.
[ 1(3,2(3-^ ] Corticosterone (specific activity greater than 30 Ci/mmol) 
and [i(2)-^ h ] dexamethasone (specific activity 22 Ci/mmol) were obtained 
from the Radiochemical Centre, Amersham, Rucks. They were at least 98$ 
pure (Solvent systems VII, VIII and V, VI respectively) on receipt 
(See 2.8,6). [l6a, 16p-methyl-^s] Bethamethasone (specific activity
170 mCi/mmol) was a gift from Glaxo laboratories Ltd. Greenford, Middlesex, 
The radiochemical purity of all three steroids was checked by thin layer 
chromatography (t.l.c.) using solvent system III for corticosterone and 
both systems I and II (2.8.6) for betamethasone and dexamethasone. All 
were stored at 4°C as ethanolic solutions/and used without fiirther 
purification. Subsequent periodic determination of their radiochemical 
purity showed that this was never lower than 94$.
2.1.2 Drug metabolism substrates.
Biphenyl, aniline and aniline hydrochloride were obtained from 
B*B*H., Poole, Dorset. Ethyl morphine was purchased from May and Baker, 
Dagenham, Essex. 4-chIoro-N-methylaniline was bought from Ralph H. 
Emmanuel, Alperton, Middlesex. Cytochrome c (Type 11-A) was purchased 
from Sigma, (London) as a „7G$ pure solid. Aniline was redistilled before 
use and biphenyl was twice recrystallised from ethanol to give a product 
of m.pt. 70°C . Other substrates were used without further purification.
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2.2 ENZYMES AND.COFACTORS.
Reduced nicotinamide-adenine dinucleotide (NADH) was initially 
purchased from Koch Light Laboratories, Colnbrook, Bucks. Nicotinamide- 
adenine dinucleotide phosphate (NADP), and its reduced form (NADHl) were 
initially obtained from Boehringer (London) Ltd. All three nucleotides 
•were later obtained fromi B~L Biochemicals (international Enzymes Ltd. 
London), fhe tri-sodium salt of DL-isocitric acid was obtained from 
Sigma, London*
Isocitric acid dehydrogenase (ex porcine heart) was purchased from 
Boehringer (London) Ltd* as a 50$ glycerol solution* (3-glucuronidase 
(ex Bovine liver* type Bl) and sulfatase (ex Helix pomatia, type H0) were 
obtained from Sigma, London*
2.5 0IfflEft CHEMICALS*
S-Hydroxybiphenyl, 4-hydroxybiphenyl, 4-aminophenol, 4-chloroaniline 
and formaldehyde were purchased from B.D.H*, Poole, Dorset* Bovine serum 
albumin and 3*3i’-dianisole-4,4r-bis-(3,5-diphenyl) tetrasolium chloride 
(tetrasolium blue) were obtained from Koch Light Laboratories, Coinbrook, 
Bucks* Deoxyribonucleic acid (DNA) sodium salt (ex calf thymus) was 
bought from Sigma, London* 2,5-Diphenyloxasole (PPO) and toluene 
standard were purchased from Packard Instrument Company, Inc*, Illinois, 
tf.S*A* 1,4-bis-2-(4~Methy1-5-phenyloxa : olyl)-benzene (dimethyl P0P0P) was 
obtained from Nuclear Enterprises Ltd*, Edinburgh. All other compounds 
used were of laboratory reagent grade unless otherwise stated, and were 
used as purchased*
2.4 SOLVENTS.
All solvents used were obtained from B.D.H. , Poole, Dorset and 
were generally of laboratory reagent grade. Water used was distilled 
and stored in polypropylene aspirators.
2.5 OTHER MATERIALS.
PP25 Polythene tubing for bile-duct eannulations was obtained from 
Portex Ltd., Hythe, Kent. Other surgical equipment was purchased from 
Holburn Surgical Ltd., London.
Glass-teflon homogenisers of the Potter-Elvehjem type were obtained 
from A.H, Thomas Co., Philadelphia, U.S.A. A Polytron mechanical 
sonicator (’Ultraturrax*) was purchased from Northern Media Supply Ltd., 
Brough, Yorkshire.
All gases were obtained from B.O.C., Crawley, Sussex.
2.6 ANIMALS.
Rats were randomly bred Wistar-albino (Porton Strain) derived from 
a breeding colony obtained from Laboratory Animals Centre, Carshalton, 
Surrey. Syrian hamsters were a pure line golden strain purchased from 
Wrights of Essex. Guinea pigs were obtained from the random bred colony 
of the animal breeding unit of the University of Surrey.
All animals were kept in polypropylene cages with stainless steel 
covers, made by North Kent Plastic Cages Ltd., Dartford, Kent. Breeding 
took place on wood shavings sterilized with ethylene oxide. Several 
days prior to experimental work being conducted, animals were transported 
from the animal breeding unit to the departmental anginal house and re-caged 
on Sterolit bedding (W.P. Usher & Co. Ltd., London). Each species was 
isolated from others. Rats and hamsters were maintained on Spillers No. 1
diet (smal.. animal diet autoclaved), and guinea pigs on Dixons R.G.P. 
diet, ad libitum. All were allowed free access to tap water. Guinea 
pigs were kept singly, but hamsters and rats were caged as litter mates. 
Control and test groups were separated.
Both the animal breeding unit and animal house were maintained 
under closely controlled conditions. Temperature was 22°C, relative 
humidity was 50$, and lighting was on a constant twelve-hour cycle 
(06.30 - 18.30).
Rats aged 38 days (ll0-190g body weight) were used in all drug 
metabolism studies, and were 50 days old (l70-285g body weight) in the 
distribution and steroid metabolism experiments. Hamsters aged 42 days 
(70-80g body weight) were used for the drug metabolism studies. Their 
weights were more variable in the diurnal rhythm experiments. Guinea 
pigs weighed around 350g.
M E T H O D S
2.7 PROTOCOL OF ANIMAL USAGE.
2.7.1 Tissue Preparation.
If blood was required, animals were killed by decapitation and 
blood collected in heparinised glass beakers. Otherwise, animals 
were killed by cervical dislocation. In the distribution experiments, 
all tissues were removed as rapidly as possible and transferred to dry 
beakers maintained between 0° and 4°C. After removal of adhering 
blood, connective tissue and fat, tissues w e re  washed with i c e  cold 
saline (0*9$ NaCl w/v), blotted d ry  and w e ig h ed  p r i o r  to  subsequent 
work-up. Where only the liver was removed the process was the same, 
apart from initial transfer of the tissue from the animal i n t o  ic e  c o ld  
aq. KC1 (1.15$ w/v), No su b seq u en t s a l in e  wash was r e q u i r e d .  All 
further procedures were conducted at 0-4°C.
Livers were homogenised in 2.5 volumes (approx) of 1.15$ aq* KCl 
using 3 return strokes of a Potter-Elvehjem glass and teflon homogeniser, 
driven at 2950 r.p.m. The resultant suspension %/as spun at 10,000 g
0V
(15,000 gQv in the diurnal rhythm experiments) for 20 minutes at 4°C 
in an M.S.E. High Speed IB centrifuge with an 8 x 50 ml rotor. The 
supernatant was decanted and recentrifuged at 105,000 ggv for 1 hour 
at 4°C (8 x 25 ml rotor in an M.S.E. Superspeed 50 centrifuge). The 
supernatant was discarded and the remaining microsomal pellet %/as 
resuspended in aq. KC1 (1.15$ w/v) such that the microsomes from Ig 
%/et %/eight of liver %/ere taken up into 4 ml (25$ suspension). Where 
%/ashed microsomes were required, the microsomal pellet %/as resuspended 
in aq. KC1 (1.15$ w /v )  and a further spin at 105,000 gQv %/as effected.
The resultant pellet %/as then resuspended in 0.1M phosphate buffer, pH 7.4
containing 30$ (v/v) glycerol, such that the microsomes from lg wet 
%/eight of liver %/ere taken up into 1.5 ml (67$ suspension).
2.7.2 Urine and faeces collection.
The collection of urine and faeces after administration of the 
radioactive steroids %/as made in metabolism cages (jencons Ltd., Hemel 
Hempstead, Herts., or made in our workshop). Both types provided 
satisfactory separation of urine and faeces. Animals were allo%/ed 
at least 24 hours acclimatisation to the cages before the experiment 
commenced. Urine %/as collected under toluene to limit bacterial 
contamination and deep frozen before processing, if necessary.
2.7.3 Biliary cannulatlon and bile collection.
Approximately 1 hour prior to surgery*' rats were injected
subcutaneously %/ith urethane (l.75g/&g) interscapularly. Short 
exposure to diethyl ether rapidly achieved complete anaesthesia, if 
necessary. After thorough bathing of the necessary area %/ith Wescodyne 
iodophor (Bengue & Co. Ltd., Wembley, Middlesex), a two inch mid-ventral 
line incision %/as made posteriorly from the position of the xiphoid 
cartilage, through both skin and body %/all. The common bile duct %/as 
located, cleared of its connective tissue %/ith blunt forceps and very 
loosely ligated at positions anterior and posterior to the area of 
intended incision. Using a pair of small sharp iris scissors a 
v-shaped cut %/as made in the duct bet%/een the ligations, and the 
slightly tapered end of a t%/elve inch long piece of cannula tubing 
%/as inserted. Both ligatures were then tightened to hold the cannula 
firmly in position. Using a %/ide~bore hypodermic needle to facilitate 
the process, the cannula %/as passed through both layers of the abdominal
wall, (if necessary, it was manipulated until bile could be seen to 
be freely running.) The incision was then closed using suture thread 
for the body wall, and suture clips for the skin, The entire process 
could be completed in 20 minutes*
Administration of steroid was made only after completion of the 
- cannulation procedure. Where the intravenous route was .employed 
injection was made into the right jugular vein, which had been exposed 
with a small ventral incision.
Bile was collected at half-hourly intervals in weighed vessels.
The volume of bile %/as determined by mass difference (Harper, 19^ 9)* 
High standards of surgical cleanliness %/ere observed at all times.
2.8 ANALYTICAL TECHNIQUES.
2.8.1 Estimation of protein.
The method %/as essentially that of Lowry et al (l95l)* Suspensions 
of biological material %/ere diluted in 0.5M NaOH* Aliquots of these 
%/ere transferred to test tubus, made to 0.5ml %/ith 0.5M NaOH and 5ml 
of copper reagent %/ere added* This comprised I $ (u/v) aq. CuSO^ ,
2$ (w/v) aq. sodium - potassium tartrate and 2$ (%//v) aq. Na^CCU, 
mixed in proportions of Is it100 respectively* Tubes %/ere shaken on 
a V/hirlimixer (Fisons Scientific Apparatus Ltd., Loughborough, 
Leicestershire) and left for 10 minutes. Folin-Ciocnlteou phenol 
reagent (0.5ml), diluted 1:3 %/ith %/ater, %/as then added to each tube, 
with immediate shaking,'
Standards of bovine serum albumin ranging from 50-2Q0pg (over 
%/kick range a linear relationship %/ith chromogen intensity existed) 
were taken through the same procedure, as %/ere MaOII blanks.
Colour development occurred over 30 minutes, after which time 
the dark blue chromogen %/as read against %/a ter at 720 tm in a Cecil 
CE 272 linear readout u.v, spectrophotometer* Cuvettes of 1cm light 
path %/ere used in this and all spectrophotometric %/ork.
2,8.2 Estimation of D M . ■
Hepatic D M  %/as determined by an adaption of the Monro and 
Fleck (1966) modification of the original method (Schneider, 1945)*
The 15,000 pellet %/as resusponded in aq. KOI (1*15$) to give a 
33$ suspension* A 2ml volume of this suspension %/as diluted %/ith 
10ml of 5$ (v/v) perchloric acid and left at 0°C for 5 minutes. The 
mixture %/as centrifuged in a •Piccolo* (Griffin and George Ltd., 
Wembley, Middlesex) bench centrifuge for 10 minutes at full speed, 
and the resultant pellet was resuspended in 10ml of 2$ perchloric 
acid and re centrifuged* Two similar perchloric acid %/ashes followed. 
The final pellet %/as resuspended in 3ml 5$ perchloric acid and 
extracted for 20 minutes at 80^ €. [After cooling, the tube %/as 
centrifuged and the supernatant carefully decanted and retained.
i ■
This extraction procedure %/as repeated and the resulting supernatant 
%/as pooled %/ith that obtained initially. Aliquots (1.2ml) of the 
extract %/ere mixed %/ith 2.4ml of 1.5$ (w/v) aq* diphenylamine and 
1*5$ (v/v) HgSO^ in glacial acetic acid* After storage in the dark 
for 48 hours, the blue chromogen %/as read against 5$ perchloric acid 
at 660nm in a Cecil 272 spectrophotometer.
The D M  standard %/as prepared by extraction of 5ml of a Img/ral 
D M  solution in 5$ perchloric acid at 80 C for 20 minutes. This 
standard %/as assayed %/ith the diphenylamine reagent as described above 
after making 0 ten-fold dilution %/ith 5$ perchloric acid.
Aliquots of the DNA standard %/ere diluted to 4 ml %/ith %/ater and asseyed 
for phosphorus (P) content by the method of Chen et al (1956). A 4 ml 
volume of colour reagent (12M H^ SO ,^ 10$ (%//v) aq. ammonium molybdate,
10$ (w/v) aq. rscorbic acid, and %/ater, freshly mixed in a l:l:i:2 ratio) 
was added, mixed and incubated for 24 hours at 37°C. When cool, the dark 
blue chromogen %/as estimated at 820nm in a Cecil 272 spectrophotometer. 
Standards in the range 0.025-0.5pg atoms P were prepared from a stock 
solution of potassium dihydrogen phosphate (Ah) containing perchloric 
acid and taken through the same procedure.
By estimation of the P content of the DNA commercial standard, any 
impurities in it are accounted for, and the unknown samples compared to 
the standard by means of the diphenylamine reaction. The DNA content 
is expressed as pg atoms DNA phosphorus per gram wet %/eight liver.
2.8.3 Estimation of corticosteroids.
a) By the absorption of 240mm light.
The characteristic intense absorption of short %/avelength light by 
ethanolic solutions of the corticosteroids arises from the presence of 
theA^-3-keto configuration (See Chapter 1). A linear relationship exists 
between the absorption at 240nm, and mass, over the range 5-250pg 
corticosterone. This relationship is similar for all glucocorticoids 
containing theA^-3-keto configuration, and also for those %/here an
I
additional double bond is present in ring A. .(* )• The non-specificity 
of the method, particularly %/ith regard to other steroid hormones, makes 
it unsuitable for routine determination of any samples which are not 
%/ell purified.
b) By the Tetrazolium Blue reaction (Recknagel and Litteria, 1956).
The ctr-keto-alcohol moiety of the corticosteroid side chain (See Chapter 1)
imparts reductive powers to the molecule. Reduction of tetrazolium 
salts by corticosteroids in alkaline conditions produces coloured,
%/ater insoluble, formazons %/ith high extinction coefficients. When 
corticosterone, in ethanol, is treated %/ith tetrazolium blue, a pink 
diformazan is produced %/ith an absorption maximum around 515nm. The 
relationship between the intensity of the diformazan and the amount of 
corticosteroid is linear between 5 and 200jig for the free alcohols and 
21-acetates of corticosterone, betamethasone, 6p-hydroxybetamethasone 
and dexamethasone* Colour development is maximal after 30 minutes for 
corticosterone, and after longer periods for other steroids studied.
The ability of several other compounds, including fructose, to similarly 
react %/ith tetrazolium blue has been described (Mader and Buck, 1952).
The reaction mixture comprised:
0.5 ml steroid in ethanol.
0.5 ml, 0.06m NaOH in ethanol.
2 ml tetrazolium blue in ethanol (0.25mg/ml),
Note: Absolute ethanol (99.9$)wes used in all cases. Although the 
solution of tetrazolium blue %/as facilitated by the use of methanol, 
this solvent inhibited colour development.
c) By the Porter-Silber reaction (Porter and Silber, 1950).
A minor adaptation of the original method, %/hich is specific for 
17,21-dihydroxy-20-ketosteroids, %/as used. Some cross-reactivity %/ith 
other reducing compounds eg. fructose exists.
The reaction mixture comprised;
0.5 ml methanolic steroid solution.
3 ml phenylhydrazine solution in H^SO^.
The latter %/as freshly prepared by dissolution of 65mg phenylhydrazine
hydrochloride in 100 ml of 11.6m H^SG^. Maximal colour development was 
attained by heating all tubes at 60°C for 1 hour and leaving for 16 hours 
at room temperature. The yellow chromogen was read at 4l0nm in a Cecil 
272 spectrophotometer, with a blank containing no steroid. A linear 
relationship between colour intensity and amount of steroid was observed 
over the range 10-50pg betamethasone*
d) By a fluorescence method.
The method used was adapted from those described by Braunsberg 
and James, (i960, 1962), Mattingley, (1962) and Sammons et al (1969). It 
was suitable only for determination of cortisol and corticosterone.
Plasma was obtained from heparinised blood by centrifugation on 
a Piccolo centrifuge for 10 minutes at top speed. Where necessary, 
it was stored at 2°C before assay. Plasma (1 ml) was extracted with 
10 ml chloroform (AR) for 10 minutes on a rotary shaker at room 
temperature. After centrifugation (MSE Mistral 6h at 2,000 r.p.m. 
for 5 minutes), the upper layer was removed by aspiration and the 
chloroform extract was washed with 1 ml of O.IM NaOH (prepared in 
double deionised water). This procedure ensures removal of bilirubin 
which may interfere -with the estimation (Sammons et al, 1969). After 
shaking for 15 seconds on a Whirlimixer, the tubes were immediately 
centrifuged and the NaOH removed by aspiration (cortisol is labile in 
alkaline solutions). The washed chloroform extract -(-5 ml) was transferred 
to a clean stoppered tube and 2 ml of freshly prepared fluorescence reagent 
was added (3 parts HgSO ,^ sp.gr. 1.84 to 1 part absolute ethanol).
The tubes were shaken for 15 seconds and after a further 2 minutes the 
upper phase was removed by aspiration. Exactly 6 minutes afit^ addition 
of the fluorescence reagent the emission at 522nm was measured using an
excitation wavelength of 469nm. (Perkin Elmer Fluorescence 
Spectrophotometer, MEF-3)*
Cortisol and corticosterone standards (10, 20, and 30(jg/l00ml 
double deionised water) and a water blank were taken through the 
same procedure.
2.8.4 Steroid derivative formation.
a) Acetylation of hydroxyl groups*
Steroid solutions were evaporated to dryness under oxygen-free 
nitrogen. After thorough dissolution in 5 drops pyridine (redistilled), 
5 drops acetic anhydride (redistilled) were added and the solution was 
mixed and left in the dark at room temperature for 16 hours. Absolute 
ethanol (lml) was then added and the solvent evaporated to dryness 
under nitrogen. If the characteristic smell of pyridine remained, 
more ethanol was added and evaporated*
Glucocorticoids are characteristically acetylated at but 
6p-acetoxy derivatives have also been identified.
b) Acetate hydrolysis.
The dry steroid was dissolved in methanol (lml) and 0.25ml 
aq. KgCO^ (2^  w/v) was added and mixed. After leaving for 16 hours 
at room temperature, or at 30°C, 3ml of water were added and the 
hydrolysed steroid extracted in ethyl acetate (3ml). The extraction 
was repeated twice and the extracts pooled.
c) Eeduction of koto groups (Norymberslci and Woods, 1955).
Although the reaction described may be generally used for steroid
j| |
keto group reduction, the presence of A. (and & 91) and use of the
conditions described, reverses the preferential reduction at to C q^.
Ice cold methanol (10ml) was added to sodium borohydride (5mg) in 
the cold. After dissolution, a 0.2ml aliquot was added to the steroid 
in a cold stoppered tube, and the tube was capped and left for 15 
minutes at 0°C. Serial additions of glacial acetic acid (l drop) and 
water (lml) followed, and the reduced steroid was extracted into ethyl 
acetate (lml x 3).
d) Oxidation of the 11-hydroxy group (Lieberman et al, 1953).
The free steroid was dissolved in glacial acetic acid (lml) and 
2$ (w/v) aq. chromium trioxide was added (0.6 volumes). The tube was 
stoppered, shaken gently and left in the dark for 20 minutes. After 
dilution with water (5 volumes), the solution was extracted with ethyl 
acetate (3x1 volume), the organic phases pooled, and washed with 
aq, NaHCO^ (0.1 volume, 2$ w/v) and water (0.1 volume).
e) Oxidation of the corticosteroid (L- side chain (Zaffaroni and 
Burton, 1951). '
Periodic acid solution (0.5ml of Ag HI0^.2H20 in 100ml 0.4M H^SO^) 
was added to 0.5ml of the methanolic steroid solution. After leaving for 
16 hours, methanol (2ml) and concentrated ammonia solution (sp.gr. 0.88, 
0.1ml) was added. After centrifugation and decantation of the 
supernatant, the precipitate was washed with methanol and the supernatant 
combined with that obtained in the first step.
2.8.5 Fractionation of steroids from urine and bile,
a) Free steroids.
Bile was diluted with water and the pH adjusted to 7.0 where 
necessary. Urine was similarly adjusted to pH 7.0 after removal of
its overlying toluene by evaporation under nitrogen. Ethyl acetate 
(2 volumes) was then added to the neutral solutions in stoppered tubes. 
The contents were mixed for several minutes on a rotary shaker and the 
phases separated by centrifugation. (MSE Mistral 6l). The upper 
(ethyl acetate) layer was removed by aspiration and retained. Two 
further extractions followed (ethyl acetate, 1 volume) and the organic 
extracts were pooled and the volume adjusted to 10ml with ethyl acetate 
or by evaporation under nitrogen. Aliquots of this fraction, the non­
conjugated or ’free1 steroid fraction, were taken for radioactivity 
determination. Where necessary, the fraction was cleaned by washing 
with 0.1M NaOH (0,1 volume) for 15 seconds, centrifuging, aspirating 
off the aqueous layer, and recounting. The ethyl acetate was evaporated 
under nitrogen and prepared for t.l*c.
b) Steroid glucurohfdes.
Two methods were used for isolation of steroid conjugates. In 
the first, samples were extracted 3 times at pH 2.0 with two volumes 
of a 3sl mixture of diethyl ether/ethanol (99*9$) and the fraction 
reconstituted with acetate buffer (pH 5.0) and then hydrolysed.
Hydrolysis was effected using j3-glucuronidase (300 Fishman units 
per ml original urine) which was added in the acetate buffer. Incubation 
was allowed to proceed for 16 hours at 37°C with an overlying toluene 
layer in stoppered tubes. Liberated steroids were extracted with ethyl 
acetate (l x 2 volumes, then 2 x 1  volume), and the extracts pooled, and 
made to 10ml as described previously. After removing aliquots for 
counting, the organic layer was washed with NgOH (0.1M, 0.1 volume) 
and water (0.1 volume), and evaporated under nitrogen in preparation 
for t.l.c.
c) Steroid sulphates.
Steroid sulphates were hydrolysed by chemical or by a combination 
of enzymic and chemical methods. Treatment by the second procedure did 
not improve the overall yield.
Enzymic hydrolysis was effected at 37°C for 16 hours using 
sulphatase (100 units per ml original urine). Acetate buffer 
(0.1M, pH 5.6) was used as the incubation medium.
Chemical solvolysis was undertaken using the method of Burstein 
and Lieberman (1958). The aqueous phase was made 20$ with respect to 
NaCl and the pH adjusted to 1.0 using HgSO^ (2M). After extraction with 
ethyl acetate (l volume), the organic phase was counted and incubated 
for 16 hours at 37°C in stoppered tubes. The extract was finally 
washed with NaOH (0.1M, 0.1 volume) and water (0.1 volume), and 
recounted. Evaporation under nitrogen was the final stage before t.l.c.
d) Non-extractable steroids.
The aqueous phase remaining after the extraction procedure 
described above was termed the •non-extractable steroid* fraction.
Its constituent steroids were probably in the form of complex 
glucuronides and sulphates not liberated by hydrolysis. After counting, 
this fraction was not further processed.
2.8.6 Thin Layer Chromatography (t.l.c.)
a) T.l.c. Plates.
Pre-made plates (silica gel 60 E. Merck AG, Darmstadt), or
plates prepared in an *automatic level-seating* plate spreader 
(Quickfit Instrumentation Ltd.) using 30g kieselgel nach stahl
(E. Merck AG, Darmstadt) and 68ml water were used. Both types of 
plate were 0.25mm in thickness, and 20cm by 20cm in dimension.
b) Method of steroid application.
The dried steroid was initially dissolved in 6 drops absolute 
ethanol and transferred to the plate using a pasteur pipette drawn 
out in a bunsen flame. Three further washings with ethanol (6 drops) 
ensured quantitative transfer to the plate (99$+).
Test solutions were applied as streaks, with reference steroids 
as spots applied to the centre of the plate.
c) Solvent systems.
150ml of all solvent systems were used. These were freshly 
prepared at least once daily and allowed to equilibrate for at least 
30 minutes in covered glass tanks lined with chromatography paper.
Solvent systems used were (v/v)s
I Chloroform/dichloromethane/ethanol (80/l0/i0)
II Dichloromethane/ethonol/ethul acetate (35/10/55)
III Chloroform/methanol/water (185/15/1)
IV Chloroform/glacial acetic acid (80/20)
V Acetone/diehloromethane (20/80)
VI Chloroform/ethanol (80/20)
VII Acetone/chloroform (80/20)
VIII Chloroform/ethanol (70/30)
d) Steroid visualisation and radioactivity distribution.
The presence of the fluorescence binder in all types of plates 
assisted localisation of steroids absorbing the light emitted by a 
single wavelength (254nm) portable u*v* lamp (Hanovia Ltd., Slough, Bucks). 
Steroids standards which did not absorb short wavelength light were 
detected by spraying the standard area (only) with alkaline 
permanganate solution* Steroids present in the test samples were
presumed to co-chromatograph with the relevant standards.
The qualitative distribution of radioactivity on the plate was 
examined using a Berthoid Thin Layer Scanner II, LB2723 in conjunction 
with the corresponding ratemeter LB2031. Carrier gas was argon/ 
methan«(90/10).
e) Extraction of steroids from plates.
After localisation, the areas of the plate required were scraped 
onto weighing paper using a razor blade or microscope slide. The gel 
was then transferred to stoppered tubes. Methanol (3ml) was added and 
the tubes were capped and shaken for several minutes on a rotary shaker. 
After centrifugation, (MSE Mistral 6l) the methanol was decanted into 
a 10ml graduated stoppered tube. Two further methanolic extractions (3ml) 
followed and the extracts were pooled and diluted to 10ml with methanol. 
Aliquots were removed for counting.
Total recoveries, in the order of 95$ for*self-made* plates and 
85$ for pre-coated plates, were maximal for the type of plate used. 
Methanol was more suitable for extraction than either dichloromethane 
0? ethyl acetate.
2.8.7 Preparation of tissues for radioactivity determinations.
The digestive procedure of Mahin and Lofberg (1966) was used.
Known amounts of homogenised tissue or heparinised blood were 
transferred to low potassium glass scintillation vials. Perchloric 
acid (0.3ml, 60$) was added and the viols were shaken and left to 
stand for 10 minutes. Hydrogen peroxide (0.6ml, 30$, 100 volumes) 
was then added and the vials were sealed with polythene inserts 
(international Bottle Company, Ltd., London) and screw caps. They 
were then transferred to an oven at 70°C and heated for 90 minutes,
during which time the caps were tightened. After cooling, 15ml 
scintillator (See 2,8.8) was added and, the vials thoroughly shaken 
before counting.
2.8.8 Liquid scintillation counting.
All determinations were made in a Packard Tri-Carb Liquid
Scintillation Spectrometer, model 3320, in conjunction with a
Teletype print-out. Counting efficiencies were determined by the
3
internal standardisation procedure, using H-toluene.
Samples dissolved in organic solvents were determined using 10ml 
scintillation mixture containing 4g PPO and 0.2g dimethyl P0F0P per 
litre of toluene (sulphur free). Gain settings were optimal for 
tritium at 45$ and windows were fully open. (0.4-10.0 volts).
Aqueous samples were counted using 15ml of the mixture, 6g PPO 
per litre toluene/2-ethoxyethanol (both scintillation grade and in 
proportions of 2/l). Optimal gain settings for tritium were 80$ and 
windows were fully open.
The problems in phase separation encountered with this scintillator 
led to its being superceded by the Toluene/Triton system, which had a 
far greater capacity for water. This comprised 5*5g PPO per litre of 
sulphur free toluene/Triton X-100 (2/l). Optimal gain settings for 
tritium were determined as 60$ with fully open window settings.
2.8.9 Statistics.
Where multiple determinations of a parameter were made, the result 
was expressed as the arithmetic mean and standard error from this 
mean (S.E.M.). Comparison of two groups to establish their significant 
difference was accomplished usiiqf Students* t-test.
The ’best fit’ of a line to a set of points obtained in kinetic 
experiments was determined using an Olivetti programme 101 to perform 
linear regression analysis. In the diurnal rhythm experiments,
Lineweaver-Burk plots (Lineweaver and Burk, 1934) were fitted to the 
data obtained using a weighted regression programme (Wilkinson, 1961). 
An Algol computer programme was kindly supplied by Dr. M.R. Kibby 
(University of Strathclyde) for the University of Surrey ICL 1905 S 
computer.
2.9 STUDIES WITH LIVER MICROSOMES.
2.9*1 Determinations of hepatic cytochromes,
a) Cytochrome bp.
This was determined using a minor modification of the method of 
Klingeriberg (1958). A 25$ microsomal suspension (l volume) was diluted 
with 0.1M phosphate buffer, pH 7.4 (2 volumes). The diluted suspension 
(3ml of 8.3$) was transferred to both of two glass cuvettes. One of 
these was placed in the reference beam of a Pye Unicam SP 1800 dual 
jfrteam recording spectrophotometer. A small amount (500 ;og) of solid 
NADH was added to the other cuvette, which was then shaken and placed 
in the sample beam position. The absorption difference spectrum 
between oxidised and reduced forms of the cytochrome was measured 
between 390 and 500nm.
The difference in optical density between the peak at 425nm and 
the trough at 410nm is used to calculate the amount of cytochrome b^ 
present, assuming a mM extinction coefficient of 171.
(
b) Cytochrome P-450.
In routine investigations the method employed was that of 
Omura and Sato (1964a), using carbon monoxide as ligand. The 
microsomal suspension (3ml diluted to 8.3$ with buffer as above) 
was pipetted into both of two glass cuvettes. A small amount of 
solid sodium dithionite (500{jg) was added to both, and the reference 
cuvette was placed in the SP 1800 spectrophotometer. Carbon monoxide 
was gently bubbled through the sample cuvette for 30 seconds and it 
was then positioned in the sample beam. The absorption difference 
spectrum over the range 390 to 500nm was recorded, and the amount of 
cytochrome P-450 present calculated from the difference in optical 
density between the peak at 450nm and the baseline at 490nm. A mM 
extinction coefficient of 9i was assumed in the calculation.
The method of Omura and Sato (1964b) was used for the determination 
of cytochrome P-450 in reduced microsomes, with ethyl isocyanide os 
ligand. Two 2.5ml aliquots of diluted buffered microsomes (8.3$ suspension) 
were reduced by sodium dithionite as described above. Ethyl isocyenide 
(50fil of 50mM aq. solution) was added to the sample cuvette and the 
absorption difference spectrum between 390 and 510nm was recorded using 
an SP 1800 spectrophotometer. The differences in optical densities of 
the two peaks at 430 and 455nm, and that of the baseline at 500nm, were 
calculated. The significance of the two peaks is discussed by Sladek 
and Mannering (1966).
c) NADPH-cytochrome c reductase.
The method used is derived from that of Gigon et al (1969) with 
modifications introduced by Gray (1974).
The incubation mixture was prepared at room temperature and 
comprised the following reagents: 3mM potassium cyanide;
1.15$ (w/v) KCL/0.02M Tris-HCl, pH 7.4; cytochrome c (1.85 mg/ml);
7.5 iriM NADPH (in buffer). These were dispensed into two glass cuvettes 
(as shown below). Microsomes were used as a 25$ ice-cold suspension.
Reagent Addition (ml) to
Reference Cuvette Sample Cuvette
KCl/Tris-HCl buffer 
Potassium cyanide
0.7
1.0
0.5
1.0
Cytochrome c 1.0 1.0
Microsomes 0.1 0.1
Reaction was initiated by the rapid addition of 0.2 ml NADPH to 
the sample cuvette* The reduction of cytochrome c was monitored at 
550nm in an SP 1800 spectrophotometer, and was manifest by a linear 
increase in optical density. A mmol extinction coefficient of 27.7 
was used in the calculation.
2.9.2 Drug metabolism enzyme assays.
The enzyme substrates used can be categorised by the type of 
difference spectra they produce (2.9.4). They were biphenyl and 
ethylmorphine (Type I), aniline and 4-chloro-N-methylaniline (Type II) 
and the carcinogen benzo[a]pyrene (also Type I).
In all the microsomal drug metabolism assays described below, the 
provision of a system for production of NADPH was necessary. Mixed- 
function oxygenation proceeds as follows:
Substrate + NADPH + 0( cytochrome oxidised substrate + NADPo ■  .....   ■.- ...... ►
z P-450
The in vitro NADPH generating system used always comprised 
(final amounts in the assay) 1.75 {jmol NADP, 15 pmol isocitric acid,
10 pmol magnesium sulphate and0.5 units isocitrate dehydrogenase. 
Dissolution was made in the buffer used in the particular assay and 
the entire mixture is referred to as the ’ccfactor solution*.
A 25$ microsomal suspension in 1.15$ (w/v) KC1 and containing 
between.4 and 8 mg microsomal protein Tinas used in all assays. The 
assay mixtures were constituted and maintained on ice before incubation, 
which was conducted in an atmosphere of air. Tubes were shaken at 100 
cycles per minute and at a temperature of 37°C in a thermostatically 
controlled shaking water bath. Every sample determination was made in 
duplicate; blanks and standards were xn duplicate or triplicate. A 
linear relationship with amounts of product existed for all the chromogens 
prepared, at least up to an optical density of 1.0. Fluorescence of the 
products of biphenyl was also linearly related to their amounts over at 
least twice the range of values obtained in the assay.
a) Biphenyl 2- and 4- hydroxylases.
The different fluorescent properties of the 4-hydroxy-(major) and 
2-hydroxy-(minor) biphenyl metabolites makes their detection possible 
in the same extract after microsomal hydroxylation of the parent 
hydrocarbon. A slightly modified version of the method originally 
described (Creaven et al, 1965) was used.
All sample tubes contained (final amounts in the assay) 80 pmol 
phosphate buffer (pH 7.6), 7.5 (jmol biphenyl in 1.15$ aq. KC1 (w/v)/4$ 
Tween 80 (w/v), and cofactor solution (described previously). After 
final addition of 0.2 ml microsomal suspension, the tubes were 
transferred to a water bath and incubated for ten minutes. The 
reaction was terminated by addition of 0.5 ml HC1 (4M). Substrate 
and 0.4 ml of the 2- and 4-hydroxybiphenyl standards were then added
to those tubes which had been taken through the assay, in the absence 
of substrate, as blanks and standards. (Standards were 5$ aqueous 
ethanolic solutions containing 12.2 ug/ml 2-hydroxy biphenyl and 
1? ug/ml 4-hydroxy biphenyl).
After addition of 7 ml n-heptane containing 1.5$ (v/v) isoamyl 
alcohol, the tubes were capped, mixed for ten minutes on a rotary 
shaker, and centrifuged (2,000 r.p.m. at 4°C for 10 minutes on a 
Mistral 6b). The upper (heptane) layer (2 ml) was transferred to 
clean tubes and after addition of 5 ml NaOH (O.IM), the tubes were 
capped, shaken and centrifuged as before. The upper layer and fluffy 
interphase were carefully aspirated off and the fluorescence determined 
at pH 6.0 by addition of 0.5 ml succinic acid (0.5M) to 2 ml of the 
aqueous layer. The activation and emission wavelengths of 
4-hydroxybiphenyl were 275nm aud 331nm respectively and those of
2-hydroxybiphenyl 295nm and 4llnm. A Perkin-Elmer MPF-3 fluorimeter 
was used.
As the presence of 4-hydroxybiphenyl interferes with the 
estimation of the 2-hydroxy metabolite, a correction factor must be 
introduced.
Interference due to 4-hydroxybiphenyl (Y) «
pg 4-0H x (test-blank) reading of 4-OH standard at 411nm 
concentration of 4-OH biphenyl in standard
If the 2-OH fluorescence (as read) <= X, then:
(X-Y) *= true fluorescence reading for 2-hydroxybiphenyl.
Calculation of nmol of both metabolites formed per unit time 
per unit protein can then be made conventionally. (The mol. wt. of 
both hydroxybiphenyls is 170.2).
Noises The conditions used in kinetic ^ experiments in which biphenyl 
was substrate are described in the relevant experimental chapters.
b) Aniline-4-hydroxylase.
The method used to detect the formation of 4-aminophenol, the 
major metabolic product of aniline hydroxylation, was modified from 
that of Guarino et al, 1969a.
All sample tubes contained (final amounts in the assay) 210 pmol 
Tris-HCl buffer (ph 7.4), 20 pmol aniline hydrochloride (adjusted to 
pH 7.0), and cofactor solution (described previously). The reaction 
was initiated by addition of 0.3 ml microsomal suspension and transfer 
from ice to the incubation bath. After fifteen minutes the reaction 
was stopped by plunging the tubes into ice and adding NaCl («.lg). 
Substrate and standard (4-aminophenol, 0.05 pmol) were added to those 
tubes taken through the assay, in the absence of substrate, as blanks 
and standards.
Diethyl ether (10 ml) containing 1.5$ (v/v) isoamyl alcohol was 
added to all tubes and they were capped, mixed for 30 minutes on a 
rotary shaker, and centrifuged (Mistral 6L: 4°C, 2,000 r.p.m. for
10 minutes). The ether layer (7 ml) was transferred to clean tubes 
and after addition of 4 ml tripotassium phospate (0.5M) containing 1$ 
phenol (w/v), the tubes were capped and shaken for 10 minutes. One 
hour later the aqueous solution was transferred to glass cuvettes 
using a pasteur pipette (the overlying ether stabilises the chromogen) 
and read at 620nm in a Cecil 272 spectrophotometer. Calculation of 
the amounts of 4-aminophenol produced during the assay were readily 
determined by comparison with the standard.
Notes The conditions used in kinetic experiments in which ainiline
was substrate are described in the relev* _^t experimental chapters.
c) Benzo[a]pyrene hydroxylase.
3-Hydroxybenzpyrene is one of the fluorescent products of microsomal 
hydroxylation of the parent polycyclic hydrocarbon, benzo[a]pyrene 
(Conney et al, 1957). The identical fluorescent properties of these 
metabolites makes individual determinations impossible. Consequently 
enzymic activity represents the hydroxylation of benzo[a]pyrene to a 
number of inseparable metabolites which are measured together and 
represented as nmol equivalents of 3-hyroxybenzpyrene by the method of 
Kuntzman et al, (1966).
Because of the photosensitive nature of the metabolites, the 
incubation and extraction procedure was performed in the dark, where 
possible. The incubation mixture comprised (final amounts in the assay) 
120 pmol phosphate buffer (pH 7.^ )* 0.2 pmol benzo[a]pyrene (in 0.1 ml 
acetone) and cofactor solution (described previously). Reaction was 
initiated by addition of 0.2 ml microsomal suspension and transfer of 
the incubation mixture to a water bath. Ten minutes later it was 
terminated by plunging the tubes into ice and adding acetone ( 2 ml). 
Substrate was added to the blank, which had been incubated in its 
absence, and n-hexane ( 3 ml) was then dispensed into all tubes.
The tube contents were mixed for 20 minutes on a rotary shaker and 
4 ml of the hexane layer was transferred to clean tubes. After the 
addition of 5 ial of NaOH (M), the tubes were capped, shaken for 2 minutes, 
centrifuged (Mistral 6L; 4°C, 2,000 r.p.m. for 5 minutes) and the upper
layer removed by aspiration* Using an excitation -wavelength of 382nm, 
the emission at 510nm was read immediately on a Perkin Elmer MFF-3 
fluorimeter.
In the absence of any standard, a constant extraction of 67$ was 
assumed and daily fluctuations in fluorimeter performance were checked 
using a quinine sulphate standard (0.5 ml stock solution of quinine 
sulphate, 336 pg/ml, was added to 4.5 ml H S^O^ , 0.05M and read at 340nm 
excitation and 445nm emission). This standard gave a fluorescent reading 
equivalent to 0.01412 nmol 3-hydroxybenzpyrene per ml, and the amount of 
product formed could, therefore, be determined.
d) Ethyl morphine-N-demethylase.
Oxidative removal of an angular methyl group is another 
characteristic reaction of the mixed-function oxygenase system. Details 
of the mechanisms involved in the enzymic demethylation of ethyl morphine 
are given by Parke (1968). The method used in the present study is 
modified from that described by Holtzman et al (1968).
All sample tubes contained (final amounts in the assay) 270 pmol 
Tris-HCl buffer (pH 7.4), 10 jjmol ethyl morphine in 1.15$ (w/v)KCl,
0.2 ml semicarbazide (2$ (w/v) aqueous solution adjusted to pH 7.0) and 
cofactor solution (described previously). The semicarbazide was present 
os a chemical trapping agent for the formaldehyde released in the oxidative 
process. Reaction was initiated by addition of 0.2 ml microsomal suspension 
and transfer to a water bath. The ten minute incubation was terminated 
by plunging the tubes into ice and adding 1 ml aq. ZnSO^  (15$ w/v).
Substrate and standard (0.3 pmol formaldehyde) was added to those tubes 
taken through the assay, in the absence of substrate, as blanks and 
standards.
After addition of 1 ml saturated aqueous barium hydroxide (to remove 
sulphate anions which interfere with the subsequent reaction), the pellet 
liras compacted by centrifugation (Mistral 6Lj 4°C, 2,000 r.p.m. for 15
minutes). The supernatant (2 ml) was transferred to clean tubes, 2 ml 
of freshly prepared Nash reagent (0.4$ (v/v) acetylacetone in 4M ammonium 
acetate) was added and the tubes were incubated at 37°C for 40 minutes 
(Nash, I953). After cooling, the pale yellow chromogen was read at 
420nm in a Cecil 272 spectrophotometer. Calculation of the amounts of 
formaldehyde released from the samples could be readily determined by 
comparision with the standard.
e) 4-Chloro-N-methylaniline-N-demethylase.
Whereas the demethylation of ethyl morphine was quantitatively 
determined by measurement of the released formaldehyde, that of 
4-chloro-N-methylaniline is assayed by determination of the product,
4-chloroaniline• The method used was that of Kupfer and Bruggeman (1966), 
with some modifications.
The incubation mixture comprised (final amounts in the assay)
120 (jmol phosphate buffer (pH 7.4), 3.75 pmol 4-chloro-g-methylaniline 
in buffer, and cofactor solution (described previously). After addition 
of 0.2 ml microsomal suspension, tubes were transferred to a water bath 
and incubated for 10 minutes. Reaction was terminated by plunging the 
tubes into boiling water for 5 minutes. This was I found to have no 
effect on subsequent colour development and assisted in precipation of 
enzymic protein, which was otherwise difficult to remove. Substrate and 
standard (1.8 pmol 4-chloroaniline) were added to those tubes taken through 
the assay, in the absence of substrate, as blanks and standards. After 
final addition of 3 ml 4-dimethylaminobenzaldehyde (2$ in 0.5M H^SO^) 
the tubes were left overnight and the resultant yellow chromogen read 
at 445nm in a Cecil 272 spectrophotometer.
Calculation of the 4-chloroaniline produced during the incubation 
could be readily determined by comparison with the standard.
2.9.3 Corticosteroid metabolism enzyme assay.
A rapid method for the determination of microsomal metabolism 
of corticosteroids was developed in ’which steroids were incubated with 
microsomes in the presence of NADPH. While no direct quantitative 
determination on a basis of steroid utilisation could be made, the rate 
of oxidation of NADPH could be estimated. As none of the reduced 
nucleotide disappeared in the absence of steroid, this parameter was 
a monitor of the corticosteroid metabolism occurring. No indication 
of the metabolic routes prevailing was given, however*
To both of two quartz cuvettes were added 96 pmol phosphate buffer 
(pH 7.4) and 0.2 ml microsomal suspension (2 mg microsomal protein). 
Absolute ethanol (O.l ml) was added to the reference cuvette and the 
same amount of ethanol containing 0.275 pmol corticosteroid was added to 
the sample cuvette* After mixing, both cuvettes were placed in a Pye 
Unicara SP 800 dual beam recording spectrophotometer, and allowed to 
equilibrate to 37°C in the themostatically controlled cell compartment.
The reaction was initiated by addition of 0.3 ml aqueous NADPH (2 pmol) 
to both cuvettes with rapid shaking. The decrease in absorption at 
340nm was monitored every minute using an SP 825 Programme Controller, 
and the reaction allowed to proceed for at least 20 minutes. Carbon 
mon qcide inhibition studies were conducted by bubbling the gas through 
both cuvettes for 60 seconds before temperature equilibration.
The rate of NADPH utilisation was determined over the early, linear
3part of the curve using a molar extinction coefficient of 6.22 x 10 .
2.9.4 Spectrally apparent interactions of steroids and xenobiotics with 
liver microsomes.
The demonstration that the spectral interactions of various compounds 
with microsomal haemoprotein could be classified into more than one type
was first made by Imai and Sato (1966 ) and Remmer et al (X966). Their 
work identified two distinct types of interaction which were manifest by 
two similarly different types of spectral changes. That of Type I 
compounds was characterised by a trough at 420nm and an absorption peak 
at 3S5~390nm, and that of Type II compounds by a trough at 390nm and an 
absorption peak at 430nm, Orrenius et al (1970) and Schenkman et al (1972) 
later identified a novel spectral change characterised by a trough at 
390nm and an absorption peak at 420nm. This was termed a ’Modified 
Type II’ or 'Reversed Type I' spectrum. The implications of the various 
types of difference spectra have been discussed elsewhere (Schenkman, 197o)*
In the present study, difference spectra for a number of compounds 
were determined by the following method. The ranges of substrate 
concentration used are described in the relevant experimental chapters.
Microsomal suspension (2.5 ml) containing 2-3 mg microsomal protein 
was pipetted into l&bth of two stoppered glass cuvettes* These were 
sealed with ’Subaseal* stoppers (Gallenkamp Ltd., London) and placed in 
the reference and sample beams of a Perkin Elmer 356 dual beam* dual 
wavelength recording spectrophotometer* set in the ’split’ mode. A 
baseline was obtained by scanning over the range 350 to 500nm* Serial 
additions of microlitre quantities of concentrated solutions of the 
compound under study were made to the sample cuvette* while the same 
volume of pure solvent was added #0 the reference cuvette* After each 
addition, the cuvettes were shaken* returned to their respective positions, 
and the difference spectrum was obtained over the range 350-500nm. (The 
addition of pure solvent to the reference cuvette ensured that relative 
volume changes were eliminated).
Solvents used for dissolution were absolute ethanol and 
dimethylsulphoxide (AR). Both compounds themselves induce spectral
changes (Reversed Type l), hut addition in equal volumes to both sample 
and reference cuvettes negates any spectral effect. The possibility of 
other interactions with microsomal components cannot be discounted* 
however, and for this reason total additions were limited to 25 pi.
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5.1 INTRODUCTION.
Demonstration of the tissue and intracellular localisation of 
various steroid hormones was the first step that led to a clearer 
understanding of their physiological and biochemical effects. Thus, 
the discovery that administered oestradiol was concentrated in the 
nuclei of uterine cells (Jensen and Jacobsen, 1962) was the first 
indication that the action of oestrogens involves promotion of de novo 
protein synthesis (Mueller, 1953). While the effects of oestrogens are 
primarily exhibited at only one or two target tissues, the glucocorticoids 
produce a range of responses in a variety of different tissues (See 
Chapter I). Although this multiplicity of effects does not preclude a 
common mode of action, it indicates that no tissue would dramatically 
accumulate glucocorticoids as occurs in the case of the uterus with 
oestrogens.
Because of difficulties in determining small amounts of steroid 
hormones, and anomalies inherent in the use of large, non-physiological 
doses, satisfactory tissue distribution studies could only be conducted 
with radioactively labelled steroids of high specific activity. Several 
such studies using isotopically labelled natural glucocorticoids, usually 
in rodents, have been reported*
The tissue distribution of cortisol in rat has been examined by 
several workers, even though cortisol is not normally present in 
significant amounts in this species (Bush, 1953) and the major 
glucocorticoid of the rat, corticosterone, has been shorn to differ 
significantly from cortisol in its biochemistry (Colby & Kitay, 1972;
Ibid, Chapter 5). Although studies with cortisol are not without some 
relevance, it seems more appropriate to investigate the fate of 
corticosterone in this species.
While the qualitative picture of the variation of tissue 
distribution with time is of some interest, more useful information 
can be obtained by studying the corresponding quantitative^picture.
However, most published data on glucocorticoid distribution is concerned 
with determination at only one particular time after dosage.
Gross tissue distribution of natural glucocorticoids.
In a recent autoradiographic study, Waddell (1972) noted poor uptake
14 .of C- labelled cortisol, corticosterone and deoxycorticosterone into
foetal tissue of pregnant mice. This confirmed previous results obtained
by Hanngren et al (1964), although the latter group did show appreciable
accumulation of radioactivity in a large number of tissues including
kidney, bronchial mucosa, adrenal cortex, brown fat, pituitary gland and
parts of the eye. By far the greatest concentrations were in liver and
intestine, however, the intestine accumulating radioactivity with increasing
14 14time after the intravenous administration of C-cortisol or C-cortisone
(Hanngren et al, 1964). As the levels of radioactivity in the liver fell
as those in the gut increased, this suggested that radioactivity in the
gut was derived from hepatic metabolism and biliary excretion. This had
been previously demonstrated by Wyngaarden et al (1955) who could show
14no direct uptake of subcutaneously administered C-cortisol into the gut
of rats with cannulated or ligated bile ducts.
14Gulyassy et al (1958) conducted a study of C-cortisol distribution 
in male rats. They, too, shoY/ed massive accumulation of radioactivity in 
the liver and later in the gastrointestinal tract. In addition, they 
detected a rapid clearance of the administered steroid from the plasma 
and an equally rapid uptake by both liver and muscle. They also revealed 
a difference in distribution patterns related to the route of 
administration - intracardiac injection producing a less rapid distribution
to the peripheral tissues culminating in a more rapid overall excretion.
This was accredited to the trauma of the intracardiac injection by the 
authors.
Firschein et al (1957) used the intracardiac route to study the 
14
tissue distribution of C-cortisol after 5> 15 and 60 minutes in a large
number of tissues, and also studied the effects of stress and co-administration
of corticosterone on this distribution. As well as demonstrating a time-
dependant pattern of distribution, which varied from tissue to tissue,
these workers also showed that the effects of stress were, in some cases,
similar to those produced by co-administration of corticosterone. Despite
initially similar radioactivity levels in comparative tissues of the control,
stressed, and corticosterone ireatdd groups, the subsequent retention of
the dose by various tissues, especially muscle, was markedly increased
in the stressed and corticosterone treated animals. These results
indicated metabolic limitations in the removal of the higher circulating
levels of glucocorticoid in the two test groups and emphasised the importance
of using small doses in such studies.
While much other published work exists, it largely serves to
emphasise the complete distribution of administered corticosteroids
throughout many tissues. Thus, Schapiro and Kats (1959) demonstrated
14preferential concentration of C-cortisol in the posterior pituitary
gland of rats, guinea pigs and rabbits and Bellamy et al (1962) also 
14showed uptake of C-cortisol into pituitary gland, as well as in the
various salivary glands and the adrenal. Grosser and Reed (1972) showed
3 3specific uptake of H-cortisol and H-corticosterone into the cerebral
cortex of intact and adrenalectomised rats. Roy and Pasqualini (1972)
3
examined the distribution of H-corticosteronc in rat foetuses, and 
obtained results which were largely comparable with those obtained by
other authors in adult animals, except that the levels of radioactivity 
were lower in the intestines from foetuses than in those from mature rats. 
As only 50$ of the administered dose was recovered, the importance of this 
finding is difficult to interpret*
Gross tissue distribution of synthetic glucocorticoids.
In comparison with the endogenous corticosteroids, published work 
on the tissue distribution of their synthetic analogues is rare.
Consequently, the paper by Florini et al (1961a) describing the tissue
3distribution of intravenously injected H-triamcinolone in rats is almost 
unique. While the initial distribution of the radioactivity showed a 
general pattern similar to that obtained with cortisol and corticosterone, 
differences emerged when the distribution after longer periods was examined 
(Firschein et al, 1957; howy et al, I969)* The main distinctions were 
that the administered radioactivity remained in the skeletal muscles for 
much longer periods than with the natural glucocorticoids, and accumulated 
in the gastrointestinal tract to a lesser extent. As corticosteroids in 
the gut largely arise from their hepatic metabolism, a lower level of 
radioactivity in, or a lower metabolism by, the liver would explain these 
findings. However, the ability to maintain the initially high hepatic 
radioactivity levels, as was the case with cortisol, was also apparent in 
the triamcinolone injected rats. As the half life of triamcinolone, both 
in the liver and plasma, was considerably longer than that found with 
cortisol, this suggested a slower release of the synthetic steroid from 
the peripheral tissues,
Zimmerman & Bowen (1972) used H-triamcinolone acetonide in a maternal 
and embryonic study of tissue distribution in mice. The authors noted a 
pattern of radioactivity distribution in the pregnant females which was
generally similar to that shown by Florini et al (1961) in rats. In 
addition, they showed that radioactivity, largely as the unchanged 
compound, was present in both placentas and foetuses after 30 minutes 
and hod not been cleared even after 24 hours. Despite this, there was 
no evidence for concentration of the steroid by the foetuses.
Other published data on the fate of synthetic glucocorticoids are 
confined to human studies in which examinations of tissue distribution are 
necessarily limited. Melby & St. Gyr (1961) reported plasma half lives of 
around 200 minutes for the intramuscular^ injected 2l-phosphatos of 
prednisolone and dexasethasone. The corresponding figure for triamcinolone 
acetonido is apparently in the order of days (Kusama et al, 1971). All 
these values are in excess of those obtained using endogenous compounds - 
Peterson and Pierce (i960) gave values of 80 minutes for corticosterone 
and 110 minutes for cortisol. Similarly, Murphy et al (1964) reported a 
half life of betamethasone in saliva of 600 minutes, whereas that of 
cortisol was only 60 minutes.
Subcellular tissue distribution of glucocorticoids.
Attempts to obtain further, and more detailed, information on the
distributive fate of the glucocorticoids have been made by following their*
subcellular distribution. Although all published data concurs on the
greatest percentage of radioactivity being associated with the supernatant
fraction of tissues, the proportion of counts within each particulate
fraction varies from study to study. While the methods of preparation and
purity of the tissue subfractions are most probably responsible for this,
the origin of the tissue from which they were derived seems unimportant.
14Thus, subfractions obtained from the livers of C-cortisol injected rats 
have the same radioactivity profile as those derived from livers incubated
*11
with C-cortisol in vitro (Bellamy. 1965). Bottoms and Goetsch (1967) 
demonstrated greatest accumulation of ’n-corticoetcrone in liver nuclei, 
while BeVenuto et al (1962) showed that mitochondria were the particulate
fraction of the liver with most associated activity after injection of
14 14C-cortisol or C-corticostcrone, In comparison, Ulrich (1959) showed
highest labelling in the mierosomes after in vitro incubation of liver 
1 h
homogenate with C-cortisol* While this was in agreement with results 
obtained in vivo (Litwack et al, 1965I Morris and Romes, 196?),
Beato et al (1969a) found fractionally fewer counts off iciated with this 
fraction than with the mitochondria* In addition, Beato et al (1969a) 
determined the degree to which this radioactivity was specifically bound 
to the particles, and in a metabolieally unchanged fora.
Glucocorticoid- specif ic intro cel lularrbinding proteins *
It was Beato and his colleagues who first established that the 
unchanged fraction of administered cortisol was associated with 
ma cromolocule© in the soluble and nuclear fractions of rat liver 
(Beato et al 1969a and 19&9b respectively). They later demonstrated that 
the cytoplasmic hinder (A) was apparently responsible for transfer of 
cortisol to the cell nucleus and its associated nuclear binding protein 
(Beato et al, 1970aj 1970b5 1971). A further cytoplasmic binding 
protein (B) was identified which greatly resembled tranncortin and which 
was implicated in the transfer process (Beato et al, 1971? Beato et al, 1972b). 
The importance of the specificity of binding which the receptors demonstrate 
has been emphasised in recent papers (Beato et al 1972a; Rousseau et al 1972).
Many report© have followed substantiating those findings end 
showing the presence of glucocorticoid binding protein© or •receptors* 
in several other tissues. Most of these receptors are located in the
nucleus and cytoplasm of cells isolated from intact animals and cultured 
tissues. Much work has been done using thymocytes (Brunckhorst, 1969?
Kaiser et al, 1973, Munck and Wira, 1971? Munck et al, 1972?
Schaumberg, 1970, 1972; Van Der Meulen et al, 1972; Wira and Munck, 1970), 
but the presence of receptors has also been indicated in rabbit 
polymorphonuclear leukocytes (Simonsson, 1972), mouse fibroblasts 
(Hackney and Pratt, 1971), bovine mammary cells (Tucker Ot al 1971), 
mouse placenta (Wong and Burton, 1973), rat lens (Ono et al, 1972: 1972/3b), 
rat brain (Gerlach and McEwen, 1972; Grosser et al, 1971? McEwen et al, 1972) 
and rat skeletal muscle (Simpson and White, 1973)* Identification has also 
been made in neoplastic cells from liver (Baxter and Tomkins, 1971) and 
lymphoid tissue (Kirkpatrick et al, 1972; Bosenau et al, 1972).
The system which exists for glucocorticoid intracellular binding 
in the liver (proposed by Beato and described previously) is largely 
representative of that in other tissues. Although the characteristics of 
the macromolecules isolated vary slightly in different tissues,
(Stith and Bottoms, 1972? Kaiser et al, 1973) they generally resemble 
those of other steroid hormone receptors. Their importance in mediating 
the response of a tissue to circulating glucocorticoid has been indicated 
several workers. Baxter and Tomkins (1971) showed an association with 
the induction of hepatic tyrosine aminotransferase, Van Der Meulen et al (1972) 
with ENA synthesis in thymus cells and Simpson and White (1973) with 
ribosomal function in skeletal muscle.
The localisation of the nuclear receptor is not clearly defined.
Beato et al (1971) found that both the liistone and non-histone proteins
3isolated from nuclei incubated with H-cortisol absorbed radioactivity.
However, Sluysler (1969) showed preferential uptake of the hormone by 
histone, whereas Dastugue et al (1971) demonstrated a higher affinity
of the acidic non-histone proteins for corticosterone.
Glucocorticoid/protein interactions have also been demonstrated
in other subcellular fractions of liver. Mayewski and Litwack (1969)
3
showed rapid uptake of administered H-cortisol by the smooth 
endoplasmic reticulum of rat liver, but not by free ribosomes or rough 
endoplasmic reticulum. Although metabolic transformation of the steroid 
occurred after its binding, this does not preclude membrane binding in a 
functional capacity. Effects of cortisol and corticosterone on the 
structuralstote of the endoplasmic reticulum have been demonstrated by 
James et al (1969), Mills and Topper (1969) and Itancourt and Litwack (1968).
Glucocorticoid metabolite binding proteins.
As well as containing the receptor proteins described above, rat
liver cytoplasm has been shown to possess macromolecules which bind
metabolites of glucocorticoids. Singer and Litwack(l97l)_showed the
presence of four such binding proteins associated with radioactivity arising 
•2
from H-cortisol. Two of these have been characterised (Morey and Litwack, 1969) 
The »Y' binding protein (Reyes et al, 1969), the p-dimethylaminoaaobenzene 
binding protein (Ketterer et al, 1967) and the 3-methylcholanthrene binding 
protein (singer and Litwack, 1971) were shorn to be apparently identical 
to the Corticosteroid Binder I of Litwack's group. Singer and Litwack (1971) 
reported that the protein also bound certain carcinogens, bilirubin, an 
oestradiol metabolite and various other anions, as well as corticosteroids 
and their anionic metabolites. The function of these binding proteins 
has not yet been determined, but roles in intracellular transport, in 
control of protein synthesis and in a metabolic capacity have been 
proposed (Morey and Litwack, 1969).
Nature of the present study.
From the data so far presented it is apparent that the tissue 
distribution of synthetic glucocorticoids has been severely neglected.
While such studies using the endogenous types are more numerous, they 
vary widely in experimental format, which makes comparisons difficult.
In addition they were often conducted in rats, using cortisol, which is 
not normally present in this species. Also, most studies were made at 
only one time after administration of the steroid and no idea of its 
retention by the tissues can be obtained. This parameter can provide 
most information about the increases in potency which characterise the 
synthetic glucocorticoids. It would not be expected that synthetic 
derivatives, which fractionally differ from their parent compounds 
largely in terms of potency, would manifest these differences by changes 
in gross tissue distribution when their physiological and biochemical 
effects are essentially similar. However, their retention by a tissue, 
and their interactions with it, may differ considerably from those of 
the natural compound and give rise to their increased effic. acy.
For these reasons the gross tissue distribution of small amounts
3 3of H-corticosterone and H-betamethasone was examined at various times
after their separate administration to adult male rats, and under
carefully controlled conditions. In the light of the result obtained by
Firschein et al (1957) the intraperitonea1 route was selected for
administration of the compounds. The advantages of this method are that
no anaesthesia is required, and the injection is completed rapidly and
with minimum animal manipulation. The problems of stress are, therefore,
largely overcome. The main disadvantage envisaged was that the
administered dose would largely be absorbed through the capillary network
of the gut mesenteries and would pass initially to the liver, rather than
into the general circulation as is the case after intravenous administration.
3.2 MATERIALS AND METHODS.
Animals.
In all cases 50 day old male Wistar albino rats were used. Their 
origin has been previously described (2.6).
Steroids and dose.
Unlabelled and tritium-labelled corticosterone and betamethasone
were used (2.1.1).
Steroids from stock ethanolic solutions were transferred to 5 ml
test tubes and evaporated under Ng. Tritiated steroids were similarly
transferred to the same tubes and also evaporated. Final dissolution was
made in 10$ ethanolic/saline (v/v). Equimolar amounts of corticosterone
and betamethasone were given intraperitoneally using an all glass
tuberculin syringe. The doses used were:
3Corticosterone : 5 pCi H-corticosterone; total mass of 20 pg
corticosterone by addition of cold compound.
3Betamethasone s 5 pCi H-betamethasone; total mass of 23.7 pg
by addition of cold compound.
Experimental Protocol.
Animals were injected 5, 15. 30, 60, 120 and 2A0 minutes before 
sacrifice, which was always between 10.00 and 12,00 hours.
After decapitation, blood was collected in glass beakers containing 
1 ml of heparin solution and the following tissues were rapidly removed 
and chilled on ice: Liver, thymus, kidneys, heart, adrenal, lung, spleen,
testes, stomach (and contents), small intestine (and contents), large 
intestine (and contents) and skeletal muscle (from right hind limb).
The contents of the various parts of the gastrointestinal tract 
were extruded using forceps and the tissues then washed with saline.
The mucosa from the small intestine were removed by longitudinally 
slitting the intestine and scraping the mucosa from their associated 
smooth muscle using a microscope slide. The entire separation procedure 
was performed at 0-4°C. All tissues were then deep frozen at -20°C, a 
process which does not affect their radioactivity profile on subsequent 
processing (Zimmerman and Bowen, 1972).
After thawing, homogenisation was effected using 1,15$ (w/v)KCl 
as the suspension medium, A Potter-Elvehjem homogeniser was used for 
the soft tissues, while those more resistent to disruption were homogenised 
with an Ultraturrax.
Radioactivity determinations.
Aliquots of homogenised tissue (50 and 100 mg initial wet tissue 
weight equivalents) were chemically digested and counted as described in 
2.8.7 and 2.8.8 respectively.
V"
\
5.5 RESULTS AND DISCUSSION.
tissue radioactivity levels ore expressed as specific activities 
i.e. total radioactivity per g initial wet tissue weight (or per ml, in 
the case of blood). Each point represents the mean obtained from 4 animals 
in the corticosterone study and 5 animals with betamethasone. Actual mean 
values and the standard error from this mean are given in the Appendix 
(Tables A3:l and A5:2).
Differences in uptake of corticosterone and betamethasone.
The most apparent difference in the patterns of distribution of 
corticosterone and betamethasone appear to arise from the mobilisation 
of the steroids from the peritoneum. Blood radioactivity levels (Figure 3*1) 
indicate that the uptake of corticosterone is rapid and almost complete 
at 5 minutes, whereas that of betamethasone is still occurring at 30 minutes. 
There appear to be three possible reasons for this. Firstly, that 
differences in polarity influence the uptake of the two compounds; 
secondly, that corticosterone is carried in the blood both by transcortin 
(specifically) and albumin, whereas betamethasone is only transported by 
albumin; thirdly, that biological limitations to the free diffusion of 
betamethasone into the blood exist. In view of the very small dose of 
steroid used and the high capacity of albumin binding, the second 
alternative seems improbable. As evidence exists for the free diffusion 
of betamethasone across cells (Munck and Wira, 1971) it seems unlikely 
that any biological limitation to the free diffusion of betamethasone 
into the blood is present. However, the rapid removal of corticosterone 
from the blood (primarily by the liver) would facilitate its uptake. As 
corticosterone is more lipid soluble than betamethasone, the first option 
is, perhaps the most feasible.
In agreement with previous findings' the distribution of radioactivity 
arising from corticosterone is complete throughout all the tissues studied
(Lowy et al, 1969). Betamethasone is similarly widely distributed.
/
Corticosterone distribution.
Maximal radioactivity levels after corticosterone administration are 
attained in all tissues except kidney, muscle, and small intestinal 
mucosa after 5 minutes, at which time plasma levels are also maximal.
The maxima in kidney and muscle are found at 15 minutes and that in mucosa 
at 30 minutes (Figures 3:5» 6 and 13 respectively). In all tissues except 
mucosa the distribution of dose with time decreases exponentially after 
the initial maximum. This is true also for all parts of the gastrointestinal 
tract (Figures 3*10, 12, 15)» despite exposure to their contents whose 
inherent radioactivity provides a different time dependent profile (Figures 
3:11, 14, 16). This is also true of distribution in the small intestinal 
mucosa (Figure 3:13) where both the patterns in the small intestinal smooth 
muscle (Figure 3:12) and its contents (Figure 3:14) are different. The 
most feasible explanation for this is that the mucosa is involved in the 
recirculation of metabolites which are present in the bile at this time 
(Chapter 4). This proposal is upheld by the slower clearance of 
radioactivity from the small intestinal muscle when compared to other 
tissues. The presence of this enterohepatic recirculation of 
corticosteroids has been previously established (Wyngaarden et al, 1955). 
There is also evidence that this phenomemon is occurring in the large 
intestine, for after 240 minutes the radioactivity levels in the tissue 
increase dramatically (Figure 3:15). While this could be attributed in 
part to the exposure of the tissue to the high level of radioactivity 
present in its contents (Figure 3:16), it is interesting to note a 
comparable rise in circulating radioactivity in blood (Figure 3:1).
(The specific activity of blood at 240 minutes is significantly greater 
than that at 120 minutes; p<0.001)*
Betamethasone distribution.
As stated previously, uptake of betamethasone from the gut into the 
blood is far slower than that of corticosterone. Maximal tissue levels 
of radioactivity are at 30 minutes for all tissues except those of the 
gastrointestinal tract, where maxima are at 5 minutes. In.addition, the 
stomach, small intestine and large intestine are the only tissues in which 
their specific activity after the administered betamethasone is 
significantly greater than those after corticosterone injection figures 3:10, 
12, 15 respectively). These parts of the gut, directly exposed to the 
administered compound, therefore appear to have a greater affinity for 
betamethasone than for corticosterone and this may be a further reason for 
the slower uptake of the synthetic steroid into the blood. However, any 
manifestation of direct adsorption of corticosterone by these tissues 
would be masked by the rapid influx of radioactivity from the plasmai 
Furthermore, the almost immediate uptake of corticosterone from the 
peritoneum would make such interactions with those tissues directly 
exposed to the compound kinetically unfavourable. The converse would 
be true for betamethasone, however.
Following the attainment of maximal tissue radioactivity levels 
after betamethasone administration, the tissue specific activities at 
subsequent times generally decrease in a similar fashion to those observed 
with corticosterone. However, supplementary maxima, o:r much delayed 
clearance rates, are observed in kidney, skeletal muscle, testis, spleen 
and the parts of the lower gastrointestinal tract. The metabolic 
involvement of the kidneys and small and large intestine in steroid
excretion and enterohepatic recirculation is of obvious importance in 
this context, Although glucocorticoid effects have been demonstrated 
in skeletal muscle (Simpson and White, 1973), the prolonged half-life 
of betamethasone in testis and spleen is more difficult to explain.
Tissues half-lives of corticosterone and betamethasone.
Comparative values of the retention of radioactivity by the tissues 
examined after corticosterone and betamethasone administration are 
presented in Table 3:1* The half-lives of radioactivity within the 
tissues are greater after betamethasone than after corticosterone in 
almost every case, This is true although comparisons had to be made 
over the late time points (because of the slower absorption of betamethasone 
and, as the tissue/log dose relationship is not linear over the whole time 
course, these values are larger than those obtained over the early time 
points. The differences which exist over the two time ranges used are 
shown for corticosterone in Table 3:1.
Despite the restrictions to interpretation which the slow uptake of 
betamethasone impose, it is apparent that its associated radioactivity has 
a longer tissue half-life than that of corticosterone. If the differences 
demonstrated between the pattern after corticosterone and betamethasone are 
due to different properties of the two administered steroids, then the 
tissue retention of betamethasone is apparently greater than that of 
corticosterone. This may significantly affect its glucocorticoid potency, 
possibly by prolonged exposure to the tissue glucocorticoid binding proteins
The implications of tissue retention of steroids.
While the exact relationship between glucocorticoid binding proteins 
and the mode of action of the steroid remains to be elucidated, it is
TABLE 3:1 TISSUE HALF-LIVES OF CORTICOSTERONE AM) BETAMETHASONE RADIOACTIVITY.
CORTICOSTERONE BETAMETHASONE
TISSUE Half-life over period Half-life over period
5-30 mins 30-120 mins 30-120 mins 5-30 mins
Blood 15 23 74 -
Liver 19 30 72 -
Heart 13 33 50 -
Lung 18 75 54 -
Kidney 17 36 176 -
Muscle 22 40 104 -
Testis 15 50 210 -
Thymus 24 160 83 -
Spleen lk 94 114 28
Stomach 18 35 39 20
Small intestine 31 - - 14
Large intestine 10 - - 21
certain that they exist in a functional capacity. Their ability to 
specifically bind and to retain corticosteroids and to facilitate their* 
action, is indicative of this, as is their presence in established 
glucocorticoid sensitive tissues such os liver and thymus* Tissues 
which manifest these specific binding proteins are therefore likely to 
be sensitive to the action of glucocorticoids. Although no characterisation 
of the metabolic state of the administered radioactivity was made after 
its distribution in the present study, its retention by the tissues can 
be readily determined* While this cannot be used, per se, as a 
determinant of glucocorticoid sensitivity, the data of Table 3:2 suggests 
an application for preliminary characterisation of tissues in this respect.
Table 3:2 RETENTION OF ■ RADIOACTIVITY IN VARIOUS TISSUES AFTER 
 ,________ ADMINISTRATION OF ^H-CORTICOSTERONE.______ _
Tissue % Dosj 
Maximum
/g tissue^ 
Minimum'
Retention ratio 
(Max/Min)
Blood 0.550 0.012 45
Liver 4. 340 0.265 16
Kidney 0.980 0.086 11
Striated muscle 0.193 0.020 9
Spleen 0.460 0.062 7
Testis 0.310 0.026 12
Thymus 0.210 0.061 3
Lung 0.560 0.094 6
Heart 0.240 0.008 30
Stomach 0.330 0.017 20
Small intestinal 
smooth muscle 1.040 0.250 5
Large intestinal 
smooth muscle 0.890 0.112 8
1 Maximum levels were at 5 minutes except for kidney and muscle (15 min).
2 Minimum levels were taken as values at 120 minutes.
The results in Table 3:2 give an indication of steroid retention 
by the various tissues examined. If the role of such tissues as kidney 
and liver in steroid metabolism and excretion is considered, it can be 
proposed that tissues which contain glucocorticoid receptors will absorb 
and retain steroidal material proportionally to the capacity of the 
tissue for such binding. Thus, those tissues with a low retention ratio 
have a greater affinity and glucocorticoid sensitivity than those in which 
the ratio is higher. The importance of retention in the hypothesis is 
emphasised when the high retention ratio of blood is considered. Although 
plasma contains a specific glucocorticoid binding protein (transcortin) 
it is present only to facilitate transport to the site of steroid action.
This type of binding is therefore distinct from tissue binding where a 
definitive biochemical effect results e.g. enzyme induction.
Using this hypothesis, the presence of glucocorticoid receptors 
is likely in those tissues with a low retention ratio - liver, kidney, 
striated muscle, spleen, testis, thymus, lung and small and large 
intestinal smooth muscle. Characterisation of such receptors has already 
been made in liver, thymus, skeletal muscle, lung, and kidney 
(Beato et al, 1971? Munck and Wira, 1971? Simpson and White, 1973?
Giannopoulos et al, 1972? Funder et al, 1973). Several other of these 
tissues have recently been shorn to possess receptors (Baxter and Forsham, 197z), 
Their presence in such tissues as heart and stomach is not contraindicated 
by the hypothesis, but it appears that their inherent function in these 
tissues is less pronounced than in those where the retention ratio is 
lower. Perhaps the most interesting demonstration is the presence of 
glucocorticoid receptors in small and large intestine. The implications 
of this are presently unclear for there is little published work on the 
effects of glucocorticoids in the gut (Daniels et al, 1972a, 1972b?
David et alt 1970? Spiro and Millcs, i960).
When considered in the light of published work, the theory 
proposed above appears valid and its extension to studies on other 
hormones seems both possible and viable.
Conclusions.
The present study provides evidence that the intraperitoneal 
route of administration is most satisfactory in the study of 
corticosterone distribution. The results obtained indicate that 
corticosterone is widely distributed throughout many of the tissues 
of the !*bdy* but that its retention by these tissues is apparently 
dependent on some facet of their glucocorticoid sensitivity. 
Betamethasone, a potent synthetic glucocorticoid was found to be 
similarly widely distributed* Although its initial uptake from the 
pei'itoneum is much slower than that of corticosterone, the tissue 
specific radioactivity levels are similar to those found with the 
natural steroid. The retention of betamethasone by the tissues is 
significantly longer than for corticosterone, however. It seems likely 
that this prolonged tissue life, more than any other direct action of 
the hormone per se, is instrumental in the increased biological potency 
of the synthetic glucocorticoids.
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FIGURES 3:1 to 3:4 TISSUE LEVELS OF RADIOACTIVITY AT VARIOUS TIMES AFTER
THE ADMINISTRATION OF 3H-CORTICOSTERONE (-a -a -) AND ^-BETAMETHASONE
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FIGURES 3:5 TO 3:8 TISSUE LEVELS OF RADIOACTIVITY AT VARIOUS TIMES AFTER
THE ADMINISTRATION OF IT-CORTICOSTERONE *-) AND II-BETAMETIIASONE ( - & - * - ).
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FIGURES 3:9 to 3:12 TISSUE LEVELS OF RADIOACTIVITY AT VARIOUS TIMES AFTER
'Z "T
THE ADMINISTRATION OF II-CQRTICOSTERONE (-*—&-) AND II-BETAMETHASONE (-a-*-).
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FIGURES 3:13 to 3:16 TISSUE LEVELS OF RADIOACTIVITY AT VARIOUS TIMES AFTER
THE ADMINISTRATION OF 3II-C0RTIC0STER0NE ( -a — a-) AM) ^II-BETAMETIIASONE (-a- a-) .
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4.1 INTRODUCTION
General considerations.
The biological response of a tissue to steroid hormones is 
primarily determined by the availability of these hormones, and is 
consequently influenced by their synthesis and degradation. The 
degradative metabolism of steroids provides a controlling mechanism 
in the duration of this tissue response. As glucocorticoid metabolism 
has been reviewed comprehensively elsewhere (Chen and Rorrevang, 1970 5 
Cope, 1972; Fotherby and James, 19725 Peterson, 1971? Rosenfield 
et al, 19675 Schriefers, 1967)* only particular aspects of the field 
will be considered here.
The catabolism of natural glucocorticoids.
Glucocorticoid metabolism is primarily effected by the liver, 
but can also occur, in a secondary capacity, at various extrahepatic 
sites including kidney’(Ganis et al, 1956), skin (Hsia and Hao, 19665 
Hsia et al, 1964, 1965), lung (Sowell et al, 197l)» gastrointestinal 
tract, spleen, adrenal, pituitary (Brown et al, 1957), brain (Grosser 
and Bliss, 1963; Rommerts and Van Der Molen, 1971), blood (Rongone 
et al, 1957), prostate (Frederiks en and Wilson, 1971), the eye 
(Ono et al, 1972/3a) and other tissues,(Berliner et al, I96O5 
Forker et al, 1963; Wilson et al, 1956). Several aspects of 
extrahepatic glucocorticoid metabolism have been considered by 
Berliner and Dougherty (1961).
Deactivation of natural glucocorticoids occurs primarily by 
reduction (Gold et al, 1959), but can also proceed by oxidation and 
carbon-bond cleavage. Prior to excretion, conjugation usually follows
these steps. Reductive metabolism can occur at the and C^g carbonyl 
groups and at in ring A} oxidation re suit’s^ in conversion of the 
lip-hydroxy group to an 11-keto moiety, and in hydroxylation at the 
2a, 2(3, 6(3, 7a, 15a and 16a positions % cleavage is responsible for 
removal of the a-ketol side chain at C^ ,-, and dehydroxylation of the 
ll|3-hydroxyl group may occur. The various enzymes concerned in these 
processes are located in various fractions of liver cells (DeVenuto and 
Westphal, 1961), and their properties are discussed by Schriefers (1967). 
Conjugation occurs primarily at the transformed position.
The catabolism of synthetic glucocorticoids.
The structurally modified nature of the synthetic analogues is
responsible for the differences which exist between their metabolism and
that of endogenous glucocorticoids. Where the structural modifications
are limited to rings A or B, metabolism proceeds similarly to that of
the endogenous compounds. Thus, prednisolone, prednisone and
9o-fluorocortisol are metabolised largely by dehydrogenation of the
11 (3-hydroxy group, side-ehain cleavage and reduction. However, some
changes in the relative importance of these routes of metabolism was
noted when comparisons were made with natural glucocorticoids (Bush
and Mahesh, 1964; Caspi and Pechet, 1958} Schriefers, 1961;
Todd and Hechter, 19551 Tomkins, 1956| Vermeulen, 1956, 1957, 19595
Vermeulen and Caspi, 1958). Where the structural modifications include
substitutions in ring D, os well as in rings A and B, all degradative
routes become secondary to hydroxylation, probably because of the
JL 4extreme resistance of the cross-conjugated A  * -3-kcto system to 
reductive metabolism (Butler and Gray, 1970; Florini et al, 1961b;
Eupfer and Partridge, 1970; Murphy et al, 1964).
The metabolism of synthetic glucocorticoids occurs primarily 
in the liver and proceeds more slowly than that of the endogenous steroids 
although this is not the fi^ in reason for the greater potency of the 
synthetic analogues (Brown and Anason, 1958, Florini and Buyske, 1959} 
Glenn et al, 1957} Rongone et al, 1957} Silber and Morgan, 1956)* In 
addition to ibis slower metabolism, synthetic glucocorticoids appear to 
be conjugated to a lesser extent than the natural steroids. This has 
been attributed to the slower rate of conjugation at positions other 
than Cy  necessitated by the intact 3~kcio group of ring A present in 
many metabolites of the synthetic steroids (Vermeulen, 1959)*
Bex differences in glucocorticoid metabolism.
As previously stated, reduction of glucocorticoids occurs at the
4Cgg-kcto position and at the A -3-keto group. The nature of the 
double-bonds involved results in the production of stereospecific 
isomers whose configuration is determined by the enzyme involved*
The relative proportions and activities of these various reductase 
enzymes are influenced by a number of factors, especially the sexual 
and adrenal status of the animal. Thus, 20- and 3-keto-reductase 
activities are higher in the isolated livers of male rats than in 
females (Hagen and Troop, 1960$ Hubin and Streclcer, 1961;
Schriefers et al, 1962% Troop, 1959). Similarly, male rats have 
a greater capacity than females to transform cortisone to its 
biologically active form (cortisol) by reduction of the 11-keto 
group (HUbcnor and Amelung, 1953). In comparison, A^ ~5ar*oxidoreductase 
activity is greater in isolated livers from female rats than in males 
(Forchielli et al, 1958; Hagen and Troop, I960).
Yates and his colleagues examined the developmental nature of 
these enzymic sex-differences in growing rats, and proposed a 
dependence on hepatic, aexual and adrenocortical status (Urquhart 
et al, 1959; Yates et al, 1958a). Kitay and co-workers substantiated 
these views, but suggested additional involvement of the pituitary 
gland in this regulation (Colby and Kitay, 1972J Colby et al, 1973;
Kitay, 1961).
Other routes of metabolism are also influenced by sex-differences.
Thus, steroid hydroxylation occurs more readily in male rats than in 
females (Conney et al, 1965a)) although 15orhydroxy derivatives of 
glucocorticoids are found solely in females (Eriksson and Gustafsson, 1971). 
Possibly as a consequence of the generally elevated levels of metabolic 
enzymes in male rats, a higher capacity for glucuronide conjugation has 
been reported in male rats than in females (itao and Taylor, 196 5). The 
authors also noted sex-differences in glucuronide formation in hamsters, 
but in thin species there was greater activity in females. In rats, 
females are similarly more active in the sulphate conjugation of 
steroids (Roy, 1956). If is interesting to note that all these sex- 
differences in steroid metabolism, in common with those found in dr^g 
metabolism (Chapter 5), are most pronounced in rats and hamsters, but 
are less apparent in other species.
Substrate, hormonal and dietary influences on glucocorticoid metabolism.
The differences which exist between the preferential routes of 
metabolism of natural and synthetic glucocorticoids, and which result 
from structural changes, have already been described. In addition,
Colby and Kitay (1972) noted that the sex-dependent patterns of metabolism 
of the endogenous steroids (Corticosterone and 11-deoxycorticosterone)
wore different from those of cortisol and 11-dcoxycortisol, in rot 
liver hemogenaies* Similar differential effects on corticosterone 
end cortisol metabolism, resulted offer castration of male rots 
(Colby and Kitay, 1972).
A num ber of h orm onal f a c t o r s  in f lu e n c e  g lu c o c o r t ic o id  c a ta b o lis m .~  
As m I I  a s  th e  n a t u r a l  sex-di f fc r e n c o s ,  a d m in is t r a t io n  o f  s y n t h e t ic  
o e s tro g e n o  and a n a b o lic  s te r o id s  a ls o  in d u c e s  changes in  m e ta b o lis m  
( S c h r ie f e r s  e t  a l ,  1 9 6 5 b ) .  T h y ro id  s ta tu s  i s  a ls o  im p o r ta n t  
( G a l la g h e r ,  1 9 6 4 ) ,  and  th y r o x in e  a d m in is t r a t io n  r e s u l t s  i n  in c re a s e d  
r e d u c t io n  and re d u c ed  h y d r o x y la t io n  i n  r a t s  ( l lo e m e r  and H o l t o n ,  1 9 6 4 }  
M cG u ire  and T o m k in s , i9 6 0 }  Y a te s  a t  a l ,  1 9 5 8 b ) a n d  in- mm ( H e l t o n  
e t  a l ,  i f 6 i ) .  G lu c o c o r t ic o id s  a ls o  in f lu e n c e  t h e i r  mm m e ta b o lis m  
i n  v i t r o ,  p ro d u c in g  b o th  i n h i b i t i o n  (H agen  a n d  T ro o p , i9 6 0 }  tT rq u h a rt  
e t  a l ,  1 9 3 9 )  an d  s t im u la t io n  ( B l a i r  a n d  B o te ,  19651 B row n e t  a l ,  1 9 5 7 }  
Sutan e t  a l ,  1 9 5 9 ) ,  a c c o r d in g  t o  th e  s t e r o id  u sed  f o r  p r e t r e a tm e n t  
i n  vivo. K ypophyscctom y and a d re n a le c to m y  re d u c e  th e  r a t e  o f  
g lu c o c o r t ic o id  m e ta b o lis m  i n  v i t r o  ( B l a i r  and U a ie ,  1 9 6 5 }  Brown  
e t  a l ,  I 957) ,  and th e  d iu r n a l  v a r i a t i o n  i n  c i r c u l a t i n g  c o r t ic o s t e r o id s  
i s  p a r a l l e l l e d  b y  a  rh y th m  i n  h e p a t ic  s t e r o id  m e ta b o lis m  i n  v i t r o  
( i b i d ,  C h a p te r  6 ) .
Food in t a k e  a ls o  in f lu e n c e s  v a r i e d  a s p e c ts  o f  g lu c o c o r t ic o id  
m e ta b o lis m , in c lu d in g  r in g  A r e d u c t io n  ( B l a i r  and  tic  t o ,  1 9 6 5 }
Horbst e t  al, 19!0)» 20-keio reduction (Schriefers et al, I9S2) and 
glucuronide conjugation (Schriefers et al, 1965a,1966).
The effects of anutricnts on glucocorticoid metabolism.
ChungQB in  s t e r o id  m e ta b o lis m  can  a ls o  r e s u l t  fro m  p r e t r e a tm e n t  
w it h  d ru g s  and o th e r  c m u t r ie n ts ,  o r  fro m  in c lu s io n  o f  th e s e  s u b s ta n c e s
m  i n  v i t r o  in e u b e t io n  s y s te m s . I n h i b i t i o n  u s u a l ly  r e s u l t s  fro m  
a d d i t io n  o f  stioh compounds i n  v i t r o ,  w h ereas  p r e ir e a im o n t  o f t e n  
causes  in c re a s e s  i n  e to r o id  m e ta b o lic  a c t i v i t y  ( S c h r ie f e r s ,  1 9 6 ? ) .
Conney o t  a l  (1 9 6 5 b )  c o u ld  show m  enhancem ent o f  th e  r e d u c t io n  o f  
c o r t ic o s t e r o id s  a f t e r  p h e n o b n r b lia l  p r e t r e a tm e n t ,  h u t  d id  d e t e c t  a n  
in c r e a s e  i n  th e  am ounts o f  s e c o n d a ry  h y d r o x y la t io n  p ro d u c ts *
H y d r o x y la t io n  o f  te s to s te r o n e  end  o e s t r a d io !  was a ls o  in c r e a s e d .
These ■'results indicate on interesting differential effect of 
inducers an steroid catabolism, and imply that reductive deactivation 
of glucocorticoidb proceeds at a constant level, and that increases in 
Overall i^toholiea result tmm m'/ Increase in hydroxylation. This is 
endorsed by the findings of hiymn et al (1962) who shoved increased 
hydroxylation Of cortisol in tissue slices obtained from patients 
exposed to oestrogen therapy. In addition, elevated levels of 
6f3~!ydro:ycortise 1 have bean detected in the urine of pregnant women 
(Frantz at al, i960), and the neonate (ulstrom et al, i960), where 
endogenous steroid levels are high. Human and animal cuhjects exposed 
to certain pesticides end drugs nice demonstrated increased glucocorticoid 
hydroxylation (Bledsoe et al, 106%| Burstein ’ and Bhavini, 196?$ 
Chamberlain, 1971,} Connoy ot al, ip5af’1967f Itaqne ot al, 1978}
Kantwoi e t  ot, 19-68} K u p fe r  and  B e e t i ,  1966), F u r t h e r m r e ,  th e  • 
d iu r n a l  rh y th m  in  endogenous g lu c o c o r t ic o id  c a ta b o lis m  c an  ho la r g e ly -  
a s c r ib e d  t o  c o rre s p o n d in g  v a r ia t io n s  in  h y d r o x y la t io n  ( i b i d ,  C h a p te r  6 ) ,  
These f in d in g s ,  and th e  p r t o r y  r o lo  o f  h y d r o x y la t io n  i n  s y n t h e t ic  
g lu c o c o r t ic o id  d e a c t iv a t io n ,  em phasise  i t s  im p o rta n c e  i n  s i t u a t io n s  
w h ere  r e d u c t iv e  m e ta b o lis m  i s  o f  l i m i t e d  a p p l i c a t i o n ,  and s u p p le m e n ta ry  
r o u te s  a r e  dem anded.
Urinary and faecal excretion of glucocorticoids.
Many of the factors affecting glucocorticoid metabolism also 
influence excretion patterns, and the route used for excretion of 
a steroid and its metabolites* Endogenous and synthetic glucocorticoids 
and their metabolites are excreted almost completely in both urine and 
f a e c e s ,  although the relative importance of these two excretory routes 
varies with species* In man, administered corticosterone or cortisol 
are excreted largely in urine (Peterson and Pierce, I960; Peterson 
'et al, 1955) whereas, in rat, greater amounts of administered cortisol 
appear in the faeces(Hyde and Williams, 1957; Wyngaarden et al, 1955).
The relative proportions of synthetic glucocorticoids found in 
urine andfaeces vary with the nature of the steroid administered. In 
man, prednisolone is excreted rapidly, and almost exclusively, in the 
urine (Sandberg and Slaum/hite, 19575 Vermeulen, 1959). However, 
increasing substitution of the glucocorticoid molecule results in 
slower and less complete urinary excretion (Butler and Gray, 1970;
Murphy et al, 1964; Slaunwhite and Sandberg, 1961) and to an increase 
in the relative proportions of unconjugated steroids.
Biliary excretion of glucocorticoids.
Glucocorticoid metabolites present in faeces arise from their 
biliary excretion (Wyngaarden et al, 1955) and often differ substantially 
from the products of hepatic metabolism, due to the degradative actions 
of the intestinal flora (Eriksson et al, 1971). Steroids in the gut 
can be reabsorbed, and pass into the systemic circulation (Hyde and 
Williams, 1957) and the existence of this enterohepatic recirculation 
explains why smaller amounts of glucocorticoid metabolites are found 
in thefaeces than are initially present in the bile (Hyde and Williams, 1957
Migeon et al, 1956? Wyngaarden et al, 1955)* Such recirculation 
is by no means complete, however, and faecal steroid levels 
consequently reflect the degree to which a steroid is excreted in 
the bile. Thus, biliary excretion of endogenous glucocorticoids 
is considerable in rat, but less marked in guinea pig (Wyngaarden 
et al, 1955). In man, the biliary excretion of cortisol is far 
less than that of corticosterone (Migeon et al, 1956), although both 
are substantially lower than comparable levels in rat or guinea pig.
No published data exists on the biliary excretion of synthetic 
glucocorticoids.
Nature of the present study.
The relative paucity of information which exists on the metabolic 
fate of synthetic glucocorticoids prompted the present investigation.
The metabolism and excretion of two synthetic glucocorticoids, 
betamethasone and dexamethasone, has therefore been examined in rat, 
and compared with that of corticosterone. Because of the known species 
differences in endogenous glucocorticoid metabolism, the metabolism and 
excretion of betamethasone has also been studied in guinea pig. Studies 
have also been conducted to determine the importance of hydroxylation 
reactions in glucocorticoid metabolism.
4.2 MATERIALS AND METHODS.
Animals.
Male Wistar albino rats (50 days old),, and male Duncan-Hartley 
guinea pigs (42 days old) were used. The conditions under which they 
were housed have been previously described (2.6).
Where necessary, rats were pretreated with 7 consecutive daily
intraperitoneal doses of dexamethasone at a dose level of 3®g per kg
(see 5.2) or with phenobarbital (lOOmg per kg, intraperitoneally, for 
3 consecutive days). In both cases, animals were used at least 16
hours after the final do«e of the inducers.
Steroids and dose.
The origin of the unlabelled and tritium-labelled steroids used 
has been detailed elsewhere (2.1.1). Their preparation for administration 
has also been previously described (3.2). Equimolar amounts of 
corticosterone (20pg), betamethasone and dexamethasone (both 23*7pg) 
and approximately 5pCi of each steroid were administered using an all 
glass tuberculin syringe. These dose levels were used in all experiments 
and were identical to those employed in the tissue distribution work 
(Chapter 3).
Experimental protocol.
In the urinary and faecal excretion studies, animals were injected 
intraperitoneally around 10.00 hours and samples were collected 6, 24 
and 48 hours later for corticosterone and also after 72 and 96 hours 
for the synthetic steroids. The methods of collection of urine and 
faeces havebeen described in 2.7.2 Biliary excretion studies were
conducted as described in 2.7.3. The isolation of metabolites from 
bile and urine was made as detailed in 2.8*5. Small amounts (200pg) 
of the appropriate steroids were added, before extraction, to act 
as carriers.
Thin layer chromatography (t.l.c.).
The materials and methods used for t.l.c. have been previously 
described. Prior to removal of labelled steroids from t.l.c. plates^  
the radioactivity distribution was determined to assist localisation 
(2.6.6).
Radioactivity determinations.
Faeces were chemically digested, prior to counting, as described 
in 2.8.7. All radioactivity determinations were made as detailed in 
2.8.8.
4.3 RESULTS AND DISCUSSION.
Where results are presented as means S.E.M., the values were 
obtained using 4 animals in the urinary and faecal excretion studies 
and at least 3 animals in the biliary excretion studies. Error bars 
in Figures 4j3 to 4:5 represent the limits of 2 x S.E.M.
Urinary and faecal excretion.
In Table 4jl the rates of urinary and faecal excretion of 
administered corticosterone, betamethasone and dexamethasone in rat 
are compared. In agreement with previous studies, these results 
demonstrate that natural corticosteroids are excreted largely in 
the faeces*.with smaller amounts occuring in the urine (Hyde and 
Williams, 1957? Wyngaarden et al, 1955)* While the faecal route 
also predominated for betamethasone and dexamethasone excretion, 
greater amounts of these two synthetic glucocorticoids were excreted 
in the urine. The amounts of radioactivity excreted in the urine 
following dosage with betamethasone or dexamethasone were almost 
identical (29*5$ and 30*4$ of dose, respectively), as was their rote 
of excretion. However, greater amounts of radioactivity were found 
in the faeces after betamethasone (55-60$) than after dexamethasone 
administration (40-45$)*
Comparative values for the urinary and faecal excretion of 
betamethasone in rat and guinea pig are given in Table 4j2. The 
urinary excretion was slightly greater in guinea pig (35$ against 
30$ in rat) although it proceeded more slowly during the first 
six hours. However, excretion in the faeces was far less complete 
in guinea pig (22$) than in rat (58$). Consequently only 57$ of the
dose was excreted in four days by guinea pig, while 87$ was excreted
in the same period by rat. The low levels of radioactivity present
in faeces of guinea pigs might be due to poor biliary excretion of
steroids in this species, to a considerable enterohepatic recirculation
of betamethasone, or to a low level of hepatic metabolism. Although
14the biliary excretion of C-cortisol was less in guinea pigs than in
rats, it was still substantial (Wyngaarden et al, 1955), and the low
14faecal levels of radioactivity after C-cortisol administration 
indicated a high degree of reabsorption from the gut. In the case 
of cortisol this was manifest by high urinary radioactivity levels 
(Wyngaarden et al, 1955)* but in the present study these were not as 
pronounced after betamethasone. Consequently, poor hepatic metabolism 
of the compound is implicated, and this is confirmed by the results of 
the urinary fractionation.
Fractionation of urinary radioactivity.
No attempt was made to fractionate the urinary metabolites after 
corticosterone administration* because of their already established 
nature. The distribution of radioactivity in the free (unconjugated), 
glucuronide-conjugated, sulphate-conjugated and non-extractable fractions 
are shown in Table 4:5* The 0-6 hour urine collection from rats and the 
6-24 hour collection from guinea pigs was selected, because these fractions 
contained the largest proportion of the total urinary radioactivity.
In rat, there were more free steroids and less conjugates and 
non-extractable compounds after dexamethasone than after betamethasone.
In guinea pig, the free steroid fraction contained a similar amount of 
radioactivity to that found in rat after betamethasone. It also appears 
that sulphate conjugation is the sole means of phase 2 (williams, 1967)
metabolism in guinea pig, while rat conjugates betamethasone (and 
dexamethasone) both with glucuronic acid and sulphate.
Further fractionation of the free steroids.
The chromatography profiles of the pooled free steroid fractions, 
after t.l.c., are shown in Figure 4*1. Most of the radioactivity after 
dexamethasone administration to rats resided in a band found to 
co-chromatograph with on authentic dexamethasone standard (R^  0.45). 
Large amounts of radioactivity were also associated with a more polar 
component with R^ around 0.37 (Figure 4:IB). After removal from the 
t.l.c. plate, these fractions were separately acetylated, replated 
and chromatographed in solvent system I, again removed from the plate, 
hydrolysed, replated, and finally chromatographed in solvent system I. 
After final extraction from the silica gel, mass determinations were 
made by the tetrazolium blue method, and the fractions were counted.
All procedures were conducted as previously described in 2.8.3, 2.8.4, 
2.8.6 and 2.8.8. Throughout the entire procedure, one of the fractions 
co-chromatographed with an authentic sample of dexamethasone taken 
through the same process. The other fraction similarly co-chromato- 
graphed with 6|3-hydroxybetamethasone, As it was impossible to 
differentiate between betamethasone and dexamethasone, or their 
derivatives, in any of the Solvent systems used, this second fraction 
probably comprised 6{3-hydroxydexamethasone. By the reverse isotope 
dilution technique, the original free urinary steroid fraction was 
found to comprise 20$ of unchanged dexamethasone and 32$ of the 
proposed 6p-hydroxydexamethasone metabolite.
The same fractionation schemes were used to isolate the major 
metabolites of betamethasone in rat and guinea pig. The chromatography
profiles of the free urinary steroid fractions after initial 
subjection to t.l.c. are shorn in Figure 4;1A for rat and Figure 4:1c 
for guinea pig. Two major bands of radioactivity were present in 
rat urine and consisted of unchanged betamethasone and its 6(3-hydroxy 
metabolite (tentative identification by t.l.c.). These comprised 11$ 
and 50$ of the original urinary free steroid activity.
In guinea pig, most of the radioactivity of the urinary free 
steroid fraction was associated with two bands after initial t.l.c. 
(Figure 4:1C):. The more polar of these, with R^ around 0.34, 
co-chromatographed with an authentic standard of 6p-hydroxybetomethasone 
at this stage and throughout subsequent purification. The major band,
II^ 0.44, co-chromatographed with a betamethasone standard at this 
stage and after acetylation, but after acetate hydrolysis two peaks of 
radioactivity resulted. One of these again co-chromatographed with 
betamethasone, while the other ha d . an It^ greater than that of 
betamethasone* Hydrolysis of an authentic sample of betamethasone-21- 
acetate showed that this less polar compound was not a product of the 
acetylation procedure itself* Furthermore, the metabolite was also 
present in the free steroid fraction of a fresh 6-24 urine sample 
initially subjected to t* 1.c* in solvent system I (instead of system II) 
The percentages of radioactivity in a single band of R^ 0*44 in solvent 
system II also agreed well with the sum of percentages of the 
betamethasone and less polar metabolite bands in solvent system I*
The only metabolites of betamethasone with greater R^ values than 
the compound itself are the 11-keto and 17-keto derivatives* As the 
similar chromatographic properties (in solvent system II)of 
betamethasone hud the isolated, less polar metabolite of guinea pig 
urine suggest structural similarities,this less polar metabolite of
betamethasone is unlikely to be a product of side-chain cleavage.
It is, therefore, suggested that this metabolite, less polar than 
betamethasone, contains the ll-lceto group. While comparisons of 
the of the isolated metabolite (R^  0.38) and that of an authentic 
sample of I6f3-methyl-9a-fluoro~17a,21-dihydroxy-pregna-l,4-diene- 
3,11,20-trione (r  ^0.40) confirm this, no further identification was 
attempted.
Further fractionation of the glucuronides.
As previously stated, guinea pig urine contained no glucuronide
conjugates. However, small amounts of glucuronides were present as
3 3radioactive metabolites after H-betamethasone or H-dexamethasone
administration to rats. In Figure 4s2 the chromatography profiles
of these hydrolysed steroid glucuronides are presented. No
characterisation was attempted because of the small amounts of
radioactivity associated with the fractions, but it appeared that
the glucuronide fraction after dexamethasone consisted largely of
unchanged steroid, while, after betamethasone, polar metabolites
were preferentially conjugated with glucuronic acid.
Biliary excretion of corticosterone and betamethasone in the rat.
After intraperitonea1 administration of betamethasone, the biliary 
excretion of the steroid was slower and less complete than that of 
corticosterone (Figure 4:3). As slower uptake of betamethasone had 
been previously demonstrated after its intraperitonea1 injection 
(Chapter 3), a further experiment was conducted using the intravenous 
route for administration of both steroids. The results in Figure 4:4 
indicate that, with both corticosterone and betamethasone, the initial
biliary excretion rate was slightly faster after intravenous 
administration of the steroids. The overall excretion pattern was 
little changed, however.
Since betamethasone is metabolised primarily by hydroxylation, 
and this route is less used in endogenous steroid metabolism,- it 
appeared likely that the rate of hydroxylation, or some other step 
in the metabolism of betamethasone, might be limiting its biliary 
excretion. Bats were, therefore, pretreated with phenobarbital or 
dexamethasone in an attempt to induce the hepatic enzymes responsible 
for steroid metabolism. Effects of these inducers are shown in 
Figure 4:5. While the biliary excretion of betamethasone was still 
slower than that of corticosterone, it was considerably faster in the 
phenobarbital and dexamethasone pretreated animals than in the controls. 
Excretion was also more complete in the treated groups.
After isolation of the constituent steroid fractions of the bile 
from test and control groups, only the sulphate conjugated fractions 
were proportionally increased after inducer pretreatment. In comparison, the 
free and glucuronide fractions contained slightly lower proportions of 
the total radioactivity excreted in the bile (Figure 4:6), It, therefore, 
appears that the slow biliary excretion of betamethasone in control rats 
results from limitations to its overall rate of phase 1 and phase 2 
metabolism. Thus, pretreatment of rats with enzyme inducers increased 
the overall biliary excretion rate, but did so with little effect on 
the relative proportions of the biliary steroid subfractions. As 
further fractionation of theieeparate steroid fractions was not made, 
it is presently impossible to say whether any particular metabolite was 
present in greater amounts after inducer pretreatment. This appears likely, 
however.
Overall considerations.
Despite the rapid and almost complete biliary excretion of 
3radioactivity after H-coriicosterone administration to rats* only 
50% of the dose was excreted in the faeces after 48 hours. Considerable 
enterohepatic recirculation of the steroid was, therefore, occurring.
These conclusions are in agreement with the results of Wyngaarden
/ \ 14et al (1955), who studied the excretion of C-cortisol in rat and
reported that excretion of cortisol occurred largely in the faeces.
This was also the case after corticosterone in the present study,
although the amounts of radioactivity involved, and its rate of
excretion, were greater in both urine and faeces after cortisol than
in this study (Wyngaarden et al* 1955). However, this could be
accredited to the use of cortisol, not corticosterone, the larger
dose of cortisol administered, and the different route of
administration employed.
In rat, the synthetic glucocorticoids betamethasone and 
dexamethasone are excreted more rapidly than is corticosterone.
Although the biliary excretion of radioactivity after dexamethasone 
administration was not studied, that after betamethasone was considerably 
slower and less complete than after corticosterone. Furthermore, the 
amount of radioactivity excreted in the faeces after betamethasone 
was almost identical with that found in the bile. If, as seems 
likely, this is also the case for dexamethasone, then synthetic 
glucocorticoids apparently undergo very little enterohepatic 
recirculation.
Urinary radioactivity after administration of betamethasone and 
dexamethasone was considerably higher than after corticosterone, and 
this probably reflects the more polar nature of the synthetic steroids
and their simple metabolites, facilitating their urinary excretion.
This is endorsed by the higher proportion of unconjugated steroids 
found in the urine after betamethasone and dexamethasone administration.
Although the urinary excretion rates of radioactivity after 
betamethasone and dexamethasone were similar, dexamethasone was 
excreted more slowly in the faeces. As higher proportions of 
unchanged steroid were found in the urine after dexamethasone than 
after betamethasone, this slower faecal excretion may indicate slower 
metabolism of dexamethasone. Also, dexamethasone is biologically 
more potent than betamethasone and may be bound in the tissues to 
a greater extent than betamethasone - a factor which may also influence 
its rate of metabolism.
A similar slower rate of metabolism may explain the much reduced 
excretion of betamethasone in the faeces of guinea pigs, when compared 
to the levels found in rat faeces. Confirmation again comes from the 
high levels of unchanged betamethasone in guinea pig urine. The poor 
ability of the guinea pig to hydroxylate administered compounds 
reported by Dring et al (1966) is, therefore, confirmed by the present 
study* This defect may also explain the presence, in guinea pig urine, 
of a major metabolite in addition to the 6{3-hydroxy derivative which 
predominates in rat urine.
Conclusions.
The present study indicates that several differences exist 
between the metabolism and excretion of betamethasone and dexamethasone 
and that of their simpler synthetic analogues and the natural parent 
compounds.
1) Betamethasone and dexamethasone are excreted in the urine to a 
greater extent than is corticosterone.
2) The urinary fraction contains fewer conjugates and more free 
steroids after synthetic glucocorticoid administration than after 
the natural analogues.
3) This free steroid fraction contains a larger proportion of unchanged 
steroid after betamethasone or dexamethasone.
4) The urinary metabolites of the synthetic steroids are often 
derived from hydroxylative metabolism, while a preponderance of 
reduced metabolites is found after natural glucocorticoid administration.
5) The hepatic metabolism, and biliary excretion, of the synthetic 
steroids is considerably less than of the endogenous glucocorticoids.
These differences, resulting from structural modifications and 
ultimately dependent on 5) above, may contribute towards the increased 
potency of the synthetic glucocorticoids.
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CUMULATIVE 
URINARY 
AND 
FAECAL 
EXCRETION 
OF 
H-CORTICOSTERONE, 
II-DEXAMETHASONE 
AND 
H-BE'TAMETHASONE 
IN 
THE 
RAT
TABLE 4:2 CUMULATIVE URINARY AM) FAECAL EXCRETION OF ^II-BETAMETIIASONE 
IN THE RAT AND GUINEA PIG.  ____    . ____
TIME AFTER 
ADMINISTRATION
(hours)
R i
Jo radioa< 
URINE
T^
ctivity in 
FAECES
GUINEA 
Jo radioac 
URINE
PIG 
tivity in 
FAECES
6 19.8 + 1.3 1.5 + 0.1 9.8 + 3.0 0.7 ±  0.6
24 26.4 + 1.5 41.2 +3.9 29.1 + 2.0 13.9 + 1.6
48 28.2+1.4 54.4 + 1.9 32.2 + 2.1 19.5 + 1.2
72 29.0 + 1.4 56.6 + 1.6 33.4 +2.3 21.1 + 1.2
96 29.5 + 1.4 57.5 + 1.6 34.6 + 2.6 22.3 + 1.3
.... !
Each result is expressed as mean + S.E.M. obtained from 4 animals.
TABLE 4:3 FRACTIONATION OF 0-6 HOUR URINE OF RATS INJECTED WITH 
H-BETAMETHASONE OR II-DEXAMETHASONE AND OF 6-124 HOUR 
URINE OF GUINEA PIGS INJECTED WITH ^H-BETAMETHAS ONE.
URINARY RAT GUINEA PIG
FRACTION DEXAMETHASONE BETAMETHASONE BETAMETHASONE
Total urinary 
radioactivity 18.0 (100) 19.8 (100) 19.3 (100)
Unconjugated
steroids 15.3 (85) 12.2 (65) 12.1 (62)
Glucuronide
conjugates 0.24 (1.3) 0.8 (4.3) Negligible
Sulphate
conjugates 0.29 (1.6) 1.0 (5.2) 1.7 (9.1)
Non-extractable 2.2 (12) 4.9 (26) 5.5 (29)
All results are expressed as percentages of the total administered dose. 
Figures in parenthesis indicate the percentage each fraction comprises 
of the total urinary radioactivity.
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total free steroid fraction (ordinate) against R^ (abcissa).
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A 0-6 hour urine from rats injected with "H-betamethasone.
B 0-6 hour urine from rats injected with ^H-dexam^thasone.
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5.1 INTRODUCTION.
The capacity of the body to ingest, transform and remove a vast 
number and type of compounds is not limited to those substances which 
ore of nutritive value. It is upon this ability that the therapeutic 
treatment of diseases with drugs depends, and the transformation, or 
metabolism, of these drugs, and other anutrients, is the most significant 
determinant of their pharmacological activity.
Routes and sites of drug deactivation.
Despite the diverse chemical natiu*e of drugs and anutrients 
(xenobioiics), their metabolism proceeds by a relatively small number 
of enzymic processes, which can be classified into two distinct phases 
(Williams, 1967). ’phase one1, or preconjugation phase, may involve
processes resulting in C-alkyl, C-aryl, N- and S>- oxygenation, J)-, N- and 
dealkylation, ring cleavage, aromatisation and deamination. Oxides, 
sulphoxides, amines and carboxylic acids ore other oxidation products. 
Hydrolysis and reduction are also phase one reactions. In 'phase two', 
or the synthetic phase, the polarity of the phase one metabolites, or 
their parent compounds, is further increased by conjugation with 
glucuronic acid, sulphate or various amino acids, including glycine, 
methionine and glutathione (cysteine), so facilitating their excretion.
Early investigations identified the major site of drug metabolic 
activity as the endoplasmic reticulum of the liver (Cooper et al, 195A;
Sung and Way, 1950). Furthermore, it soon became apparent that isolated 
endoplasmic reticulum (in the form of microsomes - Claude, 1969) 
contained an NADFH and oxygen dependent enzymic component which performed 
many of the above described phase one transformations. The metabolic fates
of codeine, barbiturates and sympathomimetic amines were among the first 
to be described using this in vitro system (Alder and Shaw, 1952?
Axelrod, 1954? Gould and Shideman, 1952; Latham and Elliott, 1951?
Sung and Way, 1950). Gastric mucosa, kidney, lung, placenta^  skin, 
spleen and testis have been shown to possess similar enzymic systems 
capable of metabolising xenobiotics (Lake et al, 1973? Wiebel et al, 1971).
Mixed-function oxygenation.
Since its discovery, a vast amount of work has been performed in 
attempts to further characterise the enzymic component responsible for 
drug metabolism. Its Ubiquitous activity, and its ability to oxidise 
while maintaining a requirement for NADPH, led to the terminology 
♦mixed-function oxygenase system*. However, it is still not established . 
whether a small number of enzymes with low specificity, or, conversely, 
a large number of enzymes with greater specificity, are the integral 
parts of the whole System.
Mixed-function oxygenation was shown to proceed only after activation 
of the essential molecular oxygen. The requirement for a b- type cytochrome, 
cytochrome P-450, in the activation process was later established 
(Estabrook et al, 1963? Omura and Sato, 1964a, b). Competition between 
oxygen and carbon monoxide for the drug metabolising system was documented 
by Cooler^  et al (1965), and this confirmed that oxygen formed a ligand 
complex with cytochrome P-450. Interactions of the cytochrome with 
substrates were first documented by Imai and Sato (1966 ) and Remmer 
et al (1966), and all these observations form the basis of the current 
concept for oxygen activation as a complex triplet of molecular oxygen, 
substrate and cytochrome P-450. (See Gillette et al, 1972 for a review 
on the role of icytochrome P-450 in drug metabolism.)
The importance of a number of other components of the mixed-function 
oxygenase system is now established. Their nature and inter-relationships 
are described elsewhere. (Burke, 1972 J Estabrook et al, 1971), but they 
include another b cytochrome, cytochrome b^ and two flavoproteins previously 
known as NADPH-cytochrome c reductase and NADH-cytochrome b^ reductase.
An intermediate, integral in the reduction of cytochrome P-450 by NADPH, 
apparently exists (Estabrook et al, 1971). Stoichiometric relationships 
between, and spatial organisation of, all these components within the 
endoplasmic reticulum are yet unresolved.
The mechanistic similarities which exist between the hydroxylative 
metabolism of drugs, and that of steroid hormones, led to the present 
hypothesis that steroids may be one of the endogenous substrates of the 
hepatic mixed-function oxygenase system (Kuntzman et al, 1964). A 
hydroxylating system for steroids also exists in adrenal cortical 
mitochondria (Omura et al, 1966), and its similarities with the hepatic 
mixed-function oxygenase emphasise the suitability of the latter for 
steroid hydroxylation. However, differences have been demonstrated 
between certain hepatic steroid hydroxylases and the established drug 
metabolism system (Wada et al, 1969), and this could be indicative of 
the existence of several mixed-function oxygenase-type systems whose 
affinity for different drugs and steroids is variable.
Induction of mixed-function oxygenation.
The stimulation of the hydroxylative metabolism of testosterone, 
cortisol and oestradiol by a number of drugs and by the insecticide 
chlordane has been noted (Conney et al, 1965a, bj Kuntzman et al, 1968). 
These observations again emphasise the similarities between steroid and 
drug hydroxylative metabolism, for it had been previously demonstrated 
that several drugs, polycyclic hydrocarbons and insecticides stimulated
oxidative'drug metabolism (Brown et al, 1954} Conney et al, 1961;
Hart and Fouts, 19&3). %e number of compounds shown to similarly 
stimulate, or induce, the mixed-function oxygenase system has since 
grown dramatically (Sher, 1971). However, these inducers generally fall 
into one of two categories - those typified by a barbiturate, phenobarbital, 
and those represented by 3-metkylcholanthrene, a polycyclic hydrocarbon.
While 3-wethylcholanthrene-type inducers are usually limited to the 
carcinogenic polycyclic hydrocarbons, and are, therefore, necessarily 
limited in number, most other agents fall into the phenobarbital grouping.
The ability to differentially induce the drug metabolism of certain 
compounds is what largely distinguishes 3-methycholanthrene from the 
phenobarbital type of inducer, whose characteristic induction pattern 
is much less specific.
As the effects of both types of inducers can be blocked by inhibitors 
of protein synthesis, a stimulative role in de novo protein synthesis is 
inferred. The differential induction demonstrated, therefore suggests 
similarly differential effects on protein synthesis, and this is well 
illustrated by the effects of phenobarbital or 3-methylcholanthrene 
pretreatment on cytochrome P-450. Y/hen cytochrome P-450 is determined 
using carbon monoxide as ligand (2*9.lb), the characteristic single absorption 
peak at 450nm is revealed. Pretreatment of animals with inducing amounts 
of phenobarbital (100 mg per kg for 3 days) or 3-methylcholanthrene 
(50 mg per kg for 3 days) produces increases in the size of this peak.
If, alternatively, ethyl isocyonde is used as the nucleophile (2.9.1b) 
the resultant absorption difference spectrum reveals the presence of two 
peaks in the 400 to 500 nm range. Microsomes from untreated rats exhibit 
peaks at 430 and 455nm, and although their relative sizes are pH and sex 
dependent, at pH 7.4 the ratio of these peak heights in male rats is 
approximately 3s2 respectively. While pretreatment of animals with
phenobarbital increases the size of both peaks, their relative proportions 
maintain the 3s2 ratio. However, px^ etreatment with 3-methylcli6v.anthrene 
causes a disproportionate increase in the peak sizes such that the ratio 
becomes nearer 2*3. In addition, a slight shift in the absorption 
maximum of the 450nm carbon monoxide induced peak to lower wavelengths 
(448nm) is apparent. These spectrally apparent changes in the nature 
of cytochrome P-450 induced by 3-methylcholanthrene have been attributed 
to the presence of a new haembprotein (P^ -450), whose inherent absorption 
maximum at lower wavelengths causes the blue-shift in wavelength as the 
relative amounts of it increase (Mannering, 1971? Sladek and Mannering, 1966). 
However, other investigators maintain that these changes are due to 
interconversion of two forms of the same cytochrome, the new form of which 
is termed cytochrome P-446 or P-448 (Alvares et al, 1968} Hildebrandt 
et al, 1968).
While a laxge number of Inducers can be categorised as 3-methylcholanthrene 
or phenobarbital types, other compounds demonstrate different induction 
properties. (See Kuntzman, 1969 for a review of enzyme induction.)
Chlorinated insecticides tend to selectively induce certain metabolic 
pathways (Hart and Fouts, 1963} Mullen et al, 1966). Spironolactone, an 
aldosterone antagonist with progestational, anti-androgen, but little 
corticosteroid activity (Hertz and Tullner 1958} Steelman et al, 1969), 
has also been shown to induce drug metabolism extremely selectively 
(Stripp et al, 1971). The mechanisms of these selective induction 
phenomena are, as yet, incompletely l’esolved. However, they may involve 
a differential induction of certain components of the mixed-function 
oxygenase system (Stripp et al, 1971). This hypothesis is strengthened 
by the additive stimulation sometimes produced by certain inducer 
combinations (Gillette, 1963} Mullen et al, 1966; Sladek and Mannering, 1969).
Effects of steroids on drug metabolism.
Just as established enzyme inducers have been shown to affect steroid 
metabolism, there is considerable data demonstrating the effects of steroids 
on drug metabolism (Conney, 1967} Selye, 1970} Sher, 1971). Much 
published work exists on .the effects which changes in endogenous hormone 
levels produce. Thus, the higher capacity of male rats for drug 
transformations has been accredited to the intrinsic presence of male 
sex hormones (Quinn et al, 1958)*. While castration results in a 
characteristic female drug metabolic pattern, treatment of female or 
castrated male rats with androgens restores the male pattern 
(ouinn et al, 1958} Stripp et al, 1971). The influence of sex hormones 
on drug metabolism in mice is more complex, and apparently also involves 
the endogenous corticosteroid status (Wida et al, 1972).
The sex-steroid/corticosteroid relationship is also important in 
other circumstances. After adrenalectomy, the rate of metabolism of many 
drugs decreases in the male rat, but there is little apparent change in 
female drug metabolic activity (Eadzialowski and Bousquet, 1968). These 
changes may result from reduced activity of the reductases of the mixed- 
function oxygenase system (Castro et al, 1970), but their sex dependence 
is difficult to explain. However, the importance of an intact pituitary 
gland in regulating similar interactions in steroid metabolism may be of 
relevance in this context (Colby et al, 1973). This view is endorsed by 
the demonstration that adrenocorticotrophic hormone (ACTH) is incapable 
of restoring the decreased drug metabolic activity of adrenalectomised 
rats to normal,whereas it is effective after liypophysectomy (Parke, 1972).
In comparison to the enhancement of drug metabolism shorn by androgens, 
oestrogens and the progestational steroids tend to depress enzymic activity. 
This is apparent when the lower endogenous drug metabolic capacity of female
rats is considered. Also, administration of oestrogens to male rats is 
detrimental to their metabolic activities and produces a typically female 
status (Quinn et al, 1958). Furthermore, several authors have demonstrated 
an inhibitory effect vrith oestrogens and progesterone, either administered, 
or present in large amounts in pregnant females (Creaven and Parke, 1965? 
Guarino et al,1969b; Juchau and Fouts, 1966} Lauritzen and Lehmann,1967;
Neale and Parke, 1969). In contrast to the endogenous hormones, treatment 
with many of the synthetic oestrogens and gestogens has a stimulatory effect 
on drug metabolism(Parke, 1972). However, in vitro they demonstrate the 
same inhibitory effects that characterise other steroids. Thus, cortisol, 
progesterone, testosterone, androsterone and oestradiol all inhibit in vitro 
drug metabolism when present in the incubation medium (Soyka and Long, 1972; 
Tephly and Mannering, 1968).
Enzymic effects of glucocorticoids.
From the data presented previously, describing the debilitating effects 
of adrenalectomy on drug metabolism, it would be expected that administered 
glucocorticoids would be stimulatory. While this is apparently confirmed 
by their ability to partly restore the enzymic activities of adrenalectomised 
rats to normal, some anomalies exist (Furner and Stitzel, 1968). Furthermore, 
the effects of elevated levels of glucocorticoids (by administration or 
stimulation of endogenous secretion) vary substantially. Bousquet et al (1965) 
demonstrated on increased in vivo metabolism of hexobarbital after ACTS 
or corticosterone injection into rots, and Stitzel and Furner (1967) 
produced increases in hepatic aniline-4-hydroxylase and ethylmorpliine-N- 
demethylase activity by submitting rats to stress. However, rat hepatic 
aminopyrine-N-demethylation has been shorn to be inhibited by corticosterone 
(Radzialowski and Bousquet, 1968) and a similar effect was noted, using 
cortisol, for hexobarbital oxidation (Furner and Stitzel, 1968). While
less use lias been made of synthetic glucocorticoids in this respect, 
induction is the usual outcome of pretreatment (Briggs ond Briggs, 1973; 
Hamrick et al, 1973? Orronius et al, 1969? Renner, 1958; Sonogyi 
et al, 1971). However, prednisolone was shown not to affect the 
metabolism of 5-fluorouraciI or iiropoxyphene (Ambre and Fischer, 1971;
Sc lye ot al, 1972),
Glucocorticoids hove also been shown capable of influencing a large 
number of enzymes involved in intermediary metabolism (Kenney, 1970;
Rosen and Nichol, 1953). Effects have been demonstrated on enzymes 
metabolising amino acids (Bock et al, 1972; Cox and Mathias, 19&95 
Daroczy ond Hernadi, 1971; Greengard and Machovich, 1972;
Inoue et al, 19715 Litwaclc et al, 19651 Schwarts, 1972; Tomkins 
et al, 1972), carbohydrates (Heitzman et al, 1972; Nichols and 
Goldberg, 1972), ond lipids (Friedman et al, 19^ 5). Other noteworthy 
effects include the elevation of the cell content of adenosine 
3*,5*-monophosphate (cyclic AMP) (Manganiello and Vaughan, 1972), 
of mouse liver lysosomal protein metabolism (Chertow et al, 1973) ond 
of various aspects of RNA synthesis (Altman et al, 1972; Bottoms 
et al, 1972b; Dukes et al, 1936; Greexusan et al, 1955; Kenney and 
Kull, 1963? Sojdel and Jacob, 1971; Schmid and Sekeris, 1972;
Wicks et al, 1935). Da comparison to the increases in various aspects 
of hepatic RNA synthesis described in these papers, Gabourel and Fox (1971) 
demonstrated an inhibition of this process in thymic nuclei after cortisol 
administration. Similar inhibitions have been observed in liver BNA and 
histone synthesis (Henderson et al, 1971; Jones and Irvin, 1972).
Mechanisms of glucocorticoid induced enzymic effects.
One of the earliest visible manifestations of glucocorticoid action on 
protein synthesis was demonstrated at the cytoplasmic site of this synthesis. 
Thus, after cortisol administration, Rancourt and Litwack (1968) observed 
progressive conversion of rough endoplasmic recticulum to smooth 
endoplasmic reticulum with a concurrent increase in the number of free 
ribosomes. Later, it was shown that ribosomes were aggregated into 
polyribosomes (polysomes) after cortisol administration to adrenalectomised 
rats (Loeb, 1973). However, these results are inconsistent with those of 
Cox and Mathias (1969) who demonstrated an increased polysome population 
after adrenalectomy, and the converse after cortisol administration.
These authors, and James et al, (1969), also showed an increase in the 
attachment of polysomes to smooth endoplasmic reticulum after cortisol 
administration, or after in vitro incubation of polysomes and smooth 
endoplasmic reticulum with corticosterone. As it has been suggested that 
polysome size is directly related to its capacity to incorporate amino 
acids into protein (Noll et al, 1963? V/ettstein et al, 1963), the 
changes demonstrated after corticosteroid treatment by Cox and Mathias (1969) 
and James et al (1969) are not compatible with the promotion of protein 
synthesis by these steroids. However, the in vitro nature of the study 
of James et al (1969) may be the manifestation of on independent effect, 
because of the high concentration of steroid used.
Such demonstrated changes in the extranuclear mechanisms of hepatic 
protein synthesis probably result from the previously described increases 
in RNA synthesis. Baxter et al (1972) have recently demonstrated nuclear 
binding of glucocorticoids to DNA which could initiate these changes. 
Furthermore, they established an association with the previously identified 
steroid nuclear receptors, endorsing their importance in the mediation of
cortisol action. In addition, the same group have published a considerable 
number of papers presenting evidence for control of protein synthesis at 
a post-transcriptional stage. Most of this work has been conducted in 
rat hepatoma tissue culture cells using tyrosine aminotransferase as tl. j 
model enzyme, but the results obtained appear to be capable of extrapolation 
to other relevant situations. The theory proposes that inducing steroids 
antagonise a labile post-transcriptional repressor which both inhibits 
messenger ENA (mRNA) Hyanslation and enhances its degradation (Tomkins 
et al, 1969). Attachment of the inducing steroid to this repressor
1
effectively stabilises the mRNA, and results in increased protein synthesis. 
This ocxcurs not only in the presence of actinomyein D (which inhibits 
messenger synthesis) but also if the inducer is removed immediately before 
blocking further mRNA synthesis (Gelehrter, 1971; Tomkins et al, 1972). 
Exertion of control in promoting transcription at the gene level is not 
compatible with these results. Although no direct involvement of the 
previously described glucocorticoid receptors in this process has been 
demonstrated, a large amount of circumstantial evidence exists suggesting 
that this is indeed the case (Baxter and Tomkins, 1970} Rousseau et al, 1972).
These controlling mechanisms for enzyme induction by glucocorticoids 
seem to be generally applicable. In addition, however, Cox et al (1971) 
proposed that the induction of alkaline phosphatase by prednisolone in 
He La cells was not due to an increase in the number of enzyme molecules 
present, but to a change in the specific activity of the new enzyme 
synthesised. It appears, therefore, that glucocorticoids can influence 
enzymic activity at the level of transcription, at a post-transcriptional 
stage and possibly in an allosteric capacity.
Nature of the present study.
Because of the relative paucity of information which exists on 
the effects of glucocorticoids on the mixed-function oxygenase 
system, the present study of the effects of these steroids on ensymic 
parameters, was undertaken using drug, substrates. The major purpose 
was to elucidate the nature of these interactions and to apply the 
findings to a more general explanation of glucocorticoid action.
5.2 MATERIALS AM) METHODS.
Animals.
Male rats or hamsters were used in all experiments. They were 
maintained under the conditions described in 2,6.
•'•inhere comparisons of the effects of glucocorticoids were being 
investigated, animals were injected intraperitoneally with solutions 
of steroids in propylene glycol (3 ml per kg) for 7 consecutive days; 
the last injection was given 16 hours prior to sacrifice. In all coses, 
equimolar amounts of steroids were administered (7.65 pmol per kg body 
weight per day), and control animals received propylene glycol alone.
Animals were killed between 08.30 and 09.30 and hepatic microsomal 
suspensions were prepared as rapidly as possible (2.7.1).
Experimental protocol.
Parameters examined in the comparative steroid effector experiments 
were as follows} rate of growth during the pretreatment period, liver 
weight, microsomal protein (2.8.1), cytochrome and P-450 levels 
(2.9.1a, b), and the activities of biphenyl 2- and 4~hydroxylases (2.9.2a), 
aniline-4-hydroxylase (2.9.2b) benzo[a]pyrene-3~hydroxylase (2.9.2c) 
ethyl morphine-M-demethylase (2.9.2d), 4-chloro-N-methlani1ine-N- 
demethylase (2.9.2e) and NADHI cytochrome c reductase (2.9.1c).
Drug metabolism assays conducted in the presence of steroids were 
performed under the same conditions as in the single substrate-concentration 
assays. Steroids were added in 10 pi absolute ethanol from stock 
solutions, such that the final assay concentrations were 0.01, 0.1,
1.0, 10 and 100 pM. Serial constitution of the incubation mixture was 
made from buffer, cofactor solution, steroid, substrate and microsomes, 
and this sequence was rigidly observed.
The conditions used in the kinetic metabolic experiments were also 
identical to those used in the single substrate-concentration assays, 
except that an atmosphere of oxygen was used instead of air during the 
incubations. Substrate concentrations (in the assay) were 0.1, 0.133, 
0.167, 0.217, 0.313, 0.5 and 1.0 miM for biphenyl (from stock solutions 
in 2$ aq. Tween 80), and 0.25, 0.033, 0.050, 0.067, 0.111 and 0.25 mM 
for aniline (from stock solutions of aniline hydrochloride in 0.3M 
Tris-HCl, pH 7.4).
Binding studies were conducted as described in 2.9.4. The kinetics 
of aniline and biphenyl binding were investigated using concentrations of 
0.04, 0.05, 0.06, 0.08, 0.10, 0.14, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8 and 1.0 mM 
biphenyl and 0.2, 0.3, 0.4, 0.6, 0.8, 1.2 and 2.0 mM aniline in the 
cuvettes. Stock solutions were made in ethanol in both cases, and 
were 50 and 250 mM for biphenyl and 500 mM for aniline.
Steroid binding kinetics were undertaken using concentrations of 
0.04, 0.06, 0.08, 0,12, 0.16, 0.2, 0.3, 0.4, 0.6, 0.8 and 1.0 mM in 
the cuvette. Stock solutions (100 mM) of steroids were prepared in 
dimethylsulphoxide.
5.5 KBSULTS AND DISCUSSION.
The use of a large number of compounds made simultaneous 
comparisons impossible, and results are often compared by their 
relationship to control values, therefore. Each result is represented 
in the tables and figures as. the mean determination from four animals. 
Values which differ significantly from those in control groups are 
indicated by asterisks. Where finite values and their standard errors 
do not appear, they are presented in the appendix. Kinetic data were 
plotted as described in 2.8,9.
Dosing regime.
The dose level used in the present study (corresponding to ~ 3mg steroid 
per kg per day) is far lower than those previously employed in comparable 
experiments (Hamrick et al, 1973? Eu et al, 1972? Stripp et al, 1971). 
This dose was selected after a preliminary dose/response study with 
betamethasone had demonstrated its suitability as the lowest dose 
producing a significant biological effect. By so restricting the amount 
of administered steroid, it seemed reasonable to presume that any 
changes demonstrated resulted from the direct action of the compounds, 
and not from simulated stress conditions, which high circulating 
corticosteroid levels may produce. The varied nature of the results 
obtained, ranging from decreased to elevated enzymic activities, indicates 
that such a presumption was justifiable.
Glucocorticoid induced changes in natural parameters.
A suppression of the rate of animal growth was demonstrated after 
P‘retreatment with some of the synthetic steroids (Table 5*1). Despite
this, the rats appeared healthy in all other respects. Changes in 
liver weight (expressed per lOOg body -weight) and levels of microsomal 
protein veve rare (Table 5*1). Because of the established effects of 
glucocorticoids in promoting hepatic glycogen deposition, changes in 
liver weight in the present study do not necessarily reflect similar 
changes in protein synthesis, as is the case for phenobarbital induced 
increases in liver weight. However, by influencing liver weight, 
hepatic glycogen content will affect the expression of hepatic 
microsomal protein levels, if these ore calculated per g liver.
Furthermore, changes in liver weight resulting from pretreatment with 
a particular glucocorticoid may inexplicably vary from experiment to 
experiment* Generally, therefore, changes in liver weight and microsomal 
protein content ore not easily interpreted in the present study, in order 
to reveal the quantitative changes in hepatic microsomal protein, this 
parameter is expressed as the total liver content per lOOg body weight, 
as well as as a function of llhit liver weight (Table 5*1). Only 
betamethasone and dexamethasone produced significant increases in microsomal 
protein content per whole liver per lOOg body weight.
Comparison of the effects of pretreatment with different glucocorticoids.
¥here increases in microsomal protein occurred, these may contribute 
to the increases in enzyme activity demonstrated following administration 
of betamethasone and dexamethasone (Tables 5*4 to 5*9). nowever, other 
factors must be considered, for no such protein changes parallel the 
decreases in enzyme activities resulting after corticosterone, 
6{3-hydroxycorticosterone, and cortisol (Tables 5*4 to 5*9). It is 
interesting to note that cortisol is apparently less potent in this 
respect than is corticosterone, for the enzyme activities after cortisol,
while consistently depressed, ore never significantly different from 
control values. This may reflect the hormonal status of rats, for 
cortisol is present.only in insignificant amounts in this species 
and corticosterone is the predominant glucocorticoid (Bush, 1953).
The changes resulting from 6(3-hydroxycorticosterone pretreatment are 
of the same order as those following pretreatment with corticosterone.
As equimolar dose levels were used, it is apparently not a case of an 
active metabolite producing the demonstrated effect, although 
6(3~hydroxycorticosterone must possess activity in its own right, 
since metabolic conversion to corticosterone seems unlikely. However, 
there is no evidence on the biological effects of 6(3~hydroxycorticosterone 
which confirms or repudiates the activity demonstrated here.
Unlike 6(3-hydroxycoriicosterone, the other corticosterone metabolite 
studied, hexahydroeorticosterone, was largely inactive for all the 
parameters studied (Tables 5*1 to 5*9). Three of the less potent 
synthetic compounds,9^fMorocortisol, prednisolone and triamcinolone 
were also generally inactive. However, 9a-fluorocortisol caused 
significant increases (when expressed in terms of liver weight) in the 
levels of cytochromes b^. and P-45Q and in benspyrene-3-hydroxylotion.
Any changes resulting from prednisolone pretreatment were usually 
manifest when expressed as a function of liver weight, reflecting the 
changes in microsomal protein content also observed (Table 5*1). In 
a further experiment using prednisolone, these changes in microsomal 
protein content could not be repeated, thus emphasing the difficulties 
which changes in liver weight impose on interpretation. Triamcinolone 
produced significant changes only in cytochrome b^ content, which i& 
decreased (Table 5*2) - a change which was apparently not influential 
on enzymic activity (Tables 5*4 to 5*9).
Triamqinolone acetonide, a lipophilic derivative of triamcinolone, 
is apparently more potent in its inducing actions than the free alcohol. 
Thus, increases in the activity of several enzymic parameters were noted 
after triamcinolone acetonide (Tables 5*6, 7, 8), The most feasible 
explanation for this difference is that the acetonide grouping hinders 
the rate of deactivation of the compound and consequently increases the 
duration of its action. This is confirmed by its tissue half-life, which 
is considerably longer than that of triamcinolone itself (Simpson and 
White, 1973)*
Beclomethasone, betamethasone and dexamethasone are, in increasing 
order, the most biologicaImpotent glucocorticoids used in the present 
study. Their effects on the parameters studied in these experiments 
tend to reflect this fact, for dexamethasone produced significant changes 
in every parameter, while betamethasone and beclomethasone were relatively 
less potent, but still effective. The depression of cytochrome b*- levels 
after betamethasone and dexamethasone pretreatment is noteworthy in the 
light of the overall induction produced by these steroids.
Effects of glucocorticoids on different enzymes.
An overall examination of the enzymic parameters studied indicates 
that the changes produced by each steroid are of a consistent nature.
Thus the metabolism of Type I (biphenyl, ethylmorphine) and Type II 
(aniline, p-chloro-N- methylaniline n^zyrne substrates, as well as of the 
carcinogen, benzo[a]pyrene, was affected similarly. Not surprisingly, 
however, quantitative differences v/ere shown. Bipheny1-2-hydroxylation 
(Table 5*5) was generally less markedly affected than the other 
hydroxylating enzymes - a result resembling phenobarbital pretreatment 
rather than the carcinogenic group of inducers (Cx-eaven and Parke, 1966).
In this respect the result obtained after 6p~hydroxycorticosterone is 
of interest (compare Tables 5*4 and 5*5). The activity of p-chloro-N- 
methylaniline-N-demethylase is apparently affected somewhat differently 
by glucocorticoid pretreatment than are the other enzymes (Table 5*9)* 
Corticosterone significantly induced the demethylationof p-chloro-N- 
methylaniline, while it depressed demethylation of ethyl morphine, and 
the hydroxylation of the other Type II substrate (aniline). Induction 
after prednisolone and triamcinolone is also more apparent when 
p-chloro-N~methylaniline~N-demethylase is considered. The reason for 
these differences is not readily apparent,
Timo course of gJikOcortieofd infection. ■
While the magnitude of changes in enzymic activity did not parallel 
similar changes in either cytochrome P-450 content (Table 5*2), or in 
KADPH cytochrome c reductase activity (Table 5*3), it appeared that 
additive contributions could determine the overall response. As slow 
changes in these parameters were suspected over the period of 
pretreatment, the time course of their induction was examined using 
the potent synthetic glucocorticoid, dexamethasone. The results of 
these studies are presented in Figures 5*1 to 5*6.
Microsomal protein content (Figurer5:l.):differsIsighificantly ^ rom control 
values only on days 2 and 7. This tends to Indicate a biphasic response 
to dexamethasone pre treatment, although the implications of this response 
are not immediately obvious. However, they may reflect the overall 
changes of early increases in NADFH cytochrome c reductase (Figure 5*3) 
and later increases in cytochrome P-450 content (Figure 5*2). Such 
elevated levels of these components would not markedly influence total 
protein content per se, but would be accompanied by proliferation of the
microsomal membranes with which they are intimately associated.
As stated above, NADFH cytochrome c reductase levels increase soon 
after pretreatment begins. They reach a maximum after 5 days and then 
decline slightly (Figure 5*3)* In contrast, cytochrome P-450 levels 
steadily fall over the first five days of pretreatment, but rise 
substantially over the final two days of dosing (Figure 5*2). Cytochrome 
levels follow a different pattern again, decreasing to a minimum at 
3 days and subsequently rising slowly. However, the level at 7 days is 
still significantly lower than control values (Figure 5*2), Increases 
in the 4-hydroxy la tion of aniline and biphenyl are almost identical over 
the entire pretreatment period (Figures 5*4 and 5*5)* They apparently 
mirror the initii-i changes in NADPH cytochrome c reductase activity, and 
the subsequent increases in cytochrome P-450. In contrast, the activity 
of biphenyl-2-hydroxylase appears more dependent on the reductase 
activity (Figure 5*4).
In summary, these results and those presented previously, indicate 
that pre treatment with glucocorticoids produces changes in enzyme 
activity which may be dependent on similar changes in the level of 
cytochrome P-450 and on its rate of reduction. This reduction of 
cytochrome P-450 (measured in the present study by NADFH cytochrome c 
reductase activity) is perhaps the ultimate determinant.
Glucocorticoid induced changes in the kinetics of metabolism of 
aniline and biphenyl.
In an attempt to elucidate the nature of the changes in enzymic 
properties resulting from glucocorticoid pretreatment, the kinetics of 
biphenyl- and aniline-4-hydroxylation were examined after seven day 
pretreatment with corticosterone and dexamethasone. The results obtained 
are presented in Table 5*10.
Pretreatment with corticosterone affected neither K nor V ofra max
either enzyme. (See appendix for definition of terns.) After
dexamethasone, however, significant increases in V were observedmax
for both aniline and biphenyl. The lac^ of any similar increase in 
indicates that the changes demonstrated are likely to arise from 
quantitative, and not qualitative, differences in the enzyme system(s).
One component of the mixed-function oxygenase system, cytochrome P-450, 
was almost certainly qualitatively unchanged, for examination of the 
ethyl isocyanide absorption spectrum of microsomes obtained from rats 
pretreated with dexamethasone showed no changes in the ratio of the 
430 : 455nm. peak heights.
Glucocorticoid induced changes in the kinetics of binding of aniline 
and biphenyl.
By examination of the kinetics of spectrally apparent interactions 
of biphenyl and aniline with microsomes it was hoped that any possible 
glucocorticoid induced changes in the binding of these substrates would- 
be revealed. Spectrally apparent interactions of biphenyl with microsomal 
suspensions produce a characteristic inflexion in the Linewe a ve r-Burk 
plot and two sets of kinetic values are, therefore, obtainable. These 
relate to the high and low affinity interactions of biphenyl with 
microsomes (See Appendix). The results obtained after a seven day 
pretreatment regime with corticosterone, prednisolone, betamethasone and 
dexamethasone are presented in Tables 5sii and 5sl2.
The only change revealed resulted from dexamethasone pretreatment, 
and was a marginal increase in AE^^ of the low affinity biphenyl 
interactions. (See appendix for definition of terms.) Similar, small,
but non-significant, increases in the AE of aniline, and of the highmax
affinity interaction of biphenyl, were demonstrated after dexamethasone 
and betamethasone pretreatment. As these differences were manifest at 
constant protein or cytochrome P-450 levels, they are independent of 
corresponding changes in levels of the cytochrome, and may be related 
to modifications in the nature of the binding site. No differences in 
Kg values were noted, however. Any effect that glucocorticoids exert 
on metabolic parameters, therefore appears to be independent of the 
nature of interaction of a substrate with its binding site.
Binding characteristics of glucocorticoids.
As no documented evidence existed for the kinetics of binding of the 
synthetic glucocorticoids, a study was conducted in which the interactions 
of prednisolone, betamethasone and dexamethasone were compared to those 
of cortisol and corticosterone in untreated hepatic microsomes. Two 
species were used, namely, rats and hamsters, largely because corticosterone 
predominates in the rat and cortisol in the hamster. Qualitatively, 
the results obtained demonstrate an interesting species difference in 
the binding spectra characteristics. In the hamster, all the compounds 
studied produced typical Type 1 spectra, with absorption peaks around 
385nm and troughs around 425nm (Table 5sl3). In the rat, however, only 
the endogenous glucocorticoid (corticosterone) gave a ,*fype I spectrum. 
Cortisol and dexamethasone, in comparision, produced reversed Type I 
spectra, while prednisolone and betamethasone gave spectra that were 
not easily categorised (Table 5s14).
When the binding kinetics of these steroids were examined, 
significant differences were noted between the two animal species and 
between the types of steroid used (Table 5sl5)» In all cases, the
steroids produced greater spectral changes in hamsters than in rat
microsomes (compare ^ max values). This applied to cortisol and*
corticosterone as well as to the synthetic analogues. A single
concentration comparative test demonstrated that corticosterone
produced greater spectral changes in the rat than did cortisol. In
this respect cortisol behaves more like an endogenous steroid - which
is effectively the case in the rat. Interestingly, the same phenomenon
was demonstrated in the hamster. As cortisol predominates in this
species, the differences existing must be due to the structural
properties of the steroids and not their relative abundance. This
seems a logical determinant,
Differences in Kg also exist, and it appears that this parameter is
again influenced by structure* Thus, corticosterone has a higher IC in
the rat than do the synthetic steroids, and the same is true for cortisol
in the hamster. However, corticosterone has a K value comparative withs
thos# of the synthetic steroids in the hamster. In absolute terms, the
K values of corticosterone in the rat, and of cortisol in the hamster, s 9
are comparable with other Type I compounds (cf. biphenyl, K around£5
1.5 s llfl!). The lower K values of the synthetic steroids (aroundS . ' '
—55 x 10 M) are paralleled by those of several compounds, however 
(l-anilino-8-naphthalene sulplionate, R* warfarin; Al-Galainy, 1973).
In vitro effects of glucocorticoids on enzymic hydroxylations.
The final series of experiments comprising this study were designed 
to ascertain whether any of the changes demonstrated in the drug 
metabolism studies could be ascribed to residual amounts of steroid 
present in the prepared microsomes. AM 16 hours had elapsed between 
the final injection and sacrifice, it seemed likely that any steroid
remaining would be present as a metabolite. In view of the preferential 
hydroxylation of the synthetic steroids (Chapter 4), the only hydroxylated 
metabolite available, 6(3-hydroxycorticosterone, w a s  used in the study, as 
well as several intact glucocorticoids.
The results obtained when the steroids were present during aniline-4- 
hydroxylation are presented in Figures 5:6 and 557. For all the steroids 
used, a small reduction in metabolic activity was noted, which increased 
with higher steroid concentrations. Although no attempt was made to 
classify the nature of this inhibition, it existence confirms the results 
of other workers using cortisol (Tephly and Mannering, 1968), Less 
consistent, but similar effects were produced when the steroids were 
incubated with biphenyl and its 4-hydroxylation was examined (Figures 5:8 
to 5:13).
The 2-hydroxylation of biphenyl was affected by the glucocorticoids 
in a totally different manner (Figures 5:8 to 5:13). In the presence of 
high concentrations (10 \l) of corticosterone, prednisolone, betamethasone, 
and dexamethasone, significant increases in bipheny1-2-hydroxylation 
resulted. These varied from values 160$ of controls for prednisolone 
to 780$ for betamethasone. While 6p-hydroxycorticosterone produced 
similar, but small and non-significant increases, cortisol had no effect.
The reason for these effects on biphenyl-2-hydroxylation are not 
immediately apparent. However, Hahin and his colleagues have demonstrated 
a stabilising effect of corticosterone and several sex steroids on 
isolated rough endoplasmic reticulum (Blyth et al, 1972; James 
et al, 1969). They attributed this effect to facilitation of the 
binding of polysomes to smooth endoplasmic reticulum - a phenomenon 
they measured by monitoring the activity of a disulphide interchange 
enzyme located in the smooth endoplasmic reticulum, and whose activity
was inhibited by polysome attachment. In a recent paper, Bridges 
et al (1973) have reported increases in biphenyl-2-hydroxylation by 
inclusion of various carcinogens in the in vitro incubation system.
They attributed these changes, similar to those found in the present 
study, to an effect on polysome binding.
While a two fold increase in bipheny1-2-hydroxylation occurs Within 
10 minutes with corticosterone, slightly higher concentrations of the 
steroid produce only a 5$ change in polysome binding after 30 minutes 
(James et al, 1969), It, therefore, appears that the changes demonstrated 
in the two studies are neither quantitatively nor temporally compatible. 
Furthermore, McPherson (1973) has demonstrated that the increases in 
bipheny1-2-hydroxylation produced by a number of carcinogens can be 
demonstrated after 5 minutes.
Little is known of any characteristics of biphenyl-2-hydroxylation 
that distinguish it from other drug metabolic transformations.
Consequently if is diffibtilt to provide an explanation for the peculiar 
properties it demonstrates in this context, further than ascribing these 
to induced changes in the nature of the enzymic component, or in its 
associated membranous environment. Such changes, possibly allosteric 
in nature, would most readily satisfy the individual nature of 
differences demonstrated. They would demand that the 2-hydroxylation 
of biphenyl is mediated through a distinct enzymic component, however.
In the light of other evidence (Burke, 1972; Creaven and Parke, 1966; 
Ibid, this chapter) this could be the case.
General considerations.
The results described in this chapter show that glucocorticoids exert 
a significant effect on various parameters of the hepatic microsomal
drug metabolising enzymes. The changes manifest show both reductions 
and elevations of enzymic activity, depending on the steroid used.
Y/hcre enzymic induction occurs, the nature of the overall changes ore 
dissimilar to those produced by phenobarbital or 3-methylcholanthrene. 
Dexamethasone pretreatment, for example, results in no large increases 
in hepatic microsomal protein content (as is found with phenobarbital) 
nor in the nature of the absorption difference spectra of reduced cytochrome 
P-450 using ethyl isocyanide as ligand (as with 3-methylcholanthrene). 
Moreover, dexamethasone produces no change in the binding of Type I or 
Type II compounds, whereas phenobarbital enhances both, and 3-meihyl- 
cholentkrene increases Type I and decreases Type II interactions 
(Kutt et al, 1971> Shoeman et al, 1969).
Generally, therefore, the induction characteristics of dexamethasone 
are different from those of both phenobarbital and 3-methylcholanthrene, 
and more closely resemble -those of 3P~hydroxy-20-keto-pregn-5-ene-l6a- 
carbonitrile [PCN] (Lu et al, 1972). Y/hile a full comparison cannot be 
made, and differences in effect do exist (especially on protein synthesis), 
PCN and dexamethasone both increase the levels of NADPH - cytochrome c 
reductase and cytochrome P-450. They, therefore, differ from 
spironolactone, which increases only the reductase (stripp et al, 1971).
As stated previously, glucocorticoid pretreatment can result in 
increased or decreased levels of drug metabolic activity, depending on 
the biological potency of the steroid used. Increased activity (manifest 
after dexamethasone pretx'eatment) can be attributed to the elevated 
levels of cytochrome P-450, and its faster reduction. Depressed 
enzymic activity (after corticosterone) is less obviously explained, 
but is not without precedent. Such depression has been noted after
corticosterone administration^  adrenalectomy (Radzialowski and 
Bousquet, 1968), and after hypophyse ctomy (Parke, 1972). Despite 
the apparently different nature of these effectors, it is suggested 
that some similarities do exist. Administration of all the biologically 
active steroids used in the present study would cause a diminution in 
the synthesis of endogenous glucocorticoids, mediated through a 
similar depression of release of ACTH from the adenohypophysis. This 
suppression of glucocorticoid synthesis would abolish the sustained 
secretion of endogenous glucocorticoids, together with their continuous 
effects. In its place would be substituted the resultant effect of a 
single, higher level of administered steroid, whose tissue retention 
and catabolic fate largely determined its duration of action. The 
saturable nature of the glucocorticoid receptors involved in their 
mediating actions (Chapter 3), as well as the factors just mentioned, 
would also limit the effectiveness of a single dose. Thus, the 
effects of an administered 3teroid, rapidly mobilised to the liver, 
would be less marked than the equivalent dose of another steroid to 
which the liver was exposed more gradually.
The hypothesis would explain why replacement therapy by rapidly 
mobilised natural glucocorticoids is less effective in the restoration 
of drug metabolic activity in adrenalectomised rats than is similar 
replacement with their synthetic derivatives (Firmer and Stitzel, 1968; 
Remmer, 1958). It also suggests that the effects of administered 
glucocorticoids are determined by a combination of their suppressive 
and inductive actions. In the present study, the apparent inactivity 
of several of the less potent synthetic compounds used (9ctr-fluorocortisol, 
prednisolone and triamcinolone) could result from the quantitatively 
similar responses they produce in these two parameters.
It seems reasonable to presume that the induction caused by 
the synthetic glucocorticoids in the present study is of a similar 
origin to that noted in certain intermediary metabolism enzymes using 
natural corticosterooids, and described earlier. In both cases, 
the resultant increases in enzymic activity are not a product of 
widely mediated changes (as found after phenobarbital pretreatment), 
but arise from selective increases in a restricted number of parameters.
The present studies on the kinetics of metabolism of aniline and 
biphenyl have shorn that increases in drug metabolic activity are 
a result of elevated levels of the same enzyme(s) found in untreated 
animals (Table 5:10). These conclusions are in agreement with those of Reel 
et al(l970) who studied the induction of tyrosine aminotransferase 
by cortisol, but in contrast to those of Cox et al (1971) who studied 
alkaline phosphatase induction by prednisolone. In addition, however, 
the results of the in vitro incubations of glucocorticoids on biphenyl- 
2-hydroxylation suggest that these compounds may exert a direct effect 
on the conformational state of some existing enzymes.
Conclusions.
Unlike phenobarbital or 3-methylckolanthrene, glucocorticoids 
apparently exert their effects on drug metabolism largely by influencing 
the amounts of cellular Oytochrome P-450 and its rate of reduction. In 
this respect they also differ from spironolactone, which only influences 
the rate of P-450 reduction, and more nearly resemble 3p~hydroxy-20-keto- 
pregn-5-ene-l6ar-carbonitrile, a potent synthetic steroid. The actions of 
glucocorticoids in inducing these changes in drug metabolism activity, 
are apparently directed at one or several steps in promoting de novo protein 
synthesis. However, the results of the present work also indicate that 
glucocorticoids may exert some allosteric effects on existing enzymic protein.
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TABLE 5:13 SPECTRALLY APPABENT CHARACTERISTICS OF BINDING OF A NUMBER OF 
GLUCOCORTICOIDS TO HAMSTER LIVER MICROSOMES._______________
ABSORPTION
GLUCOCORTICOID MAX (nm) MIN (nm) TYPE OF SPECTRUM
Cortisol 385 426
Corticosterone 384 423
All-
Prednisolone 386 425
typical
Betamethasone 386 425
Type I
Dexamethasone 386 425
TABLE 5:14 SPECTRALLY APPARENT CHARACTERISTICS OF BINDING OF A NUMBER OF 
GLUCOCORTICOIDS TO RAT LIVER MICROSOMES. ____________
GLUCOCORTICOID
ABSORPl 
MAX (nm)
MON
MIN (nm) TYPE OF SPECTRUM
Corticosterone 394 425 Type I
Cortisol 408 440 Reversed Type I
Prednisolone 425 380 Type II?
Betamethasone 415 375 Type II?
Dexamethasone 409 430 Reversed Type I
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FIGURE 5:6 EFFECT OF CORTICOSTERONE AND PREDNISOLONE, IN VITRO, ON HEPATIC
ANILINE-4-1IYDR0XYLASE ACTIVITY.____
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Enzyme activities were calculated as nmol 4-aminophenol produced per mg 
microsomal protein per hour.
Assay conditions are described in the text.
FIGURE 5:7 EFFECTS OF BETAMETHASONE AND DEXAMETHASONE, IN VITRO, ON
HEPATIC ANILINE-A-HYDROXYLASE ACTIVITY.______________
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DIURNAL VARIATIONS IN STEROID METABOLISM, DRUG METABOLISM AND 
SOME ASSOCIATED PARAMETERS IN THE MALE GOLDEN HAMSTER.
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6.1 INTRODUCTION.
Diurnally rhythmic parameters.
The presence of a diurnal rhythm in the level of circulating 
glucocorticoids, and their metabolites, has been established for over 
25 years (Pincus et al* 1948). The observation of this phenomenon^ , has 
been made in several mammalian species, fish and reptiles, as well as 
in man. Bottoms et al (1972a) stated that those animals which are active 
during the daylight hours have maximal circulating corticosteroid blood 
levels between 0 8,00 and 10*00 hours, whereas: tEose animals which can be 
classed as nocturnal demonstrate peak levels at 20.00 to 22.00 hours.
This is confirmed by the results of Hoffsis et al (1970) in the horse,
Whipp et al (1970) in the pig, Harwood and Mason (1956) in the dog,
Migeon et al (1955) in the monkey, Orth and Liddle (1967) in man, and 
by Guillemin et al (1959) in the rat and Halberg et al (1958) in mice.
In contrast, there was a novel rhythm in the catfish(ictalurus punctatus) 
with peaks at 06.00 and 14.00 hours for cortisone and at 07.00, 10.00 and 
24.00 hours for corticosterone (Boehlke et al, 1966). The desert iguana 
(Dipsosaurus dorsalis) demonstrated a rhythm in plasma corticosterone 
resembling that of the rat (Chan and Callard, 1972). Birds, however, 
show twin peaks in circulating corticosterone in the early morning and 
evening, and seem to manifest a twelve hour cycle (Boissin and Assenmacher,
1968; Chan and Phillips, 1970).
In addition to the variations in plasma corticosteroids described 
above, similar diurnal rhythms have been described for a number of 
cellular parameters. These include glycogen synthesis (McVerry and 
Kim, 1972; Sollberger, 1964), cholesterol synthesis (Edwards et al, 1972), 
intraocular pressure and blood flow in human eyes (Boyd and McLeod, 1964),
RNA liver content (Doring and Reusing, 1973)* chromatin template 
activity (Steinhart, 1971) and levels of smooth endoplasmic 
reticulum, (Chedid and Nair, 1972). Some of these rhythms could 
he ascribed to circadian variations in the levels of associated 
enzymes. Many such periodicities have been described for enzymes 
involved in amino acid metabolism (Ulrich and Yuwiler, 19715 
Shambaugh et al, 19671 Given et al, 19&7; Eapoport et al, 1966;
Sullivan et al, 1972; VJurtman and Axelrod, 1967)* lipid metabolism 
(Shapiro and Ro dwell, 196 95 1971) and carbohydrate metabolism
(Glick et al, i960; Chandrabose et al, 1971)*
Circulating plasma levels of glucocortiocoids are dependent 
on their synthesis in, and release from the adrenal cortex, as well 
as their metabolism. While no direct determinations of variations in 
hepatic corticosteroid metabolism over a 24-hour period have been 
reported, similar studies on glucocorticoid synthesis and release have 
been made. Thus, Saba et al (1963) detected a diurnal rhythm for adrenal 
secretion of corticosterone in rats, although this did not temporally 
correlate with the rhythm in circulating hormone which was also 
determined. A circadian variation in the adrenal secretion of 
corticosteroids has also been demonstrated in dogs (Galicich et al, 1964). 
These results probably manifest the changes shown in adrenal cortical 
parenchymal cells whose mitoses are subject to a diurnal rhythm in mice 
(Halberg et al, 1959), and to a circadian variation in adrenocorticotrophic 
hormone (ACTH) secretion (Demura et al, 1966).
Factors affecting diurnal rhythms.
Several endocrine glands have been shown to exert effects on 
demonstrated diurnal rhythms, although these effects may vary with the
parameter studied (compare Fiske and Leeman, 1964 with Fiske and 
Lambert* 1962 for the effects of gonadectomy). The massive reduction 
in circulating corticosteroid levels produced by adrenalectomy and 
hypophysectomy are usually debilitory (Hickman et al, 1972;
Rapoport et al, 1966; Chiefetz et al, 1968)* While this would, perhaps, 
be expected, the similar detrimental effects to circadian rhythms 
produced after thyroidectongr are more difficult to explain 
(Shambaugh et al, 1967). Pinealectomy had little apparent effect 
(Nir et al, 1971).
As well as the above hormonal effects, environmental conditions, 
have been shown to influence diurnal rhythms. Fiske and her co-workers 
(19625 1964) demonstrated that exposure to continuous light abolished
the circulating corticosterone diurnal rhythm in intact female rats, and** 
reduced their adrenal size. A similar elimination of the rhythm was 
observed by Critchlow et al (1963) in blinded rats. These experiments, 
and the work of Van Pilsum and Halberg (1964) and Sullivan et al (1972), 
in which changes in periodicity of the enzyme activities studied were 
observed when the controlled light/dark cycle was reversed* indicate the 
importance of a regular, alternating light cycle. Similar changes in 
periodicity have resulted from enforced modifications in feeding habits 
(Edwards et al, 1972; Booth et al, 1972). Starvation has, apparently, 
no effect (Sollberger, 1964; Steinhart, 1971)*
Diurnal rhythms in steroid and drug metabolism.
Although a large number of studies of rhythmic variations in 
endogenous enzymes exist, there is little published work on similar 
rhythms in e nzymes responsible for hepatic steroid and drug metabolism. 
Also, few reports exist of the effects of drugs on endogenous rhythms 
(Critchlow et al, 1963; Chedid and Nair, 1972; Radzialowski and 
Bousquet, 1968),
The hydroxylation of 3P-hydroxy-androst-5--en-17-one (DIIA) by rat 
liver microsomes was examined by Co.las et al (1969) and a diurnal rhythm 
detected. Interestingly, the rhythms of the two DHA hydroxylations 
studied (at the 7ar- and l6a- positions) were almost 12 hours out of phase 
with each other. The circadian rhythm of aminopyrine-N-demethylase 
generally resembled that of DHA 7ar-hydroxylation, with a peak at 02.00 
hours. However, a supplementary maximum at 10.00 hours was also apparent 
for the drug metabolising enzyme. This second peak was not present in 
the data published by Radzialowski and Bousquet (1967; 1968), Nair and
Casper (1969) and Jori et al (1971 a, b) concerning the N-demethylation 
of aminopyrine. These authors demonstrated similar rhythms in the various 
other drug metabolism enzymes studied, namely hexobarbital hydroxylase, 
4-nitroanisole-0-demethylase, imipramine-N-demethylase and 
4-dimethylaminoazobenzene reductase. Maximal activity in all cases was 
around 24.00 hours and the corresponding minimum occurred in the early 
afternoon. These rhythmic extremes were found to be 12 hours out of phese 
with those of plasma corticosterone (Radzialowski and Bousquet, 1968),
In the only study on levels of hepatic cytochrome P-450, no diurnal 
rhythm was detected (Colas et al, I969).
Correlation between in vitro and in vivo metabolism of hexobarbital 
was demonstrated by Nair and Casper (1969). They showed that the 
microsomal metabolism of the barbiturate was inversely proportional to 
the sleeping-times it induced, at corresponding times of the rhythmic 
cycle. Circadian variations in the in vivo metabolism of other drugs 
has been reported (Marte and Ilalberg, 1961; Davis, 1962).
The interactions of various environmental and hormonal parameters 
with drug metabolism enzymes have been examined in these investigations.
So too have various implications of central nervous control. Not 
surprisingly, many of the demonstrated effectors are the same as those
shorn to influence the diurnal rhythms found in natural parameters, and 
described previously.
Thus, adrenalectongr -was shewn to abolish the oxidative drug 
metabolising rhythms, as did sustained, elevated plasma levels of 
corticosterone (Radzialowski and Bousquet, 1968). Changes in feeding 
habits produced corresponding changes in rhythmic periodicities 
(Nair et al, 1970). Fasting however had no effect (iladzialowski and 
Bousquet, 1967)- The importance of a regular, alternating light/dark 
cycle was again demonstrated. Jori et al (1971a) produced a reversal 
of the rhythmic metabolic extremes by exposing rats to a reversed light 
cycle, and Nair and Casper (1969) abolished normal rhythms by housing 
rats in constant light or darkness, Nair and his colleagues also 
examined the effects of bilateral superior ganglionectomy and hypothalamic 
medial and lateral lesions, While the former shifted the temporal 
extremes of hexobarbital hydroxylation* hypothalamic lesions completely 
abolished the rhythm (Nair et al, 1970)* Although the authors ascribed 
these changes to a partial dependence on sympathetic innervation of the 
pineal gland, the results of Nir et al (1971) suggest that this may not 
be the case*
Naiure of the present study.
From the information presented above it is apparent that the factors 
effecting diurnal rhythms are numerous. While their origin and raison 
■d’etre remains unresolved, existing evidence indicates that the 
placement of extremes in rhythmic bodily parameters is determined by 
the interaction of a number of endogenous and environmental components.
It seemed likely that information on the biochemical processes 
involved in the promotion of rhythmic variations in enzymic activity 
could promote a fuller understanding of their causative factors.
Changes in enzyme metabolic behaviour at the molecular le$&l are manifest, 
to some extent, by their kinetic properties. Studies of this type have 
not been previously conducted. The possibility of a rhythmicity in the 
spectrally apparent interactions of substrates with the microsomal systems 
also appeared to be worthy of investigation. Finally, the dearth of 
information on the rhythmic nature of glucocorticoid metabolism and the 
rhythmic responses of other integral components of the mixed-function 
oxidase system, merited further investigation.
This study was undertaken as a joint project with two previous 
postgraduate students of the department, Brian Lake and Danny Burke.
To them go my sincere thanks - both for their experimental contributions 
and for their wit and unflagging enthusiasm, which made the long hours 
investigating circadian rhythms more tolerable.
6.2 MATERIALS AND METHODS.
Animals.
Adult, male golden hamsters were used inwall experiments. They 
were caged in groups containing one animal more than was required for 
the experiment at each time point (to minimise stress at the time of 
sacrifice) and under the conditions previously described (2.6).
Every effort was made to reduce noise and disturbance as well as 
extraneous; rhythm proraotors, such as thermostat indicator lights.
Animals were handled daily in the month prior to sacrifice in an attempt 
to reduce the effects of pre-death stressing.
Animals comprising a ^ particulartime group were brought individually
)
to a closed killing room and decapitated immediately, and at close intervals 
in time. Blood was collected and the livers removed and processed as 
described in 2.7.1. Microsomes were prepared as previously described
(2.7.1) except that the initial homogenisation was made in 1.15$ (w/v) EC1 
buffered with 0.01M phosphate buffer, pH 7.4. Resuspension of microsomes 
was made in one volume 1.15$ (w/v) KC1 and the protein content determined
(2.8.1). Further additions of EDI were then made to produce suspensions 
containing 10 mg microsomal protein per ml.
Experimental protocol.
Values for the parameters studied were obtained in three distinct 
experiments (referred to as I, II and III) at the times shown.
I: 02.00, 06.00, 10.00, 14.00, 18.00, 22.00 and 02.00 of the following day.
II! 00.00, 04.00, 08.00, 12.00, 16.00, 20.00 and 24.00.
Ill; 04.00, 06.00, 08.00, 10.00 and 14.00, 16.00, 18.00 and 20.00.
Single substrate-concentration aniline metabolism was determined 
as described in 2.9.2b. Kinetic experiments were conducted using (final
amounts in the assay) 0.02, 0.03, 0.04, 0.06, 0.1 and 0.8 jjmol aniline 
hydrochloride. Apart from incubating in an atmosphere of oxygen, the 
conditions used were identical to those of the single concentration assay. 
Biphenyl 2- and 4- hydroxylases were measured using the modification of 
Burke (1972). The assay mixture comprised (final amounts) 200 jjmol 
phosphate buffer (pH 7.6), 0.5 jjmol NADP, 5 jjmol isocitric acid, 10 jjmol 
MgSO^, 0.4 units isociirate dehydrogenase and 5 jjmol biphenyl in the 
single substrate-concentfation determinations. In kinetic experiments 
the amounts of substrate (in the assay) were 0,15* 0.2, 0.275, 0.4, 0.55, 
0.75, 0.9, 1.2 1.5 and 2.5 pmol biphenyl. In both cases incubation was 
carried out in an atmosphere of oxygen for 10 minutes and the extraction 
was effected as described in 2.9.2a. Microsomal protein (2 mg) was used 
in the biphenyl assays and 3 mg for aniline.
The spectrally apparent interactions of aniline, biphenyl, 
corticosterone and cortisol were studied at single concentrations, using 
microsomal suspensions diluted to 2 mg protein per ml with 0.1M phosphate 
buffer (pH 7.6). Final cuvette concentrations were 0.8niM for aniline, 
0.208mM for biphenyl, and O.lmM for cortisol and corticosterone.
(Additions were made from stock ethanolic solutions which were 500mM, 
l30mM and 50mM respectively). In the kinetic binding studies, cuvette 
concentrations were 0.2, 0.3, 0.4, 0.6, 0.8, 1.2 and 2.0mM for aniline 
and 0.04, 0.06, 0.08, 0.1, 0.14, 0.2, 0.3, 0.4, 0.6, 0.7, 0.8, 0.9 and 
l.OmM for biphenyl. All determinations were made as described in 2.9.4 
using an SP 1800 spectrophotometer.
Plasma cortisol was determined as described in 2.8.3d, hepatic DNA 
as in 2.8.2, hepatic corticosteroid metabolism as in 2.9.3, and cytochromes
The activity of individually caged hamsters was also determined 
over 24 hour periods. Activity wheels (E.K. Bowman Co. Ltd., London 
modified in these laboratories for electronic recording, were used in 
the investigations.
6.5 RESULTS AND DISCUSSION.
Results of microsomal metabolism of corticosterone and cortisol, 
and of spectral interactions of the steroids, are single value 
determinations made from pooled liver samples. Plasma cortisol levels- 
are means of duplicate determinations oti pooled blood samples* All 
other results are represented as the means of three duplicated determinations 
for experiments I and II and of four similar determinations for experiment 
III. Standard errors and the: mean values appear .in ^ Re appendix' ^
(Tables A6:l-A6:6 inclusive). Where a significant difference exists 
between a value at a particular time and the mean of all the determinations 
in that experiment, or at another stated time, it is indicated by on 
asterisk.
General considerations.
An overall consideration of the results obtained (Sec Table 6sl) 
indicates that many of the parameters studied possess significent 
circadian rhyihmiciiies. Hamsters, therefore, manifest the some rhythmic - 
changes in drug metabolic activity as do rats and mice (fiadzialowski 
and Bousquet, 1968). Maximal values are usually two or three times the 
corresponding minima, and these extremes are often significantly 
different. In addition to confirming previous findings (Nair and Casper,1969), 
our results demonstrate that extremes which exist ore not sharply defined 
in time and ere manifest os broad peaks or troughs. Although this is 
consequent of our determinations being made on three distinct occasions, 
it seems likely that these results reflect the true patterns of circadian 
variation more accurately than the sharp maxima and minima of other 
workers.
X8BIE 6t 1 s m s m  OF HKGb OF DIUENAL MAXIMA .AND MINIMA IN THE
PARAMETERS STODB3).
Parameter i^tnes (h 
Maximum
ours) of 
Minimum
Significance (p) 
between 
max. and H&&.
Biphonyl~4-hydroxyla iion
06.00I 18.00 0.01
II 08.00 16,00 0.01
III 10.00 16.00 0.05
Bipbeayi~2-bydroxylation
I x%.oo 18.00 0.01
II 12.80 16.00 0.01
I I I 04*00 16.00 0.05
/mil in o -4 -h y c !ro x y  lo  ti«a
06,00I 18.00 0.01
XI 04.00 16.00 0.01
III 06.00 14.00 0.01
Cytochrome B-450 09.00 18.00 0.05
Cytochrome 12,00 Variable M.S.
Corticosterone
m e ta b o lis m 07.08 Variable
Plasma cortisol 16.00 Variable -
Biphenyl binding 08.00 16,00 0.05
Aniline binding 10.00 18.00 Variable
Steroid binding 
D m
Microsomal protein
08,00 
Mo dem 
Ho on
Variable 
ansirated rhythm 
©nsiraied rhythm
* *
Rhythms in drug metabolism.
The diurnal rhythms found to exist for the 4-hydroxylation of 
aniline and biphenyl (Figures 6:1 and 6:3) are slightly out of phase with 
those reported for other drug metabolism studies. Whereas we showed maxima 
around 06.00 hours, Radzialowski and Bousquet (1968) and Nair and Casper (1969) 
found peak metabolic activity around 02.00 hours. A comparison of the 
demonstrated minima shows a similarly shifted extreme (around 17.00 instead 
of 14.00 hours found by previous workers). As these differences are not 
large, they could be accounted for by a number of factors including 
species (with possibly different eating and activity patterns), lighting 
regime and experimental design.
The rhythmic pattern of biphenyl-4-hydroxylation is closely matched 
by the spectral interaction of biphenyl with liver microsomes (Figure 6:9).
The maxima alid minima for both parameters occur around 08.00 and 16.00 
hours respectively. The corresponding times for the binding of aniline 
(Figure 6:10) are around 10.00 and 18,00 hours, however, 4 or 6 hours 
later than the analogous metabolic extremes. The periodicity of aniline 
binding, therefore, allies well with that of microsomal cytochrome P-450 
content (Figure 6:4). If, as current theories suggest, Type II spectral 
changes represent interactions with the haem of cytochrome P-450 (and this 
is the component being measured in the P-450 assay) then an interesting 
correlation exists.
The presence of a diurnal rhythm is also indicated for levels of 
circulating cortisol (Figure 6:8). It is impossible to be categorical 
about these and other results obtained using steroids, because the values 
were obtained from pooled liver samples. This was necessary because of 
the nature of the assays and the work load involved. However, it appears 
that peak levels of plasma cortisol occur at 16.00 hours, roughly 12 hours
out of phase with the metabolic maxima. This is in agreement with 
published data (liodsiolowski and Bousquet, 1968). It is also of 
interest to not© that the maxima in corticosteroid metabolism 
(Figures 6:6 and 6:7) are similarly 12 hours out of phase with plasma 
levels, and correspond with the maxima in their own binding (Figures 6:11 
Ond 6:12) and with that of drug metabolism activity.
In contrast to the above parameters, there appear to be no 
rhythmic variations in bipheny1-2-hydroxylation (Figure 6:2) nor in 
hepatic DNA (Figure 6:13). The demonstration that cell numbers (as 
manifest by D M  levels) are apparently constant confirms previous data 
(Boring and Reusing, 1973)* Again, in agreement with our results,
Colas et al (1969) demonstrated no rhythms in microsomal protein and 
cytochrome b^ . They also concluded that cytochrome P-450 levels were 
not diurnally rhythmic. In our studies, howover, the extremes around 
09.00 and 18.00 hours are significantly different and an overall 
circadian pattern of P-450 levels apparently exists (Figure 6:4).
While experiments I and II suggest a rhythmicity in biphenyl-2- 
hydroxylation, the data of experiment III refutes this (Figure 6:2).
This observation provides further evidence that the 2-hydroxylation 
step is mechanistically different from that at the 4 position. A 
discrepancy in the existence of rhythms for related parameters is not 
unknown, however. Civen et al (196?) could demonstrate no circadian 
variation in the levels of hepatic phenylalanine aminotransferase, while 
tyrosine aminotransferase levels were certainly rhythmic. These authors 
noted o correlation between the presence of a circadian rhythm and the 
ability of these aminotransferases to respond to inducing amounts of 
glucocorticoids. However, the demonstration that hypophysectony or 
adrenalectomy did not abolish the rhythm of tyrosine aminotransferase
(v/urtman and Axelrod, 1967) suggests that the correlation is probably 
fortuitous. Furthermore, both routes of biphenyl hydroxylation appear 
to be similarly affected by a wide range of endogenous and synthetic 
glucocorticoids (chapter 5). Bipheny1-2-hydroxylation therefore, 
resembles a number of other enzymic parameters which do not demonstrate 
circadian rhythmicities, namely, hepatic glucose-6-phosphate 
dehydrogenase, lipoprotein lipase and phenylalanine aminotransferase 
(Chandrabose et al, 19715 Civen et al, 1967).
Rhythms in steroid metabolism.
It is interesting to consider the nature of the metabolic 
rhythms involved in corticosteroid metabolism, as determined in the 
present study. Their maxima and minima approximately correspond to 
the respective minimum and maximum of circulating plasma cortisol, and 
could be determinate of these levels. This seems more likely than the 
converse, since it has been demonstrated that constantly elevated plasma 
corticosteroid levels result in sub-minimal metabolic activities 
(Radzialowski and Bousquet, 1968). Both corticosterone and cortisol 
are similarly metabolised, primarily by the liver, through predomin^Hg 
reductive degradative routes. Relatively little hydroxylative metabolism 
occurs, but this is known to increase in certain physiological conditions 
(Chapter 4). These hydroxylations proceed under conditions which greatly 
resemble those required for oxidative drug metabolism and can be inhibited 
by carbon monoxide (Conney et al, 1965b; Kuntzman et al, 1964).
Results obtained for corticosteroid metabolism also demonstrate 
the effects of carbon monoxide on the overall metabolism (Figures 6;6 
and 6:7). It is apparent, especially from experiment II of the 
corticosterone series, that carbon monoxide exerts its greatest effect
at the time of maximal metabolism. (This is manifest by differences 
between the overall metabolism and that of the baseline of reductive 
metabolism i.e. when carbon monoxide is present. The largest difference 
occurs when total metabolism is maximal, around 08.00 hours). The 
maximum rate of corticosteroid metabolism therefore represents a 
similar maximum in hydroxylating activity, and this corresponds to a 
temporally similar1maximum in drug hydroxylation activity. Kuntzman 
et al (1964) suggested that steroids may be the normal endogenous 
substrates of the nftc'rosomal mixed-fmiction oxidases. The results just 
presented tend to support this theory, as do the phase similarities in 
steroidal circadian spectral interactions which resemble those of 
biphenyl. Unfortunately no kinetic data are available for the steroidal 
metabolism or binding, and this makes further comparisons impossible.
Diurnal rhythms in the kinetics of binding and metabolism.
The kinetic results obtained by examination of the metabolic and 
cytochrome P-450 binding properties of biphenyl and aniline are 
presented in Tables 6:2 and 6:3,. The common factor affecting both these 
determinations is cytochrome P-450, whose rhythmicity has been discussed 
previously. It seems improbable that this parameter could elicit the 
well defined rhythmic changes manifest, per se, as its own pattern is 
le ss regular. When expressed on a constant protein content basis, 
significant differences between the rhythmic extremes of both A 
and Kg are manifest for both aniline binding and the high affinity 
interactions of biphenyl. (See appendix for definition of terms). 
However, if the same data are expressed on the basis of constant
cytochrome P-450, only significant differences in K ore observeds
It is, therefore, apparent that changes in both the amount and affinity 
of binding are occuring on an equal protein basis, whereas only the
latter is altered when the cytochrome P-450 content is equalised.
Thus, variations in the amount of binding can be ascribed to the 
corresponding modulations in P-450 content. The P-450 independent 
changes in Kg are more difficult to explain and could result from 
competition by other rhythmically variable compounds, or from 
alterations in the nature of the binding site. The low affinity 
biphenyl interaction (see appendix) is apparently less contingent 
on these cytochrome P-450 independent changes, since comparisons on 
an equal P-450 basis tend to negate the differences demonstrated when 
protein content has been equalised.
In the kinetic metabolic studies, changes with time of both 
and V are generally apparent, although these ore less marked 
than in the binding studies. A difference also emerges between the 
2- and 4- hydroxylation of biphenyl, not surprisingly when the single 
substrate-concentration metabolic studies are considered. The overall 
pattern again seems to indicate complex modifications of the amount and 
affinity of substrate binding to the enzyme(s) during the rhythmic 
process.
Conclusions.
Multiple changes in K , V  K andAE are apparent in the1 ^  nr max, s max *
kinetic experiments just described. It, therefore, seems reasonable 
to propose that the changes occuring over the rhythmic cycle are, to 
some extent, the manifestations of de novo protein synthesis. Diurnal 
rhythm changes in hepatic iMA and RHA polymerase, which have been 
detected in recent studies (Doring and Reusing, 1973; Steinhart, 197l)» 
support this argument. Y/hile no studies were conducted on the effect 
of protein synthesis inhibitors in the present work, previous investigators
have demonstrated that purorriycin and cycloheximide are both capable 
of abolishing the rhythmic changes normally manifest in the activity 
of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Kandutsch and 
Saucier, 19&9? Shapiro and Rodwell, 1969# 1971). Furthermore,
Edwards and Gould 1(i972) report that cycloheximide does not affect 
the half-life of the enzyme (4.2 hours), again implicating regulation 
of protein synthesis. McVerry and Kim (1972) have demonstrated a 
similar abolition of the rhythm of glycogen synthetase activity using 
cycloheximide.
Periodic de novo enzyme synthesis is, therefore, important and 
could determine the increased amount of substrate binding. However, 
we have also detected changes in the nature of this binding, and this 
is more difficult to explain. The presence of rhythmically variable 
amounts of steroids, (especially corticosteroids, but also androgens) 
is established, and this may be contributive. In our experiments we 
have determined that hamsters are most active during the dark phase, and 
this may also be important. The maximum ingestion of food, containing 
both nutrients and anutrients, is greatest during this high activity 
period (Suttie, 1968; Edwards et al, 1972) and can also be influential 
on established circadian rhythms (Booth et al, 1972). All these factors, 
themselves rhythmic, could influence the nature of enzyme binding sites, 
and thereby produce the changes manifest. However, it;seems unlikely 
that they are the causative agents, rather than important effectors.
Alternating light/dark regimes are influential on the placement 
of rhythmic extremes. In view of the number of other factors which 
light influences eg. food intake, it is not surprising that continuous 
light or darkness abolishes b&isting rhythms. The light phase could, 
therefore, be causative. However, the observation of Nair et al (1970)
that hypothalamic lesions abolished the circadian rhythm of 
hexobarbital metabolism is perhaps most significant.
While our results provide no new information as to the causative 
factors of circadian variations, they indicate that the changes occuring 
are resultant both of de novo enzyme synthesis and of intex-actions with 
a number of environmental components. In this respect the microsomal 
mixed-function oxidase system appears to behave like other endogenous 
enzymes.
FIGURE 6:1 CIRCADIAN VARIATION IN HEPATIC BIPHENYL-4-HYDROXYLASE ACTIVITY.
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All results are expressed as nmol product formed per mg microsomal protein 
per minute (ordinate) against time in hours (abcissa).
* Indicates a result significantly different (p-^0.05) from the overall 
mean of the group.
FIGURE 6:2 CIRCADIAN VARIATION IN HEPATIC BIPIIENYL-2-IIYDR0XYLASE ACTIVITY.
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All results are expressed as nmol, product formed per mg microsomal 
protein per minute (ordinate) against time in hours (abcissa).
* Indicates a result significantly different (p<0.05) from the 
overall mean of the group.
FIGURE 6:3 CIRCADIAN VARIATION IE HEPATIC ANILINE-4-IIYDROXYLASE ACTIVITY.
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All results are expressed as nmol product formed per mg microsomal 
protein per minute (ordinate) against time in hours (abcissa).
* Indicates a result significantly different (p<C0.05) from the 
overall mean of the group.
FIGURE 6:4 CIRCADIAN VARIATION IN HEPATIC MICROSOMAL CYTOCHROME P-450.
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All results are expressed as extinction units per mg microsomal 
protein (ordinate) against time in hours (abcissa).
*■ Indicates a result significantly different (p*<0.05) from the 
overall mean of the group.
FIGURE 6:5 CIRCADIAN VARIATION IN HEPATIC MICROSOMAL CYTOCHROME b.
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All results are expressed as extinction units per mg microsomal 
protein (ordinate) against time in hours (abcissa).
* Indicates a result significantly different (p^ .0 .05)  from the 
overall mean of the group.
FIGURE 6:6 CIRCADIAN VARIATION IN CORTICOSTERONE METABOLISM BY LIVER
MICROSOMAL PREPARATIONS._______________________________
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All results are expressed as nmol NADPH consumed per rag microsomal 
protein per minute (ordinate) against time in hours (abcissa).
_0_0_ Substrate utilisation in air.
_q —o- Substrate utilisation in carbon monoxide/air.
FIGURE 6:7 CIRCADIAN VARIATION IN CORTISOL METABOLISM BY LIVER
MICROSOMAL PREPARATIONS.______ ________ ________
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All results are expressed as nmol NADPH consumed per mg microsomal 
protein per minute (ordinate) against time in hours (abcissa).
. q  q  Substrate utilisation in air. 
q q Substrate ultilisation in carbon monoxide/air.
FIGURE 6:8 CIRCADIAN VARIATION IN PLASMA CORTISOL LEVELS.
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All results are expressed as pg cortisol per 100 ml plasma (ordinate) 
against time in hours (abcissa).
FIGURE 6:9 CIRCADIAN VARIATION IN THE BINDING OF A TYPE I COMPOUND (BIPHENYL)
TO CYTOCHROME P-450.________________________________________________
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against time in hours (abcissa).
* Indicates a result significantly different (p^-0.05) from the 
overall mean of the group.
FIGURE 6:10 CIRCADIAN VARLATION IN THE BINDING OF A TYPE II SUBSTRATE
(ANILINE) TO CYTOCHROME P-450. __________________________
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* Indicates a result significantly different (p/lO.05) from the 
overall mean of the group.
FIGURE 6:11 CIRCADIAN VARIATION IN THE BINDING OF CORTICOSTERONE TO
CYTOCHROME P-450. ____________ ______________________
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FIGURE 6:12 CIRCADIAN VARIATION IN THE BINDING OF CORTISOL TO CYTOCHROME P-45'0.
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FIGURE 6:13 CIRCADIAN VARIATION IN HEPATIC DNA CONTENT AND IN MICROSOMAL 
PROTEIN._________________ ________ _________________
26 - j
24-
22 -
II
0000 0400 0800 1200 1600 2000 2400
2400 0000 0400
DNA content (-a— A-) is expressed as (jg per gram vet weight liver; 
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Time (in hours) is the abcissa.
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Although the identity of the intracellular receptors for 
glucocorticoids has been established for some time, no differences in 
the molecular response produced by natural or synthetic corticosteroids 
have been noted. In view of their similar physiological and biochemical 
effects, this appears logical, but does not explain the markedly increased 
biological potency of some synthetic analogues. The present study has 
resolved some of the reasons for these differences in biological potency 
by comparing pharmacokinetics of the endogenous and synthetic 
glucocorticoids. The various aspects of endogenous and synthetic 
glucocorticoid biochemistry which are most influential on their different 
properties are categorised below. However, it should be emphasised that 
none of these is a truly independent determinant, and the ultimate 
differences arise from the complex interactions of these individual effects.
METABOLISM AND EXCRETION.
Both synthetic steroids studied, namely betamethasone and 
dexamethasone, are metabolised more slowly than the endogenous 
glucocorticoid of the rat, corticosterone, although betamethasone is 
metabolised faster and to a greater extent than is dexamethasone. The 
l6(3~methyl substituent present in betamethasone therefore appears less 
effective than the corresponding l6a-methyl group of dexamethasone in 
limiting metabolism. Such limitations may result from steric effects, 
which especially influence the reduction of the 20-keto group. This 
carbonyl group, present in the 17(3 side-chain, is adjacent to the 
16-methyl substituents in betamethasone and dexamethasone. It seems 
likely that the configuration of this methyl substituent could affect 
the enzyme responsible for 20-keto reduction. As fewer C0q reduction 
products are found in the urine after dexamethasone than after
betamethasone, it appears that the l6a-methyl substituent of 
dexamethasone may be most detrimental to the activity of the 
20-keto reductase enzyme. If this is the case, an interesting 
correlation exists between the present metabolic considerations and 
those of plasma protein binding of steroids. It has been shown that 
or-substituents are strong inhibitors of glucocorticoid binding by 
transcortin (Daughaday, 1967), and of gestogen binding to albumin 
(Y/estphal and Ashley, 1959). Thus, steric effects may be important 
in determining the properties of the synthetic glucocorticoids. The 
likelihood of such steric effects influencing the interactions of 
glucocorticoids with their receptor proteins seems a topic worthy of 
further investigation*
The patterns of excretion of the three glucocorticoids studied 
indicate that excretion in the faeces is more pronounced when metabolism 
is more complete. Thus, greater emphasis on urinary excretion is found 
after betamethasone or dexamethasone than after corticosterone in rat.
The same is true when the excretion of betamethasone is compared in 
guinea pig and in rat. This most probably reflects the ability of 
the liver to metabolise the administered steroid, since radioactivity 
present in the faeces arises from hepatic metabolism and biliary 
excretion. However, enterohepatic recirculation will also influence 
the amounts of steroids present in the faeces, and the synthetic 
glucocorticoids and their metabolites ore apparently less well reabsorbed 
than their endogenous analogues. The reason for this may be that 
synthetic steroids ore less susceptible to bacterial degradation and 
are consequently insufficiently polar to be reabsorbed, or that they 
are poor substrates for any active processes involved in enterohepatic 
recirculation.
Factors affecting glucocorticoid metabolism and excretion.
The major reason for the slower metabolism of the synthetic 
glucocorticoids appears to be due to the different emphasis on routes 
of metabolism. It seems likely that structural modifications make the 
synthetic corticoids poor substrates for the primary reductive routes 
of natural glucocorticoid metabolism* Furthermore, it appears that 
their hydroxylative metabolism proceeds more slowly than does reduction 
of the endogenous types. Since steroid hydroxylation occurs under the 
same conditions that facilitate the hydroxylation of tfa&gs* and since 
the components of mixed-function oxygenation are present in the liver 
in considerable amounts that can metabolise some drugs rapidly, this 
slow metabolism of the synthetic steroids is. somewhat surprising. 
However, hydroxylation alone does not transform the synthetic 
glucocorticoids into distinctly more polar products as does occur with 
some drugs of lower molecular weight, and this may influence subsequent 
excretion of the compounds. Furthermore, synthetic glucocorticoids are 
less liable to glucuronide conjugation because of their intact 3-keto 
group, and this may further restrict excretion. Thus, the slower 
metabolism and biliary excretion of the synthetic glucocorticoids may 
contribute towards their slower hepatic clearance.
An attempt to resolve the importance of metabolism and biliary 
excretion in the slower hepatic clearance of the synthetic 
glucocorticoids was made using inducing regimes of phenobarbital and 
dexamethasone pretreatment. Although both compounds increased biliary 
flow (a phenomenon previously noted for phenobarbital: Elaassen, 1969),
it is doubtfvid whether this increased flow affects the percentage 
excretion of a drug, per se. After inducer pretreatment, biliary 
steroid fractionation showed little change in the relative proportions
of the sub-fractions. However, slight increases in the amounts of 
sulphate conjugates, which normally comprise a large proportion of 
the biliary steroids, were noted after induction. This observation 
indicates that conjugation of steroids with sulphate may be metabolically 
limiting in untreated animals, (it is interesting to note that there 
are proportionally fewer glucuronide conjugates, but more sulphates, 
after dexamethasone than after phenobarbital pretreatment. This may 
result from limitations to the reduced availability of glucuronic acid 
for conjugation after dexamethasone, du$ to its effects in promoting 
glycogen deposition. The increased proportion of sulphate conjugates 
found after dexamethasone pretreatment could, therefore, be compensatory.) 
If the overall excretion process is limiting, however, induction would be 
expected to increase excretion rate without changes in the component 
steroids. If, conversely, it is metabolism that limits hepatic 
clearance, then the proportions of these component steroids would be 
expected to change after induction, especially in relation to the amounts 
of unchanged steroid. Although this seems likely, no analysis of the 
constituent steroids of the various biliary subfractions has presently 
been made, before or after induction. Confirmation of the proposal, that 
the rate of metabolism is the main cause of the slower hepatic clearance 
of synthetic glucocorticoids, awaits further work.
:TISSUE . HA1J-LI^ -
The slower hepatic clearance of the synthetic glucocorticoids will 
contribute considerably towards their increased potency. Not only will 
their ,hepatic half-life be increased (a phenomenon confirmed by the 
tissue distribution studies), but this will also kinetically delay 
clearance from extra-hepatic tissues. However, a more direct determinant
of prolonged tissue retention is the greater affinity of the tissue 
receptors for the synthetic steroids. As stated previously, it seems
unlikely that the molecular response of a tissue will differ from
steroid to steroid in terms of magnitude. In addition, no large 
differences in the amounts of steroid initially distributed to the 
tissues were demonstrated between betamethasone and corticosterone 
which would explain the greater biological potency of the synthetic 
steroid. However, by prolonging the tissue response, biological 
potency could be increased, and the greater half-life of betamethasone
in nearly all the tissues studied indicates that this may be the case.
It has been demonstrated that, after uptake, the effects of 
glucocorticoids in initiating mRNA synthesis are irreversible after 
only fifteen minutes (Beato et al, 1971)* However, no information exists 
on the fate of the nuclear steroid-receptor after its initial actions. 
This mediating complex must be in a state of dynamic exchange to permit 
flexibility of the procedure* However, it is unlikely that metabolic 
deactivation of both receptor and steroid need occur, since the 
receptor protein is inactive in the absence of steroid. Removal of 
the steroid from the steroid-i'eceptor complex is the most economic 
process preventing further action* Although the steroid must be 
stabilised after attachment to the receptor, the half-life of the 
steroid-receptor complex must be influenced by the properties of the 
steroid itself. When the steroid is removed from the complex, the 
availability of further steroid will allow repetition of the process.
The half-life of the previous components in the chain of processes 
mediating glucocorticoid effects then become important. Thus, the 
half-life of intact steroid attached to the cytoplasmic receptors 
will also influence perpetuation of the molecular response, as will
the amount of unchanged steroid retained by the tissue. Ultimately, 
therefore, the properties of the steroid which influence its tissue 
retention seem most important.
The present study has shorn that radioactivity is retained for 
longer periods after betamethasone administration than after 
corticosterone, and it is proposed that this a major determinant 
of the increased potency of the synthetic glucocorticoids. Further 
characterisation of the nature, and especially the kinetic properties, 
of the glucocorticoid-receptor protein complex is required to elaborate 
on this critical facet of glucocorticoid action. However, the work 
published so far indicates that glueocorticoid-receptor proteins possess 
similar properties to those identified in the mediation of the actions 
of other steroid hormones.
BIOCHEMICAL EFFECTS.
The mechanistically similar processes of drug and steroid 
hydroxy lation have already been mentioned, and further evidence for 
the theory that steroids may be one of the endogenous substrates of 
mixed-function oxygenation (Kuntzman et al, 196k) has been obtained in 
the present study. Thus, the synthetic glucocorticoids which are 
metabolised by hydroxylation ore better inducers of drug metabolism 
enzymes than those steroids which are primarily metabolised by reduction.
A wide range of effects on drug metabolism parameters resulted from 
pretreatment of animals, in vivo» with several natural and synthetic 
glucocorticoids. These ranged from significant increases in drug 
metabolism activity after the more potent synthetic analogues, to the 
converse depressions in activity after pretreatment with endogenous 
corticosteroids. The nature of these effects is most readily explained
by a common mode of action of the steroid on integral components of 
the nfc&d-function oxygenase system. Such changes would consequently 
affect metabolism of all the substrates studied in a mechanistically 
similar fashion. The results of this study have indicated that these 
effects are mediated primarily through changes in the concentration of 
cytochrome P-450, and in the rate of its reduction. If this is so, 
glucocorticoids will influence the metabolism of a large number of 
compounds, including drugs, and caution in the prescription of other 
drugs during long term steroid pretreatment is, therefore, warranted.
Mediation of the effects of glucocorticoids on enzymic parameters.
No examination of the effects of inhibitors of protein synthesis 
was made in the present work. However, the established effects of 
glucocorticoids in controlling other enzymic components of intermediary 
metabolism make effects on de novo protein synthesis a likely cause of 
the changes demonstrated in hepatic drug metabolism. Furthermore, studies 
with other inducers have indicated that control of synthesis is more 
likely than is control of degradation as a determinant of enzyme 
activity. Such control of protein synthesis is applicable both where 
increases and decreases in activity have been demonstrated subsequent 
to glucocorticoid pretreatment. However, further work is necessary to 
characterise the stage(s) of protein synthesis at which the glucocorticoids 
exert their effect.
It is unlikely that changes in any factor olfcher than quantity 
could explain the demonstrated variations in cytochrome P-430 content.
No qualitative changes in the cytochrome were detected using ethyl 
isocyanide (as occurs after pretreatment with 3-methylcholanthrene) and 
glucocorticoid pretreatment also failed to influence the qualitative
binding of xenobiotics to P-450 (as determined by K values). It also 
seems likely that quantitative changes are responsible for the observed 
changes in the reduction of cytochrome P-450, although Hamrick et al (1973) 
have demonstrated that changes in the efficiency of the process can 
follow pretreatment with various steroids. It is not easy to imagine 
how such changes could arise, other than by effects on configuration 
of the reductase system and its associated membranous component. Such 
allosteric effects might be detected using kinetic studies, but the 
present paucity of knowledge of the nature of the components of mixed- 
function oxygenation hinder further interpretation.
There is some confirmatory evidence to indicate that glucocorticoids 
may influence enzyme activity by allosteric effects. Thus, Cox et al (1971) 
implicated allosteric effects in the control of alkaline phosphatase 
activity. Also, in the present study, it appears that the large increases 
in biphenyl-2-hydroxylase activity following inclusion of glucocorticoids 
*n in vitro incubation system may be allosterically derived* The 
similar changes resulting from use of various polycyclic hydrocarbons 
including 3-methylcholanthrene (Bridges et al, 1973) are of interest in 
this respect, and it is possible that the glucocorticoid metabolite 
binding proteins (Chapter 3) may function in this process. This 
relationship is proposed because Singer and Litwack (1973) have demonstrated 
that the binding protein of 3-methylcholanthrene is apparently identical 
to that binding cortisol in rat liver cytoplasm. The peculiarity of 
bipheny1-2-hydroxylase in this respect indicates that it functions 
differently from the other enzymes studied. However, insufficient is 
known of the factors responsible for the differences demonstrated here, 
and in other situations, and these merit further investigation.
Importance of glucocorticoids in the expression of diurnal rhythms.
It seems unusual that allostery, which is a rapid and economic 
method of regulation of enzyme activity, appears to be of such limited 
application in glucocorticoid action. However, this appears to be the 
case both in the context of responses to glucocorticoid pretreatment, 
and in the diurnal rhythm of hepatic drug-metabolising enzyme activity. 
Such circadian variation may be mediated by glucocorticoids and appeasfe 
to largely result from cyclic variations in protein synthesis. However, 
other factors, apart from protein synthesis, are influential on this 
diurnal rhythm. This is indicated by the multiple rhythmic changes in 
kinetic parameters, and especially in those of substrate binding to 
cytochrome P-450, which are not consistent with increased levels of 
drug metabolism components alone. These changes may result from 
corresponding cyclic variations in other interacting substances.
Variable amounts of nutrients, controlled by food intake, could be 
responsible, but these seem unlikely candidates for regulation of 
drug metabolism enzymes. More likely is an involvement of endogenous 
steroid hormones. This seems likely because the rhythmic variations in 
drug metabolism temporally correlate both with those ofsteroid metabolism 
and the circulating levels of plasma glucocorticoids. Moreover, these 
studies have shown that interactions between glucocorticoids and drug 
metabolism enzymes are possible.
While mediation of the expression of diurnal rhythms by 
glucocorticoids seems likely, their function in a causative role is 
less probable. More feasible is on overall control at central nervous 
levels, which would subsequently control the rhythmic release of ACTH. 
However, the role of the central nervous system in regulating the 
function of the hypotholamus-pituitory-adrenal axis is poorly understood.
Some elaboration of this regulation, as well as of the previously 
mentioned unresolved aspects of glucocorticoid intracellular receptors, 
is necessary before the action of glucocorticoids can be finally 
established.
CONCLUSIONS.
1) The metabolism and biliary excretion of betamethasone and 
dexamethasone are slower than that of corticosterone, the endogenous 
glucocorticoid of the rat.
2) The major urinary metabolites of betamethasone and dexamethasone 
are 6j3-hydroxy derivatives, whereas the major metabolites of 
corticosterone are reduction products.
3) The retention of betamethasone in the tissues is greater than that 
of corticosterone. This, even more than the slower metabolism of the 
synthetic glucocorticoids, is probably responsible for their greater 
biological potency.
k) Glucocorticoids may influence hepatic drug metabolism, probably 
by affecting the concentrations of cytochrome P-450 and the rate of 
its reduction.
5) The changes in activity of the mixed-function oxygenase system 
following treatment with glucocorticoids are probably due to effects 
on novo protein synthesis. These effects apparently influence only 
selective components of the enzyme system.
6) Other changes in activity of hepatic drug-metabolising enzymes, 
produced by glucocorticoids, are possibly allosteric in origin.
7) The effects of glucocorticoids on enzyme activity, and their inherent 
rhytkmicity, make these steroid hormones likely effectors of the 
observed circadian rhythm in hepatic steroid and drug metabolism.
APPENDIX.
KINETIC DATA.
Lineweaver and Burk (1934) described the double inverse plot of
reaction velocity against substrate concentration in the interpretation
of reaction kinetics. Data presented by this method normally results
in the characteristic plot shown in Figure A:l.
The two parameters most widely obtained by use of Lineweaver-Burk
plots are K and V » and are the intercept values on the abcissa m max
and ordinate respectively. Km is defined as the concentration of
substrate causing one half the maximal rate of metabolism, and V1 max
as the maximal velocity attainable by the reaction under consideration. 
Data obtained in binding spectra studies can be presented as ,a
f
pseudo Lineweaver-Burk plot in which the magnitude of the spectral 
change (AE) is substituted for the reaction velocity. The analogues 
values of K and V in these plots of 1/A e  against l / [ s ]  are Kg 
and AE * K is defined as the concentration of a substance causing
d & X  S
one half of the maximal spectral change and A e as the maximalr max
spectral change attainable. In all cases, spectral changes were 
calculated as the sum of the absorbance differences from baseline 
values (no substrate) at the absorption peak and trough. The method 
used to obtain binding spectra has been described in 2.9.4.
Statistical evaluation of the results is described in 2.8.9.
Lineweaver-Burk plots of data obtained in studies on the 
kinetics of biphenyl binding give the characteristic curve shown 
in Figure As2. Distinguished by the inflexion in the curve, these 
plots indicate the existence of two types of spectrally apparent 
interaction, namely a high affinity interaction (with K^and 
and a low affinity interaction (with Kg2 an<* AEmax2).
Note.
The systems used for determination of the kinetics of metabolism 
and binding ore of undefined purity. All values of K^ , V t Kg and 
A E  . given in the results are# therefore, apparent.
FIGURE A:1 LINEWEAVER-BURK PLOT FOR CALCULATION OF KINETIC DATA.
max
1K
FIGUREAA.:2 TYPICAL LINEWEAVER-BURK PLOT IN STUDIES ON THE KINETICS OF 
BIPHENYL BINDING. _____ __________________
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TABLE A4:l Rf VALUES OF BETAMETHASONE, DEXAMETHASONE AND THEIR 
DERIVATIVES IN SOLVENT SYSTEMS I AND II.
COMPOUND R„ in
Solvent system I Solvent system II
Dexamethasone 0.27 0.47
Dexamethasone-21-aeetate 0.65 0.57
20-Bihydrodexamethasone
Fast isomer 0.13 0.28
Slow isomer 0.07 0.18
Betamethasone 0.27 0.47
Betamethasone-21-acetate 0.61 0.57
20-Dihydrobetamethasone
Fast isomer 0.13 0.28
Slow isomer 0.07 0.18
6(3-Hydroxybe tame thas one 0.15 0.40
11-Dehydrobetamethasone 0.40 -
6(3,21-Diacetoxybetamethasone 0.60 0.57
The constituents of solvent systems I and II are described in 2.8.6.
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CHANGES 
IN 
THE 
LEVELS 
OF 
CYTOCHROME 
bg 
AND 
CYTOCHROME 
P-450 
RESULTING 
FROM 
GLUCOCORTICOID 
PRETREATMENT
TABLE A5:3 CHANGES IN THE ACTIVITY OF NADPH CYTOCHROME c REDUCTASE 
RESULTING FROM GLUCOCORTICOID PRETREATMENT,.
STEROID USED FOR PRETREATMENT
mg
jjmcl CYTOCHROME c ] 
microsomal protein/hour
REDUCED PER
g liver/hour
Control 1 1.9 + 0.06 43 + 1
Corticosterone 1.7 +0.1 39 + 3
Control 2 5.6 +0.5 120 + 7
Prednisolone 6 . 1 Jr 0.3 135 + 2
Control 3 2.8 + 0.1 7 0 + 5
Betamethasone 3.9 + 0.06 j 87 + 5*
Control 4 3.3 + 0.07 68 + 5
6p-0H Corticosterone 2.6 + O.lD 58 + 3
Control 5 2.8 + 0 • 2 59 + 2
Cortisol 2.6 + 0.2 5 9 + 2
Hexahydrocorticosterone 2.7 + 0.2 6 0 + 5
Triamcinolone acetonide 3.9 +0.3* 72 + 3D
Control 6’ 2.8 + 0.2 62 + h
Beclomethasone 3.7 + O.lD 82 + lfl
Dexamethasone 4.9 + 0.3't 125 + 3t
Steroid pretreatment is described in 5i2. Values which differ significantly 
from controls are indicated by?
* p< 0.05 D P< 0.01 t P<0.001
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ABLE 
A5:10 
EFFECT 
OF 
DEXAMETHASONE 
PRETREATMENT 
OF 
VARYING 
DURATION 
ON 
BODY 
WEIGHT, 
LIVER 
WEIGHT, 
MICROSOMAL 
PROTEIN 
AND 
HEPATIC 
CYTOCHROME 
P-450 
and 
b,_ 
LEVELS. 
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TABLE A5:12 EFFECTS OF GLUCOCORTICOIDS IN VITRO ON VARIOUS ENZYME ACTIVITIES,
STEROID AND ASSAY ENZYME ACTIVITY (nmol product/mg microsomal protein/hour)
CONCENTRATION ( (jM ) Biphenyl--4-0Hase Biphenyl-2-0Hase Ani1ine-4-0Hase
Corticosterone
0,01 23 + 2 7.8 + 0.3 47 + 1
0.1 27 + 2 7.9 + 0.4 47 + 2
1.0 22 + 3 8.7 + 0.5 49 + 2
10 21 + 2 10.7 j. 0.7 50 + 2
100 25 4- 2 19.0 + i.6Q 53 + 2
6(3-OH Corticoster<me
0.01 16 + 1.5 4.8 + 0.5 -
0.1 21 + 2.1 4.4 + 0.08 -
1.0 22 + 1.6 • 3.9 + 0.4 -
10 24 + 1.6 4.0 + 0.3 -
100 25 + 0.5 5.5 + 0.4 -
Cortisol •
0.01 25 + 2 9.0 + 0.3 -
0.1 29 + 3 8.5 + 0.5 -
i .0 22 + 1 9.1 + 0.4 -
10 22 + 2 9.1 + 0.1 -
100 29 + 4 10.7 + 0.7 -
0 Significantly different from control values (p<O.Ol).
TABLE A5; 13 EFFECTS OF GLUCOCORTICOIDS IN VITRO ON VARIOUS ENZYME ACTIVITIES.
STEROID AND ASSAY 
CONCENTRATION (fjM )
ENZYME ACTIVITY (nn 
Biphenyl-4-OHase
10I product/mg micros 
* Biphenyl-4-OIIase
somal protein/hour) 
Aniline-4-0Hase
Prednisolone
0.01 24 + 2 3.5 + 0.4 48 + 2
0*1 23 + 2 3.3 +0.5 48 + 2
1.0 20+1 4„2 +0.6 47 + 2
10 19 + 3 3.4 + 0.6 42 + 2
100 22 + 3 6.2 + 0.8* 4 4 + 3
Betamethasone
0.01 25+1 8.2 + 0.1 34 + 5
0.1 25 + 1 8.7 + 0.2 34 + 4
1.0 23 + 2 •10.1 + 0.4* 36 + 4
10 24+2 12.8 + 0.4 D 35 + 3
100 24 + 1 54 +\3t 32 + 2
Dexamethagone
0.01 16 + 1 3.5 + 0.3 51 + 2**
0.1 18 + 1 4.2 + 0.7 5 3 + 2
1.0 18 + 2 4.6 + 1.0 59 + 2
10 16+1 4.4 +0.7 6 1 + 3
100 17 + 1 7.5 + 0.6Q 6 1+4
Values which differ significantly from controls are indicated by: 
* p <0.05 Q p-cO.Ol
** p< 0.02 t p<0.001
TABLE A6:l CIRCADIAN VARIATION IN HEPATIC BIPfflWL-4-HYDROXYLASE ACTIVITY.
. TIME
(hours)
ENZYME ACTIVITY (1 
Experiment I
imol product/mg micro 
Experiment II
somal protein/minute) 
Experiment III
0000 - 3.6 + 0.3 -
0200 5.3 + 0.7 - -
0400 - 4.0 + 0.5 2.1 + 0.05*
0600 9.1 ± 0.7 - 2.9 + 0.2
0800 - 4.0 + 0.1 2.9 +0.1
1000 6.5 + 0.7 - 3.4 + 0.1*
1200 - 4.0 + 0.1
1400 5.5 + 0.2 2.6 + 0.08
1600 - i.6 + 0.2* 2.5 + 0.3
1800 1.3 + 0.1 - 3.2 + 0.4
2000 - 2.7 + 0.4 2.6 +0.1
2200 7.4 + 0.1 - -
2400 - 3.4 + 0.1 -
0200 5.5 + 0.4 - -
Asterisks indicate values significantly different (p<0.05) from the
overall mean for each experiment.
TABLE A6:2 CIRCADIAN VARIATION IN HEPATIC BIPHENYL-2-IIYDROXYLASE ACTIVITY,
TIME
(hours)
ENZYME ACTIVITY ( 
Experiment I
nmol product/mg micro 
Experiment II
somal protein/minute) 
Experiment III
0000 - 1.1 + 0.08
0200 0.94+0.10 - -
0400 - 1.6 + 0.21 1.7 +0.18
0600 1.1 + 0.07 - 1.2 + 0.09
0800 - 0.66 + 0.04 1.1+0.07
1000 1.0 + 0.06 - 1.0 + 0.06
1200 - 2.1 + 0.04* -
1400 1.5 +.0.04* - 1.0 + 0.01
1600 - 0.52.+ 0; 05 0.95 + 0.05
1800 0.77 + 0.04 - 1.0 + 0.04
2000 - 1.5 + 0.12 1.1 + 0.05
2200 1.1 + 0.05 - ■- ■
2400 ‘ 1.5 + 0.04
0200 1.0 +0.08 - -
Asterisks indicate values significantly different (p<0.05) from the
overall mean for each experiment.
TABLE A6:3 CIRCADIAN VARIATION IN HEPATIC AN ILINE-4-HYDROXYLASE ACTIVITY.
TIME ENZYME ACTIVITY (nmol product/mg microsomal protein/minute)
(hours) Experiment I Experiment II Experiment III
0000 - 1.7 + 0.14
0200 1.4+0.09 - -
0400 - 1.8 + 0.09 0.83 + 0.04
0600 1.9 +0.10* - 0.92 + 0.09*
0800 - 1.7+0.05 0.82 + 0.01
1000 1.5 + 0.01 - 0.75 + 0.04
1200 - 1.6 + 0.10 -
1400 1.5 + 0.03 - 0.58+0.02*
1600 - 1.1+0.01* 0.62 + 0.04
1800 1.3+0.03 - 0.72 + 0.04
2000 - 1.3 + 0.15 0.65 + 0.01
2200 1.6 +0.02 - -
2400 - 1.4 + 0.11 -
0200 1.5 + 0.08 - -
Asterisks indicate values significantly different (p<0.05) from the
overall mean for each experiment.
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A6:5 
CIRCADIAN 
VARIATIONS 
IN 
THE 
BINDING 
OF 
BIPHENYL 
AND 
ANILINE 
TO 
CYTOCHROME 
P-450.
TABLE A6:6 CIRCADIAN VARIATION IN HEPATIC DNA CONTENT AND IN MICROSOMAL PROTEIN,
TIME DNA CONTENT MICROSOMAL PROTEIN
(hours) (jjg atoms DNA P/g liver) (mg/lg liver)
EXPERIMENT II EXPERIMENT I EXPERIMENT II
OOOO 24+0.7 — 25 + 0.6
0200 - 22 + 1.2 -
0400 22+0.9 24+0.5
0600 - 24 + 1.4 -
0800 23 + 0.9 - 24 + 0.7
1000 - 22 + 0.4 -
1200 24 + 0.9 - 27 + 1.3
1400 22+0.6 . - ■
1600 23 +0.6 - 23+1.2
1800 - 25 + 0.5 -
’ 2000 23 + 0.6 - 25+1.3
2200 - 22 + 1.2 -
2400 24+0.7 - 27 + 1.4
0200 - 26+0.7 -
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